WO2022224223A1 - Composés et compositions pour le traitement de maladies associées au coronavirus - Google Patents
Composés et compositions pour le traitement de maladies associées au coronavirus Download PDFInfo
- Publication number
- WO2022224223A1 WO2022224223A1 PCT/IB2022/053794 IB2022053794W WO2022224223A1 WO 2022224223 A1 WO2022224223 A1 WO 2022224223A1 IB 2022053794 W IB2022053794 W IB 2022053794W WO 2022224223 A1 WO2022224223 A1 WO 2022224223A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- independently selected
- membered
- unsubstituted
- alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 409
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 94
- 201000010099 disease Diseases 0.000 title claims abstract description 70
- 238000011282 treatment Methods 0.000 title claims abstract description 55
- 239000000203 mixture Substances 0.000 title abstract description 49
- 238000000034 method Methods 0.000 claims abstract description 90
- 230000002265 prevention Effects 0.000 claims abstract description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 22
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 537
- 229910052717 sulfur Inorganic materials 0.000 claims description 501
- 229910052760 oxygen Inorganic materials 0.000 claims description 476
- -1 C1-C6alkoxy Chemical group 0.000 claims description 420
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 358
- 150000003839 salts Chemical class 0.000 claims description 314
- 125000000623 heterocyclic group Chemical group 0.000 claims description 241
- 125000001072 heteroaryl group Chemical group 0.000 claims description 217
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 214
- 125000005843 halogen group Chemical group 0.000 claims description 172
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 154
- 125000005842 heteroatom Chemical group 0.000 claims description 144
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 130
- 229910052739 hydrogen Inorganic materials 0.000 claims description 128
- 229910052799 carbon Inorganic materials 0.000 claims description 111
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 101
- 125000001424 substituent group Chemical group 0.000 claims description 95
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 80
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 61
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 59
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims description 58
- 229910052757 nitrogen Inorganic materials 0.000 claims description 51
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 51
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 42
- 125000004432 carbon atom Chemical group C* 0.000 claims description 34
- 125000006727 (C1-C6) alkenyl group Chemical group 0.000 claims description 31
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 31
- 125000003003 spiro group Chemical group 0.000 claims description 31
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 29
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 26
- 208000025721 COVID-19 Diseases 0.000 claims description 26
- 229910052731 fluorine Inorganic materials 0.000 claims description 26
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 23
- MDFFNEOEWAXZRQ-UHFFFAOYSA-N aminyl Chemical group [NH2] MDFFNEOEWAXZRQ-UHFFFAOYSA-N 0.000 claims description 20
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 20
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 19
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 16
- 229910052794 bromium Inorganic materials 0.000 claims description 15
- 125000004552 isoquinolin-4-yl group Chemical group C1=NC=C(C2=CC=CC=C12)* 0.000 claims description 15
- 229910052721 tungsten Inorganic materials 0.000 claims description 15
- 229910052727 yttrium Inorganic materials 0.000 claims description 15
- 125000002757 morpholinyl group Chemical group 0.000 claims description 14
- 125000003386 piperidinyl group Chemical group 0.000 claims description 14
- 125000004076 pyridyl group Chemical group 0.000 claims description 14
- 125000001153 fluoro group Chemical group F* 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 12
- 125000000466 oxiranyl group Chemical group 0.000 claims description 12
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 12
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 12
- 229910052801 chlorine Inorganic materials 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 10
- HCMJWOGOISXSDL-UHFFFAOYSA-N (2-isothiocyanato-1-phenylethyl)benzene Chemical compound C=1C=CC=CC=1C(CN=C=S)C1=CC=CC=C1 HCMJWOGOISXSDL-UHFFFAOYSA-N 0.000 claims description 9
- 239000003937 drug carrier Substances 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- 108091005532 SARS-CoV-2 main proteases Proteins 0.000 abstract description 21
- 239000003112 inhibitor Substances 0.000 abstract description 10
- 125000004122 cyclic group Chemical group 0.000 abstract description 4
- 230000002194 synthesizing effect Effects 0.000 abstract description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 149
- 150000001721 carbon Chemical group 0.000 description 149
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 79
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 39
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 38
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 32
- 238000000105 evaporative light scattering detection Methods 0.000 description 30
- 239000012071 phase Substances 0.000 description 30
- 238000000825 ultraviolet detection Methods 0.000 description 26
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- 208000035475 disorder Diseases 0.000 description 24
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 23
- 125000004093 cyano group Chemical group *C#N 0.000 description 21
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 18
- 229910052805 deuterium Inorganic materials 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 15
- 239000002585 base Substances 0.000 description 14
- 235000019439 ethyl acetate Nutrition 0.000 description 14
- 241001678559 COVID-19 virus Species 0.000 description 13
- 239000002253 acid Substances 0.000 description 13
- 125000003118 aryl group Chemical group 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 125000004429 atom Chemical group 0.000 description 12
- 229920006395 saturated elastomer Polymers 0.000 description 12
- 239000013543 active substance Substances 0.000 description 11
- 239000003443 antiviral agent Substances 0.000 description 11
- 239000000460 chlorine Substances 0.000 description 11
- 238000010348 incorporation Methods 0.000 description 11
- 241000711573 Coronaviridae Species 0.000 description 10
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 10
- 229940052143 bamlanivimab Drugs 0.000 description 10
- 150000002430 hydrocarbons Chemical group 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- SRSHBZRURUNOSM-DEOSSOPVSA-N (4-chlorophenyl) (1s)-6-chloro-1-(4-methoxyphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-2-carboxylate Chemical compound C1=CC(OC)=CC=C1[C@H]1C(NC=2C3=CC(Cl)=CC=2)=C3CCN1C(=O)OC1=CC=C(Cl)C=C1 SRSHBZRURUNOSM-DEOSSOPVSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 229940051243 etesevimab Drugs 0.000 description 8
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- AWNXKZVIZARMME-UHFFFAOYSA-N 1-[[5-[2-[(2-chloropyridin-4-yl)amino]pyrimidin-4-yl]-4-(cyclopropylmethyl)pyrimidin-2-yl]amino]-2-methylpropan-2-ol Chemical compound N=1C(NCC(C)(O)C)=NC=C(C=2N=C(NC=3C=C(Cl)N=CC=3)N=CC=2)C=1CC1CC1 AWNXKZVIZARMME-UHFFFAOYSA-N 0.000 description 7
- SDQJTWBNWQABLE-UHFFFAOYSA-N 1h-quinazoline-2,4-dione Chemical compound C1=CC=C2C(=O)NC(=O)NC2=C1 SDQJTWBNWQABLE-UHFFFAOYSA-N 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 150000001412 amines Chemical class 0.000 description 7
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 239000000543 intermediate Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 125000003226 pyrazolyl group Chemical group 0.000 description 7
- 238000005160 1H NMR spectroscopy Methods 0.000 description 6
- XCNBGWKQXRQKSA-UHFFFAOYSA-N 2-(2-chloro-4-iodoanilino)-3,4-difluorobenzoic acid Chemical compound OC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1Cl XCNBGWKQXRQKSA-UHFFFAOYSA-N 0.000 description 6
- XPRDUGXOWVXZLL-UHFFFAOYSA-N 2-[[2-fluoro-4-(3-methoxyphenyl)phenyl]carbamoyl]cyclopentene-1-carboxylic acid Chemical compound COC1=CC=CC(C=2C=C(F)C(NC(=O)C=3CCCC=3C(O)=O)=CC=2)=C1 XPRDUGXOWVXZLL-UHFFFAOYSA-N 0.000 description 6
- MUOKSQABCJCOPU-UHFFFAOYSA-N 5-(3-chloroanilino)benzo[c][2,6]naphthyridine-8-carboxylic acid Chemical compound C=1C(C(=O)O)=CC=C(C2=CN=CC=C22)C=1N=C2NC1=CC=CC(Cl)=C1 MUOKSQABCJCOPU-UHFFFAOYSA-N 0.000 description 6
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 6
- 108700038111 alunacedase alfa Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- ZCGNOVWYSGBHAU-UHFFFAOYSA-N favipiravir Chemical compound NC(=O)C1=NC(F)=CNC1=O ZCGNOVWYSGBHAU-UHFFFAOYSA-N 0.000 description 6
- 229950008454 favipiravir Drugs 0.000 description 6
- 125000002541 furyl group Chemical group 0.000 description 6
- 125000002883 imidazolyl group Chemical group 0.000 description 6
- 125000000842 isoxazolyl group Chemical group 0.000 description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 6
- 230000003472 neutralizing effect Effects 0.000 description 6
- LIENCHBZNNMNKG-OJFNHCPVSA-N nirmatrelvir Chemical compound CC1([C@@H]2[C@H]1[C@H](N(C2)C(=O)[C@H](C(C)(C)C)NC(=O)C(F)(F)F)C(=O)N[C@@H](C[C@@H]3CCNC3=O)C#N)C LIENCHBZNNMNKG-OJFNHCPVSA-N 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 125000002971 oxazolyl group Chemical group 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 125000000168 pyrrolyl group Chemical group 0.000 description 6
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 6
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 6
- 229960000329 ribavirin Drugs 0.000 description 6
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 6
- 229930195734 saturated hydrocarbon Natural products 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 125000000335 thiazolyl group Chemical group 0.000 description 6
- 125000001544 thienyl group Chemical group 0.000 description 6
- 125000001425 triazolyl group Chemical group 0.000 description 6
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 5
- 101800000535 3C-like proteinase Proteins 0.000 description 5
- 101800002396 3C-like proteinase nsp5 Proteins 0.000 description 5
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 5
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- 239000007832 Na2SO4 Substances 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 241000008910 Severe acute respiratory syndrome-related coronavirus Species 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 125000005883 dithianyl group Chemical group 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- 125000001475 halogen functional group Chemical group 0.000 description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 5
- 125000001786 isothiazolyl group Chemical group 0.000 description 5
- 230000000155 isotopic effect Effects 0.000 description 5
- 239000003446 ligand Substances 0.000 description 5
- 125000004312 morpholin-2-yl group Chemical group [H]N1C([H])([H])C([H])([H])OC([H])(*)C1([H])[H] 0.000 description 5
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 5
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 5
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 description 5
- 125000004193 piperazinyl group Chemical group 0.000 description 5
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 5
- 125000004574 piperidin-2-yl group Chemical group N1C(CCCC1)* 0.000 description 5
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 5
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 5
- 125000006239 protecting group Chemical group 0.000 description 5
- 125000003373 pyrazinyl group Chemical group 0.000 description 5
- 125000002098 pyridazinyl group Chemical group 0.000 description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 125000004187 tetrahydropyran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 5
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 5
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 5
- 125000001113 thiadiazolyl group Chemical group 0.000 description 5
- 125000004569 thiomorpholin-2-yl group Chemical group N1CC(SCC1)* 0.000 description 5
- 125000004570 thiomorpholin-3-yl group Chemical group N1C(CSCC1)* 0.000 description 5
- 125000004571 thiomorpholin-4-yl group Chemical group N1(CCSCC1)* 0.000 description 5
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 5
- 125000005503 thioxanyl group Chemical group 0.000 description 5
- VUAFHZCUKUDDBC-SCSAIBSYSA-N (2s)-2-[(2-methyl-2-sulfanylpropanoyl)amino]-3-sulfanylpropanoic acid Chemical compound CC(C)(S)C(=O)N[C@H](CS)C(O)=O VUAFHZCUKUDDBC-SCSAIBSYSA-N 0.000 description 4
- AMFDITJFBUXZQN-KUBHLMPHSA-N (2s,3s,4r,5r)-2-(4-amino-5h-pyrrolo[3,2-d]pyrimidin-7-yl)-5-(hydroxymethyl)pyrrolidine-3,4-diol Chemical compound C=1NC=2C(N)=NC=NC=2C=1[C@@H]1N[C@H](CO)[C@@H](O)[C@H]1O AMFDITJFBUXZQN-KUBHLMPHSA-N 0.000 description 4
- OWOHLURDBZHNGG-YFKPBYRVSA-N (8ar)-hexahydropyrrolo[1,2-a]pyrazine-1,4-dione Chemical compound O=C1CNC(=O)[C@@H]2CCCN12 OWOHLURDBZHNGG-YFKPBYRVSA-N 0.000 description 4
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
- RVLCUCVJZVRNDC-IMJSIDKUSA-N 2-[(2s,5s)-5-methyl-3,6-dioxopiperazin-2-yl]acetic acid Chemical compound C[C@@H]1NC(=O)[C@H](CC(O)=O)NC1=O RVLCUCVJZVRNDC-IMJSIDKUSA-N 0.000 description 4
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 4
- CAOTVXGYTWCKQE-UHFFFAOYSA-N 3-(4-chlorophenyl)-N-(pyridin-4-ylmethyl)-1-adamantanecarboxamide Chemical compound C1=CC(Cl)=CC=C1C1(C2)CC(C3)(C(=O)NCC=4C=CN=CC=4)CC2CC3C1 CAOTVXGYTWCKQE-UHFFFAOYSA-N 0.000 description 4
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- AKJHMTWEGVYYSE-AIRMAKDCSA-N 4-HPR Chemical compound C=1C=C(O)C=CC=1NC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C AKJHMTWEGVYYSE-AIRMAKDCSA-N 0.000 description 4
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 4
- QNQZWEGMKJBHEM-UHFFFAOYSA-N 6-methyl-5-(2-methylpyrazol-3-yl)-n-[(5-methylsulfonylpyridin-2-yl)methyl]-2-oxo-1-[3-(trifluoromethyl)phenyl]pyridine-3-carboxamide Chemical compound O=C1N(C=2C=C(C=CC=2)C(F)(F)F)C(C)=C(C=2N(N=CC=2)C)C=C1C(=O)NCC1=CC=C(S(C)(=O)=O)C=N1 QNQZWEGMKJBHEM-UHFFFAOYSA-N 0.000 description 4
- OZOGDCZJYVSUBR-UHFFFAOYSA-N 8-chloro-n-[4-(trifluoromethoxy)phenyl]quinolin-2-amine Chemical compound C1=CC(OC(F)(F)F)=CC=C1NC1=CC=C(C=CC=C2Cl)C2=N1 OZOGDCZJYVSUBR-UHFFFAOYSA-N 0.000 description 4
- 229940125678 AZD7442 Drugs 0.000 description 4
- OLROWHGDTNFZBH-XEMWPYQTSA-N Alisporivir Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(CC)C(=O)[C@@H](C)N(C)C1=O OLROWHGDTNFZBH-XEMWPYQTSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000008904 Betacoronavirus Species 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- OFFWOVJBSQMVPI-RMLGOCCBSA-N Kaletra Chemical compound N1([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=2C=CC=CC=2)NC(=O)COC=2C(=CC=CC=2C)C)CC=2C=CC=CC=2)CCCNC1=O.N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 OFFWOVJBSQMVPI-RMLGOCCBSA-N 0.000 description 4
- LBHLFPGPEGDCJG-UHFFFAOYSA-N N(4)-{2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl}pentane-1,4-diamine Chemical compound COC=1C=C(NC(C)CCCN)C2=NC(OC)=CC(C)=C2C=1OC1=CC=CC(C(F)(F)F)=C1 LBHLFPGPEGDCJG-UHFFFAOYSA-N 0.000 description 4
- HPKJGHVHQWJOOT-ZJOUEHCJSA-N N-[(2S)-3-cyclohexyl-1-oxo-1-({(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl}amino)propan-2-yl]-1H-indole-2-carboxamide Chemical compound C1C(CCCC1)C[C@H](NC(=O)C=1NC2=CC=CC=C2C=1)C(=O)N[C@@H](C[C@H]1C(=O)NCC1)C=O HPKJGHVHQWJOOT-ZJOUEHCJSA-N 0.000 description 4
- 238000005481 NMR spectroscopy Methods 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229940125677 REGEN-COV Drugs 0.000 description 4
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 235000021355 Stearic acid Nutrition 0.000 description 4
- 229940126222 Veklury Drugs 0.000 description 4
- CAVRKWRKTNINFF-UHFFFAOYSA-N [2-[1-[[3,5-bis(trifluoromethyl)phenyl]methyl]-5-pyridin-4-yltriazol-4-yl]pyridin-3-yl]-(2-chlorophenyl)methanone Chemical compound FC(F)(F)C1=CC(C(F)(F)F)=CC(CN2C(=C(N=N2)C=2C(=CC=CN=2)C(=O)C=2C(=CC=CC=2)Cl)C=2C=CN=CC=2)=C1 CAVRKWRKTNINFF-UHFFFAOYSA-N 0.000 description 4
- SRXKIZXIRHMPFW-UHFFFAOYSA-N [4-[6-[amino(azaniumylidene)methyl]naphthalen-2-yl]oxycarbonylphenyl]-(diaminomethylidene)azanium;methanesulfonate Chemical compound CS([O-])(=O)=O.CS([O-])(=O)=O.C1=CC(N=C([NH3+])N)=CC=C1C(=O)OC1=CC=C(C=C(C=C2)C([NH3+])=N)C2=C1 SRXKIZXIRHMPFW-UHFFFAOYSA-N 0.000 description 4
- 229950004789 alisporivir Drugs 0.000 description 4
- 108010058359 alisporivir Proteins 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 229950005666 alvelestat Drugs 0.000 description 4
- 108010038239 aspartyl-alanyl-diketopiperazine Proteins 0.000 description 4
- PHEZJEYUWHETKO-UHFFFAOYSA-N brequinar Chemical compound N1=C2C=CC(F)=CC2=C(C(O)=O)C(C)=C1C(C=C1)=CC=C1C1=CC=CC=C1F PHEZJEYUWHETKO-UHFFFAOYSA-N 0.000 description 4
- 229950010231 brequinar Drugs 0.000 description 4
- 125000001246 bromo group Chemical group Br* 0.000 description 4
- 229960004272 bucillamine Drugs 0.000 description 4
- XASIMHXSUQUHLV-UHFFFAOYSA-N camostat Chemical compound C1=CC(CC(=O)OCC(=O)N(C)C)=CC=C1OC(=O)C1=CC=C(N=C(N)N)C=C1 XASIMHXSUQUHLV-UHFFFAOYSA-N 0.000 description 4
- 229960000772 camostat Drugs 0.000 description 4
- 125000001309 chloro group Chemical group Cl* 0.000 description 4
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 4
- GBBJCSTXCAQSSJ-XQXXSGGOSA-N clevudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1[C@H](F)[C@@H](O)[C@H](CO)O1 GBBJCSTXCAQSSJ-XQXXSGGOSA-N 0.000 description 4
- 229960005338 clevudine Drugs 0.000 description 4
- 125000005879 dioxolanyl group Chemical group 0.000 description 4
- 125000005411 dithiolanyl group Chemical group S1SC(CC1)* 0.000 description 4
- 229950009602 elsulfavirine Drugs 0.000 description 4
- 229940125025 emvododstat Drugs 0.000 description 4
- 108700005843 ensovibep Proteins 0.000 description 4
- 229940125027 ensovibep Drugs 0.000 description 4
- 229950003662 fenretinide Drugs 0.000 description 4
- 229950002031 galidesivir Drugs 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 125000002346 iodo group Chemical group I* 0.000 description 4
- 229950007439 lenzilumab Drugs 0.000 description 4
- 229940121292 leronlimab Drugs 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- GSNHKUDZZFZSJB-QYOOZWMWSA-N maraviroc Chemical compound CC(C)C1=NN=C(C)N1[C@@H]1C[C@H](N2CC[C@H](NC(=O)C3CCC(F)(F)CC3)C=3C=CC=CC=3)CC[C@H]2C1 GSNHKUDZZFZSJB-QYOOZWMWSA-N 0.000 description 4
- 229960004710 maraviroc Drugs 0.000 description 4
- HTNPEHXGEKVIHG-QCNRFFRDSA-N molnupiravir Chemical compound C(OC(=O)C(C)C)[C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C(=O)N=C(NO)C=C1 HTNPEHXGEKVIHG-QCNRFFRDSA-N 0.000 description 4
- HTNPEHXGEKVIHG-ZJTJHKMLSA-N molnupiravir Chemical compound CC(C)C(=O)OC[C@H]1O[C@H](C(O)C1O)N1C=C\C(NC1=O)=N\O HTNPEHXGEKVIHG-ZJTJHKMLSA-N 0.000 description 4
- 229940075124 molnupiravir Drugs 0.000 description 4
- ULTDEARCBRNRGR-UHFFFAOYSA-N n-[4-[[2-[4-bromo-3-(3-chloro-5-cyanophenoxy)-2-fluorophenyl]acetyl]amino]-3-chlorophenyl]sulfonylpropanamide Chemical compound ClC1=CC(S(=O)(=O)NC(=O)CC)=CC=C1NC(=O)CC1=CC=C(Br)C(OC=2C=C(C=C(Cl)C=2)C#N)=C1F ULTDEARCBRNRGR-UHFFFAOYSA-N 0.000 description 4
- 229950009865 nafamostat Drugs 0.000 description 4
- RHBRMCOKKKZVRY-ITLPAZOVSA-N naltrexone hydrochloride Chemical compound Cl.N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 RHBRMCOKKKZVRY-ITLPAZOVSA-N 0.000 description 4
- 229940125674 nirmatrelvir Drugs 0.000 description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 4
- 229940013982 octagam Drugs 0.000 description 4
- 229950010006 olokizumab Drugs 0.000 description 4
- 229950007074 opaganib Drugs 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 125000004290 pyrazolidin-3-yl group Chemical group [H]N1N([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 4
- 229940051283 regdanvimab Drugs 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 229960000311 ritonavir Drugs 0.000 description 4
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 229950006898 silmitasertib Drugs 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 4
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 4
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 4
- 229940033663 thimerosal Drugs 0.000 description 4
- 229960003989 tocilizumab Drugs 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 229950011232 tradipitant Drugs 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 229950010644 vidofludimus Drugs 0.000 description 4
- 229940100050 virazole Drugs 0.000 description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 3
- DSLZVSRJTYRBFB-UHFFFAOYSA-N Galactaric acid Natural products OC(=O)C(O)C(O)C(O)C(O)C(O)=O DSLZVSRJTYRBFB-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 description 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 3
- 108010076039 Polyproteins Proteins 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 3
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 3
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000004202 carbamide Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229910052681 coesite Inorganic materials 0.000 description 3
- 229910052906 cristobalite Inorganic materials 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 235000019253 formic acid Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- DSLZVSRJTYRBFB-DUHBMQHGSA-N galactaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O DSLZVSRJTYRBFB-DUHBMQHGSA-N 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 125000004438 haloalkoxy group Chemical group 0.000 description 3
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 3
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 3
- 239000012948 isocyanate Substances 0.000 description 3
- 150000002513 isocyanates Chemical class 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 3
- 125000004274 oxetan-2-yl group Chemical group [H]C1([H])OC([H])(*)C1([H])[H] 0.000 description 3
- 125000006299 oxetan-3-yl group Chemical group [H]C1([H])OC([H])([H])C1([H])* 0.000 description 3
- 125000003566 oxetanyl group Chemical group 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 125000006684 polyhaloalkyl group Polymers 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000010898 silica gel chromatography Methods 0.000 description 3
- 235000015424 sodium Nutrition 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008117 stearic acid Substances 0.000 description 3
- 229910052682 stishovite Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 125000004275 thietan-2-yl group Chemical group [H]C1([H])SC([H])(*)C1([H])[H] 0.000 description 3
- 125000006300 thietan-3-yl group Chemical group [H]C1([H])SC([H])([H])C1([H])* 0.000 description 3
- 125000002053 thietanyl group Chemical group 0.000 description 3
- 229910052905 tridymite Inorganic materials 0.000 description 3
- UCPYLLCMEDAXFR-UHFFFAOYSA-N triphosgene Chemical compound ClC(Cl)(Cl)OC(=O)OC(Cl)(Cl)Cl UCPYLLCMEDAXFR-UHFFFAOYSA-N 0.000 description 3
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 description 2
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 description 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 2
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- NQQRXZOPZBKCNF-NSCUHMNNSA-N (e)-but-2-enamide Chemical compound C\C=C\C(N)=O NQQRXZOPZBKCNF-NSCUHMNNSA-N 0.000 description 2
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- LNETULKMXZVUST-UHFFFAOYSA-N 1-naphthoic acid Chemical compound C1=CC=C2C(C(=O)O)=CC=CC2=C1 LNETULKMXZVUST-UHFFFAOYSA-N 0.000 description 2
- QPMMSLPZMCHAFM-UHFFFAOYSA-N 2-amino-3-fluoro-5-(trifluoromethyl)benzoic acid Chemical compound Nc1c(F)cc(cc1C(O)=O)C(F)(F)F QPMMSLPZMCHAFM-UHFFFAOYSA-N 0.000 description 2
- HZOXFSHBNJIBDZ-UHFFFAOYSA-N 2-amino-4-fluoro-5-(trifluoromethyl)benzoic acid Chemical compound Nc1cc(F)c(cc1C(O)=O)C(F)(F)F HZOXFSHBNJIBDZ-UHFFFAOYSA-N 0.000 description 2
- UZCLUOWLQYOFSZ-UHFFFAOYSA-N 2-fluoro-6-iodo-4-(trifluoromethyl)aniline Chemical compound NC1=C(F)C=C(C(F)(F)F)C=C1I UZCLUOWLQYOFSZ-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- NAKZCKOHULJEID-UHFFFAOYSA-N 2-methoxy-5-(trifluoromethyl)benzoic acid Chemical compound COC1=CC=C(C(F)(F)F)C=C1C(O)=O NAKZCKOHULJEID-UHFFFAOYSA-N 0.000 description 2
- 101800000504 3C-like protease Proteins 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- UYNVMODNBIQBMV-UHFFFAOYSA-N 4-[1-hydroxy-2-[4-(phenylmethyl)-1-piperidinyl]propyl]phenol Chemical compound C1CC(CC=2C=CC=CC=2)CCN1C(C)C(O)C1=CC=C(O)C=C1 UYNVMODNBIQBMV-UHFFFAOYSA-N 0.000 description 2
- KCBJGVDOSBKVKP-UHFFFAOYSA-N 4-[4,4-dimethyl-3-[6-[3-(1,3-oxazol-2-yl)propyl]pyridin-3-yl]-5-oxo-2-sulfanylideneimidazolidin-1-yl]-3-fluoro-2-(trifluoromethyl)benzonitrile Chemical compound O=C1C(C)(C)N(C=2C=NC(CCCC=3OC=CN=3)=CC=2)C(=S)N1C1=CC=C(C#N)C(C(F)(F)F)=C1F KCBJGVDOSBKVKP-UHFFFAOYSA-N 0.000 description 2
- AGQDEXWRUJOXTB-UHFFFAOYSA-N 5-fluoro-2-iodo-4-(trifluoromethyl)aniline Chemical compound NC1=CC(F)=C(C(F)(F)F)C=C1I AGQDEXWRUJOXTB-UHFFFAOYSA-N 0.000 description 2
- QMPBBNUOBOFBFS-UHFFFAOYSA-N 6-[(6-chloro-2-methylindazol-5-yl)amino]-3-[(1-methyl-1,2,4-triazol-3-yl)methyl]-1-[(2,4,5-trifluorophenyl)methyl]-1,3,5-triazine-2,4-dione Chemical compound CN1N=C(C=C(C(/N=C(\NC(N2CC3=NN(C)C=N3)=O)/N(CC(C=C(C(F)=C3)F)=C3F)C2=O)=C2)Cl)C2=C1 QMPBBNUOBOFBFS-UHFFFAOYSA-N 0.000 description 2
- BNMFQWUHWYJTRI-BQFCYCMXSA-N 7-chloro-N-[(2S)-1-[[(1S)-1-cyano-2-[(3S)-2-oxopiperidin-3-yl]ethyl]amino]-3-cyclopropyl-1-oxopropan-2-yl]-1H-indole-2-carboxamide Chemical compound ClC=1C=CC=C2C=C(NC=12)C(=O)N[C@H](C(=O)N[C@@H](C[C@H]1C(NCCC1)=O)C#N)CC1CC1 BNMFQWUHWYJTRI-BQFCYCMXSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 241000004176 Alphacoronavirus Species 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 2
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 description 2
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 description 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 description 2
- POIBEQVGFWAAOT-UHFFFAOYSA-N CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)c1cc(Cl)c(cc1Br)C(F)(F)F Chemical compound CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)c1cc(Cl)c(cc1Br)C(F)(F)F POIBEQVGFWAAOT-UHFFFAOYSA-N 0.000 description 2
- JWBTUSHEZRQZJP-UHFFFAOYSA-N CC(C)(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O Chemical compound CC(C)(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O JWBTUSHEZRQZJP-UHFFFAOYSA-N 0.000 description 2
- CADFXPDIRRJKLE-UHFFFAOYSA-N CC(C=CN=C1)=C1N(C(C1=CC(C(F)(F)F)=CC=C1N1)=O)C1=O Chemical compound CC(C=CN=C1)=C1N(C(C1=CC(C(F)(F)F)=CC=C1N1)=O)C1=O CADFXPDIRRJKLE-UHFFFAOYSA-N 0.000 description 2
- RDTWJIKTQCRHGT-UHFFFAOYSA-N COC(C(CN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O)=C)=O Chemical compound COC(C(CN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O)=C)=O RDTWJIKTQCRHGT-UHFFFAOYSA-N 0.000 description 2
- LNYRJHNJCZUEFW-UHFFFAOYSA-N COC(C=C1C(N2C3=CN=CC4=CC=CC=C34)=O)=CC=C1NC2=O Chemical compound COC(C=C1C(N2C3=CN=CC4=CC=CC=C34)=O)=CC=C1NC2=O LNYRJHNJCZUEFW-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 2
- 108700022150 Designed Ankyrin Repeat Proteins Proteins 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- DYEFUKCXAQOFHX-UHFFFAOYSA-N Ebselen Chemical compound [se]1C2=CC=CC=C2C(=O)N1C1=CC=CC=C1 DYEFUKCXAQOFHX-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 101710114810 Glycoprotein Proteins 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 108010063738 Interleukins Proteins 0.000 description 2
- 102000015696 Interleukins Human genes 0.000 description 2
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 239000002139 L01XE22 - Masitinib Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000034486 Multi-organ failure Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- GRBGMIJFUWYQRK-UHFFFAOYSA-N N#CCN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O Chemical compound N#CCN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O GRBGMIJFUWYQRK-UHFFFAOYSA-N 0.000 description 2
- DAWGNIWTSCDYBM-UHFFFAOYSA-N NC(C1=CN=CC(N(C(C2=CC(C(F)(F)F)=CC=C2N2)=O)C2=O)=C1)=O Chemical compound NC(C1=CN=CC(N(C(C2=CC(C(F)(F)F)=CC=C2N2)=O)C2=O)=C1)=O DAWGNIWTSCDYBM-UHFFFAOYSA-N 0.000 description 2
- ZCDITIPRQHCHDM-UHFFFAOYSA-N NC1=C(C=NC=C2N(C(C3=CC(C(F)(F)F)=CC=C3N3)=O)C3=O)C2=CC=C1 Chemical compound NC1=C(C=NC=C2N(C(C3=CC(C(F)(F)F)=CC=C3N3)=O)C3=O)C2=CC=C1 ZCDITIPRQHCHDM-UHFFFAOYSA-N 0.000 description 2
- WGWQVZUJTROUAY-UHFFFAOYSA-N O=C(C(C(N1)=C2)=CC(C(F)(F)F)=C2F)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(C(C(N1)=C2)=CC(C(F)(F)F)=C2F)N(C2=CN=CC3=CC=CC=C23)C1=O WGWQVZUJTROUAY-UHFFFAOYSA-N 0.000 description 2
- GIYUKEKJCDAREG-UHFFFAOYSA-N O=C(C(C=C(C(F)(F)F)C=C1)=C1O1)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(C(C=C(C(F)(F)F)C=C1)=C1O1)N(C2=CN=CC3=CC=CC=C23)C1=O GIYUKEKJCDAREG-UHFFFAOYSA-N 0.000 description 2
- QORFRXHURCKFOP-UHFFFAOYSA-N O=C(C1=C(N2)N=CC(C(F)(F)F)=C1)N(C1=CN=CC3=CC=CC=C13)C2=O Chemical compound O=C(C1=C(N2)N=CC(C(F)(F)F)=C1)N(C1=CN=CC3=CC=CC=C13)C2=O QORFRXHURCKFOP-UHFFFAOYSA-N 0.000 description 2
- XKJUVFWVEXXKEO-UHFFFAOYSA-N O=C(C1=CC(Br)=CC=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(C1=CC(Br)=CC=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O XKJUVFWVEXXKEO-UHFFFAOYSA-N 0.000 description 2
- GXHFLAJLOVVIIB-UHFFFAOYSA-N O=C(C1=CC(C(F)(F)F)=CC(F)=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(C1=CC(C(F)(F)F)=CC(F)=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O GXHFLAJLOVVIIB-UHFFFAOYSA-N 0.000 description 2
- BQFPIVLHEYZZDS-UHFFFAOYSA-N O=C(C1=CC(C(F)(F)F)=CC=C1N1)N(C2=CN=CC3=C2CCCC3)C1=O Chemical compound O=C(C1=CC(C(F)(F)F)=CC=C1N1)N(C2=CN=CC3=C2CCCC3)C1=O BQFPIVLHEYZZDS-UHFFFAOYSA-N 0.000 description 2
- NQSBAHWUQJOCAW-UHFFFAOYSA-N O=C(C1=CC(C(F)(F)F)=CC=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(C1=CC(C(F)(F)F)=CC=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O NQSBAHWUQJOCAW-UHFFFAOYSA-N 0.000 description 2
- IUSQSVLAYHNDQY-UHFFFAOYSA-N O=C(C1=CC(OC(F)(F)F)=CC=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(C1=CC(OC(F)(F)F)=CC=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O IUSQSVLAYHNDQY-UHFFFAOYSA-N 0.000 description 2
- YTPMGGNBJYPOED-UHFFFAOYSA-N O=C(CC1=CC=C(C(F)(F)F)C=C11)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(CC1=CC=C(C(F)(F)F)C=C11)N(C2=CN=CC3=CC=CC=C23)C1=O YTPMGGNBJYPOED-UHFFFAOYSA-N 0.000 description 2
- 101800004803 Papain-like protease Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 229940126246 S-217622 Drugs 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 101710167605 Spike glycoprotein Proteins 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- JQUNFHFWXCXPRK-AMMMHQJVSA-N [(3as,4r,6ar)-2,3,3a,4,5,6a-hexahydrofuro[2,3-b]furan-4-yl] n-[(2s,3r)-4-[[2-[(1-cyclopentylpiperidin-4-yl)amino]-1,3-benzothiazol-6-yl]sulfonyl-(2-methylpropyl)amino]-3-hydroxy-1-phenylbutan-2-yl]carbamate Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=C2SC(NC3CCN(CC3)C3CCCC3)=NC2=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 JQUNFHFWXCXPRK-AMMMHQJVSA-N 0.000 description 2
- YFPCUOXWZGYBEL-UHFFFAOYSA-L ac1mt69y Chemical compound C1=C(N2[Sn]N34)C(C=C)=C(C)C2=CC(=N2)C(C)=C(CCC(O)=O)C2=CC3=C(CCC(O)=O)C(C)=C4C=C2C(C=C)=C(C)C1=N2 YFPCUOXWZGYBEL-UHFFFAOYSA-L 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229940119059 actemra Drugs 0.000 description 2
- 206010069351 acute lung injury Diseases 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229940051936 alunacedase alfa Drugs 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 2
- NETXMUIMUZJUTB-UHFFFAOYSA-N apabetalone Chemical compound C=1C(OC)=CC(OC)=C(C(N2)=O)C=1N=C2C1=CC(C)=C(OCCO)C(C)=C1 NETXMUIMUZJUTB-UHFFFAOYSA-N 0.000 description 2
- 229950002797 apabetalone Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000004069 aziridinyl group Chemical group 0.000 description 2
- 229950000971 baricitinib Drugs 0.000 description 2
- XUZMWHLSFXCVMG-UHFFFAOYSA-N baricitinib Chemical compound C1N(S(=O)(=O)CC)CC1(CC#N)N1N=CC(C=2C=3C=CNC=3N=CN=2)=C1 XUZMWHLSFXCVMG-UHFFFAOYSA-N 0.000 description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 125000002100 cyclohexa-1,3-dienyl group Chemical group [H]C1([*])C([H])=C([H])C([H])=C([H])C1([H])[H] 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 150000001975 deuterium Chemical group 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 125000006003 dichloroethyl group Chemical group 0.000 description 2
- 125000004774 dichlorofluoromethyl group Chemical group FC(Cl)(Cl)* 0.000 description 2
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 description 2
- 125000006001 difluoroethyl group Chemical group 0.000 description 2
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
- 125000004982 dihaloalkyl group Chemical group 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 241001493065 dsRNA viruses Species 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- CYCFEEXTLQGJEL-XEOXDSMQSA-N ethyl 4-[(2s)-3-[3-[(e)-(hydroxyhydrazinylidene)methyl]phenyl]-2-[[2,4,6-tri(propan-2-yl)phenyl]sulfonylamino]propanoyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OCC)CCN1C(=O)[C@@H](NS(=O)(=O)C=1C(=CC(=CC=1C(C)C)C(C)C)C(C)C)CC1=CC=CC(\C=N\NO)=C1 CYCFEEXTLQGJEL-XEOXDSMQSA-N 0.000 description 2
- 125000004785 fluoromethoxy group Chemical group [H]C([H])(F)O* 0.000 description 2
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 238000001640 fractional crystallisation Methods 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 125000006343 heptafluoro propyl group Chemical group 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 229960003998 ifenprodil Drugs 0.000 description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 2
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 229960002510 mandelic acid Drugs 0.000 description 2
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 description 2
- 229960004655 masitinib Drugs 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- DPWXAZXVYWXYAW-UHFFFAOYSA-N methyl 2-amino-3-fluoro-5-(trifluoromethyl)benzoate Chemical compound COC(=O)c1cc(cc(F)c1N)C(F)(F)F DPWXAZXVYWXYAW-UHFFFAOYSA-N 0.000 description 2
- HZPNRRQUXHEWPH-UHFFFAOYSA-N methyl 2-amino-4-fluoro-5-(trifluoromethyl)benzoate Chemical compound COC(=O)c1cc(c(F)cc1N)C(F)(F)F HZPNRRQUXHEWPH-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000006682 monohaloalkyl group Chemical group 0.000 description 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 2
- RHJLQMVZXQKJKB-FPHSVDBKSA-N n-[(2s)-1-[[(e,3s)-1-(benzenesulfonyl)-5-phenylpent-1-en-3-yl]amino]-1-oxo-3-phenylpropan-2-yl]-4-methylpiperazine-1-carboxamide Chemical compound C1CN(C)CCN1C(=O)N[C@H](C(=O)N[C@@H](CCC=1C=CC=CC=1)\C=C\S(=O)(=O)C=1C=CC=CC=1)CC1=CC=CC=C1 RHJLQMVZXQKJKB-FPHSVDBKSA-N 0.000 description 2
- 229940015638 narsoplimab Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229940125675 paxlovid Drugs 0.000 description 2
- 125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 2
- 239000000816 peptidomimetic Substances 0.000 description 2
- 229950008499 plitidepsin Drugs 0.000 description 2
- UUSZLLQJYRSZIS-LXNNNBEUSA-N plitidepsin Chemical compound CN([C@H](CC(C)C)C(=O)N[C@@H]1C(=O)N[C@@H]([C@H](CC(=O)O[C@H](C(=O)[C@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(OC)=CC=2)C(=O)O[C@@H]1C)C(C)C)O)[C@@H](C)CC)C(=O)[C@@H]1CCCN1C(=O)C(C)=O UUSZLLQJYRSZIS-LXNNNBEUSA-N 0.000 description 2
- 108010049948 plitidepsin Proteins 0.000 description 2
- 238000002600 positron emission tomography Methods 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 229940125286 pruxelutamide Drugs 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 229950006348 sarilumab Drugs 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical compound OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 description 2
- 238000002603 single-photon emission computed tomography Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 229950000856 tafenoquine Drugs 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- MHYGQXWCZAYSLJ-UHFFFAOYSA-N tert-butyl-chloro-diphenylsilane Chemical compound C=1C=CC=CC=1[Si](Cl)(C(C)(C)C)C1=CC=CC=C1 MHYGQXWCZAYSLJ-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000001730 thiiranyl group Chemical group 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- FNCMIJWGZNHSBF-UHFFFAOYSA-N trabedersen Chemical compound CC1=CN(C2CC(O)C(COP(=O)(S)OC3CC(OC3COP(=O)(S)OC4CC(OC4COP(=O)(S)OC5CC(OC5COP(=O)(S)OC6CC(OC6COP(=O)(S)OC7CC(OC7COP(=O)(S)OC8CC(OC8COP(=O)(S)OC9CC(OC9COP(=O)(S)OC%10CC(OC%10COP(=O)(S)OC%11CC(OC%11COP(=O)(S)OC%12CC(OC%12COP(=O)(S)OC%13CC(OC%13COP(=O)(S)OC%14CC(OC%14COP(=O)(S)OC%15CC(OC%15CO)N%16C=CC(=NC%16=O)N)n%17cnc%18C(=O)NC(=Nc%17%18)N)n%19cnc%20C(=O)NC(=Nc%19%20)N)N%21C=CC(=NC%21=O)N)n%22cnc%23c(N)ncnc%22%23)N%24C=C(C)C(=O)NC%24=O)n%25cnc%26C(=O)NC(=Nc%25%26)N)N%27C=C(C)C(=O)NC%27=O)N%28C=CC(=NC%28=O)N)N%29C=C(C)C(=O)NC%29=O)n%30cnc%31c(N)ncnc%30%31)N%32C=C(C)C(=O)NC%32=O)N%33C=C(C)C(=O)NC%33=O)O2)C(=O)NC1=O.CC%34=CN(C%35CC(OP(=O)(S)OCC%36OC(CC%36OP(=O)(S)OCC%37OC(CC%37OP(=O)(S)OCC%38OC(CC%38O)n%39cnc%40c(N)ncnc%39%40)N%41C=C(C)C(=O)NC%41=O)n%42cnc%43C(=O)NC(=Nc%42%43)N)C(COP(=O)S)O%35)C(=O)NC%34=O FNCMIJWGZNHSBF-UHFFFAOYSA-N 0.000 description 2
- 229950002824 trabedersen Drugs 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 description 2
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 2
- 229950008529 upamostat Drugs 0.000 description 2
- 230000029812 viral genome replication Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- DNISEZBAYYIQFB-PHDIDXHHSA-N (2r,3r)-2,3-diacetyloxybutanedioic acid Chemical compound CC(=O)O[C@@H](C(O)=O)[C@H](C(O)=O)OC(C)=O DNISEZBAYYIQFB-PHDIDXHHSA-N 0.000 description 1
- KWMLJOLKUYYJFJ-DIHCEYMBSA-N (2r,3s,4r,5r)-2,3,4,5,6,7-hexahydroxyheptanoic acid Chemical compound OCC(O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-DIHCEYMBSA-N 0.000 description 1
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 1
- 125000006536 (C1-C2)alkoxy group Chemical group 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- SJJCQDRGABAVBB-UHFFFAOYSA-N 1-hydroxy-2-naphthoic acid Chemical compound C1=CC=CC2=C(O)C(C(=O)O)=CC=C21 SJJCQDRGABAVBB-UHFFFAOYSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- DCYGAPKNVCQNOE-UHFFFAOYSA-N 2,2,2-triphenylacetic acid Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(C(=O)O)C1=CC=CC=C1 DCYGAPKNVCQNOE-UHFFFAOYSA-N 0.000 description 1
- 125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- OWUAHASLKZBQTD-UHFFFAOYSA-N 2-bromo-1-methoxy-4-(trifluoromethyl)benzene Chemical compound COC1=CC=C(C(F)(F)F)C=C1Br OWUAHASLKZBQTD-UHFFFAOYSA-N 0.000 description 1
- NUSMLYKXERNHEB-UHFFFAOYSA-N 2-bromo-5-chloro-4-(trifluoromethyl)aniline Chemical compound NC1=CC(Cl)=C(C(F)(F)F)C=C1Br NUSMLYKXERNHEB-UHFFFAOYSA-N 0.000 description 1
- RMSKYTKOFDQVEL-UHFFFAOYSA-N 2-chloro-5-(trifluoromethyl)pyridine-3-carboxylic acid Chemical compound OC(=O)C1=CC(C(F)(F)F)=CN=C1Cl RMSKYTKOFDQVEL-UHFFFAOYSA-N 0.000 description 1
- ARHDUOQIXLGANT-UHFFFAOYSA-N 2-fluoro-4-(trifluoromethyl)aniline Chemical compound NC1=CC=C(C(F)(F)F)C=C1F ARHDUOQIXLGANT-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- CRRVZRDISHOQQL-UHFFFAOYSA-N 3-fluoro-4-(trifluoromethyl)aniline Chemical compound NC1=CC=C(C(F)(F)F)C(F)=C1 CRRVZRDISHOQQL-UHFFFAOYSA-N 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- 125000006164 6-membered heteroaryl group Chemical group 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010002653 Anosmia Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- VKTLLQFDTLQXEM-UHFFFAOYSA-N C#CC(N=CC1=CC=CC=C11)=C1N(C(C1=CC(C(F)(F)F)=CC=C1N1)=O)C1=O Chemical compound C#CC(N=CC1=CC=CC=C11)=C1N(C(C1=CC(C(F)(F)F)=CC=C1N1)=O)C1=O VKTLLQFDTLQXEM-UHFFFAOYSA-N 0.000 description 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 description 1
- 101710155857 C-C motif chemokine 2 Proteins 0.000 description 1
- 101710155856 C-C motif chemokine 3 Proteins 0.000 description 1
- FAZAQULOYAPLSL-UHFFFAOYSA-N C=C(CN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O)C(N)=O Chemical compound C=C(CN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O)C(N)=O FAZAQULOYAPLSL-UHFFFAOYSA-N 0.000 description 1
- RDXOZVGQMJDEGH-UHFFFAOYSA-N C=C(CN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O)C(O)=O Chemical compound C=C(CN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O)C(O)=O RDXOZVGQMJDEGH-UHFFFAOYSA-N 0.000 description 1
- QSLVKWPDLJGHMW-UHFFFAOYSA-N CC(C(C(F)(F)F)=CC=C1N(C)C(N2C3=CN=CC4=CC=CC=C34)=O)=C1C2=O Chemical compound CC(C(C(F)(F)F)=CC=C1N(C)C(N2C3=CN=CC4=CC=CC=C34)=O)=C1C2=O QSLVKWPDLJGHMW-UHFFFAOYSA-N 0.000 description 1
- QPZLANHIEJYRGM-UHFFFAOYSA-N CC(C(C(F)(F)F)=CC=C1NC(N2C3=CN=CC4=CC=CC=C34)=O)=C1C2=O Chemical compound CC(C(C(F)(F)F)=CC=C1NC(N2C3=CN=CC4=CC=CC=C34)=O)=C1C2=O QPZLANHIEJYRGM-UHFFFAOYSA-N 0.000 description 1
- FOVNQGXUVAIEEL-UHFFFAOYSA-N CC(C(C=C1C(N2C3=CN=CC4=CC=CC=C34)=O)=CC=C1NC2=O)(F)F Chemical compound CC(C(C=C1C(N2C3=CN=CC4=CC=CC=C34)=O)=CC=C1NC2=O)(F)F FOVNQGXUVAIEEL-UHFFFAOYSA-N 0.000 description 1
- CUXYLDLZOCXWCE-UHFFFAOYSA-N CC(C)(C(C=C(C(F)(F)F)C=C1C(N2C3=CN=CC4=CC=CC=C34)=O)=C1NC2=O)O Chemical compound CC(C)(C(C=C(C(F)(F)F)C=C1C(N2C3=CN=CC4=CC=CC=C34)=O)=C1NC2=O)O CUXYLDLZOCXWCE-UHFFFAOYSA-N 0.000 description 1
- QWWYEHSZTOCBIR-UHFFFAOYSA-N CC(C)(C(C=C1C(N2C3=CN=CC4=CC=CC=C34)=O)=CC=C1NC2=O)O Chemical compound CC(C)(C(C=C1C(N2C3=CN=CC4=CC=CC=C34)=O)=CC=C1NC2=O)O QWWYEHSZTOCBIR-UHFFFAOYSA-N 0.000 description 1
- CHXKOZCWAXNQTJ-UHFFFAOYSA-N CC(C)(CCN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O)O Chemical compound CC(C)(CCN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O)O CHXKOZCWAXNQTJ-UHFFFAOYSA-N 0.000 description 1
- QMTOODZVMCTUPH-UHFFFAOYSA-N CC(C)C(C=C1C(N2C3=CN=CC4=CC=CC=C34)=O)=CC=C1N(C)C2=O Chemical compound CC(C)C(C=C1C(N2C3=CN=CC4=CC=CC=C34)=O)=CC=C1N(C)C2=O QMTOODZVMCTUPH-UHFFFAOYSA-N 0.000 description 1
- LCQKIBQUBZCTJI-UHFFFAOYSA-N CC(C)C(C=C1C(N2C3=CN=CC4=CC=CC=C34)=O)=CC=C1NC2=O Chemical compound CC(C)C(C=C1C(N2C3=CN=CC4=CC=CC=C34)=O)=CC=C1NC2=O LCQKIBQUBZCTJI-UHFFFAOYSA-N 0.000 description 1
- YEZCHDSVZBOTIS-UHFFFAOYSA-N CC(C)N(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O Chemical compound CC(C)N(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O YEZCHDSVZBOTIS-UHFFFAOYSA-N 0.000 description 1
- DPMQYUUEXOHSAW-UHFFFAOYSA-N CC(C=C(C(F)(F)F)C=C1C(N2C3=CN=CC4=CC=CC=C34)=O)=C1NC2=O Chemical compound CC(C=C(C(F)(F)F)C=C1C(N2C3=CN=CC4=CC=CC=C34)=O)=C1NC2=O DPMQYUUEXOHSAW-UHFFFAOYSA-N 0.000 description 1
- MYGWTAMHBJWOSK-UHFFFAOYSA-N CC(C=C1NC(N2C3=CN=CC4=CC=CC=C34)=O)=C(C(F)(F)F)C=C1C2=O Chemical compound CC(C=C1NC(N2C3=CN=CC4=CC=CC=C34)=O)=C(C(F)(F)F)C=C1C2=O MYGWTAMHBJWOSK-UHFFFAOYSA-N 0.000 description 1
- MYOOCFOZUCUTDW-UHFFFAOYSA-N CC1=C2C(N(C(C3=CC(C(F)(F)F)=CC=C3N3)=O)C3=O)=CN=CC2=CC=C1 Chemical compound CC1=C2C(N(C(C3=CC(C(F)(F)F)=CC=C3N3)=O)C3=O)=CN=CC2=CC=C1 MYOOCFOZUCUTDW-UHFFFAOYSA-N 0.000 description 1
- HSQDGCBHCWCFMR-UHFFFAOYSA-N CCN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O Chemical compound CCN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O HSQDGCBHCWCFMR-UHFFFAOYSA-N 0.000 description 1
- OTDBHOWRLFBNEA-UHFFFAOYSA-N CN(C1=CC(F)=C(C2CC2)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O Chemical compound CN(C1=CC(F)=C(C2CC2)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O OTDBHOWRLFBNEA-UHFFFAOYSA-N 0.000 description 1
- YHEHDCHUDILTNW-UHFFFAOYSA-N CN(C1=CC=C(C(F)(F)F)C(F)=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O Chemical compound CN(C1=CC=C(C(F)(F)F)C(F)=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O YHEHDCHUDILTNW-UHFFFAOYSA-N 0.000 description 1
- JSDNIGWFHHHKMQ-UHFFFAOYSA-N CN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O Chemical compound CN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O JSDNIGWFHHHKMQ-UHFFFAOYSA-N 0.000 description 1
- CDGGGKUBBGLLDN-UHFFFAOYSA-N COC(=O)c1cc(c(C)cc1N)C(F)(F)F Chemical compound COC(=O)c1cc(c(C)cc1N)C(F)(F)F CDGGGKUBBGLLDN-UHFFFAOYSA-N 0.000 description 1
- NDQAKCREVGMZPQ-UHFFFAOYSA-N COCCN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O Chemical compound COCCN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O NDQAKCREVGMZPQ-UHFFFAOYSA-N 0.000 description 1
- ZVCPIZYILIJBEH-UHFFFAOYSA-N COCCNC(C1=CC=C(C=NC=C2N(C(C3=CC(C(F)(F)F)=CC=C3N3)=O)C3=O)C2=C1)=O Chemical compound COCCNC(C1=CC=C(C=NC=C2N(C(C3=CC(C(F)(F)F)=CC=C3N3)=O)C3=O)C2=C1)=O ZVCPIZYILIJBEH-UHFFFAOYSA-N 0.000 description 1
- OMLVMTGAHRMHKI-UHFFFAOYSA-N CS(C1=CC=C(C=NC=C2N(C(C3=CC(C(F)(F)F)=CC=C3N3CCC#N)=O)C3=O)C2=C1)(=O)=O Chemical compound CS(C1=CC=C(C=NC=C2N(C(C3=CC(C(F)(F)F)=CC=C3N3CCC#N)=O)C3=O)C2=C1)(=O)=O OMLVMTGAHRMHKI-UHFFFAOYSA-N 0.000 description 1
- XYEMCODOPNNNBC-ZDUSSCGKSA-N C[C@@H](CCO)N(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O Chemical compound C[C@@H](CCO)N(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O XYEMCODOPNNNBC-ZDUSSCGKSA-N 0.000 description 1
- OLMKSKKBYMQBTK-CYBMUJFWSA-N C[C@H](CCN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O)O Chemical compound C[C@H](CCN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O)O OLMKSKKBYMQBTK-CYBMUJFWSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000000013 Chemokine CCL3 Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 241001461743 Deltacoronavirus Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 241000008920 Gammacoronavirus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- JWSPWTOQRKTWPJ-UHFFFAOYSA-N N#CC(N=CC1=CC=CC=C11)=C1N(C(C1=CC(C(F)(F)F)=CC=C1N1)=O)C1=O Chemical compound N#CC(N=CC1=CC=CC=C11)=C1N(C(C1=CC(C(F)(F)F)=CC=C1N1)=O)C1=O JWSPWTOQRKTWPJ-UHFFFAOYSA-N 0.000 description 1
- GFVDZLDMFXNOQM-UHFFFAOYSA-N N#CC1(CN(C2=CC=C(C(F)(F)F)C=C2C(N2C3=CN=CC4=CC=CC=C34)=O)C2=O)CC1 Chemical compound N#CC1(CN(C2=CC=C(C(F)(F)F)C=C2C(N2C3=CN=CC4=CC=CC=C34)=O)C2=O)CC1 GFVDZLDMFXNOQM-UHFFFAOYSA-N 0.000 description 1
- LOWGMUBZFCEBFH-UHFFFAOYSA-N N#CCC1(CC1)N(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O Chemical compound N#CCC1(CC1)N(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O LOWGMUBZFCEBFH-UHFFFAOYSA-N 0.000 description 1
- VGUWXIPGMSQCSQ-UHFFFAOYSA-N N#CCCN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC(F)=C23)=O)C1=O Chemical compound N#CCCN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC(F)=C23)=O)C1=O VGUWXIPGMSQCSQ-UHFFFAOYSA-N 0.000 description 1
- HJHOVUOGNVIZJT-UHFFFAOYSA-N N#CCCN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O Chemical compound N#CCCN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O HJHOVUOGNVIZJT-UHFFFAOYSA-N 0.000 description 1
- YHWNBBFLSPUMLY-UHFFFAOYSA-N N#CCN(C(CC(CC(F)(F)F)C1)=C1C(N1C2=CN=CC3=CC=CC(F)=C23)=O)C1=O Chemical compound N#CCN(C(CC(CC(F)(F)F)C1)=C1C(N1C2=CN=CC3=CC=CC(F)=C23)=O)C1=O YHWNBBFLSPUMLY-UHFFFAOYSA-N 0.000 description 1
- HDTNCTMPZJLQQW-UHFFFAOYSA-N N#CCN(C(CC(CF)C1)=C1C(N1C2=CN=CC3=CC=CC(F)=C23)=O)C1=O Chemical compound N#CCN(C(CC(CF)C1)=C1C(N1C2=CN=CC3=CC=CC(F)=C23)=O)C1=O HDTNCTMPZJLQQW-UHFFFAOYSA-N 0.000 description 1
- ISIQYDHKQGITBV-UHFFFAOYSA-N N#CCN(C(CCC1CC(F)(F)F)=C1C(N1C2=CN=CC3=CC=CC(F)=C23)=O)C1=O Chemical compound N#CCN(C(CCC1CC(F)(F)F)=C1C(N1C2=CN=CC3=CC=CC(F)=C23)=O)C1=O ISIQYDHKQGITBV-UHFFFAOYSA-N 0.000 description 1
- GGHFCJKJOIKSCA-UHFFFAOYSA-N N#CCN(C(CCC1CC(F)(F)F)=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O Chemical compound N#CCN(C(CCC1CC(F)(F)F)=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O GGHFCJKJOIKSCA-UHFFFAOYSA-N 0.000 description 1
- NWDOBXYCCIPENY-UHFFFAOYSA-N N#CCN(C(CCC1CF)=C1C(N1C2=CN=CC3=CC=CC(F)=C23)=O)C1=O Chemical compound N#CCN(C(CCC1CF)=C1C(N1C2=CN=CC3=CC=CC(F)=C23)=O)C1=O NWDOBXYCCIPENY-UHFFFAOYSA-N 0.000 description 1
- ZKGNPQKYVKXMGJ-UHFFFAOYSA-N N,N-dimethylacetamide Chemical compound CN(C)C(C)=O.CN(C)C(C)=O ZKGNPQKYVKXMGJ-UHFFFAOYSA-N 0.000 description 1
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- DMCRCJQKESFVFA-UHFFFAOYSA-N NC(C1=CC=CC=C11)=NC=C1N(C(C1=CC(C(F)(F)F)=CC=C1N1)=O)C1=O Chemical compound NC(C1=CC=CC=C11)=NC=C1N(C(C1=CC(C(F)(F)F)=CC=C1N1)=O)C1=O DMCRCJQKESFVFA-UHFFFAOYSA-N 0.000 description 1
- GFPVSHSJUSYOIJ-UHFFFAOYSA-N NC(CN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O)=O Chemical compound NC(CN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O)=O GFPVSHSJUSYOIJ-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- WYBLHDNUERJOGD-UHFFFAOYSA-N O=C(C(C(N1)=C2)=CC(C3CC3)=C2F)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(C(C(N1)=C2)=CC(C3CC3)=C2F)N(C2=CN=CC3=CC=CC=C23)C1=O WYBLHDNUERJOGD-UHFFFAOYSA-N 0.000 description 1
- LNOBPCCEFTWLGK-UHFFFAOYSA-N O=C(C(C(N1)=C2)=CC=C2Cl)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(C(C(N1)=C2)=CC=C2Cl)N(C2=CN=CC3=CC=CC=C23)C1=O LNOBPCCEFTWLGK-UHFFFAOYSA-N 0.000 description 1
- FHBBTILRSWZRBJ-UHFFFAOYSA-N O=C(C(C(N1)=CC=C2C(F)(F)F)=C2F)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(C(C(N1)=CC=C2C(F)(F)F)=C2F)N(C2=CN=CC3=CC=CC=C23)C1=O FHBBTILRSWZRBJ-UHFFFAOYSA-N 0.000 description 1
- NCOXYMHMMBDGJL-UHFFFAOYSA-N O=C(C(C=C(C(F)(F)F)N=C1)=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(C(C=C(C(F)(F)F)N=C1)=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O NCOXYMHMMBDGJL-UHFFFAOYSA-N 0.000 description 1
- VTVSFDFPXXNFQR-UHFFFAOYSA-N O=C(C(CC(CC1)C(F)(F)F)=C1N1)N(C2=CN=CC3=CC=CC(F)=C23)C1=O Chemical compound O=C(C(CC(CC1)C(F)(F)F)=C1N1)N(C2=CN=CC3=CC=CC(F)=C23)C1=O VTVSFDFPXXNFQR-UHFFFAOYSA-N 0.000 description 1
- PSOPHJLWKJAJKA-UHFFFAOYSA-N O=C(C(CC(CC1)C(F)(F)F)=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(C(CC(CC1)C(F)(F)F)=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O PSOPHJLWKJAJKA-UHFFFAOYSA-N 0.000 description 1
- IAKKSWYTEBAVLV-UHFFFAOYSA-N O=C(C(N=C(C(F)(F)F)C=C1)=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(C(N=C(C(F)(F)F)C=C1)=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O IAKKSWYTEBAVLV-UHFFFAOYSA-N 0.000 description 1
- ANFWQIVMQCCGQQ-UHFFFAOYSA-N O=C(C1=CC(C(F)(F)F)=CC(Br)=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(C1=CC(C(F)(F)F)=CC(Br)=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O ANFWQIVMQCCGQQ-UHFFFAOYSA-N 0.000 description 1
- QSFVDWKFGHTQNU-UHFFFAOYSA-N O=C(C1=CC(C(F)(F)F)=CC=C1N1)N(C2=CN=CC3=CC=CC(Br)=C23)C1=O Chemical compound O=C(C1=CC(C(F)(F)F)=CC=C1N1)N(C2=CN=CC3=CC=CC(Br)=C23)C1=O QSFVDWKFGHTQNU-UHFFFAOYSA-N 0.000 description 1
- KVKJSRQTAFJQDS-UHFFFAOYSA-N O=C(C1=CC(C(F)(F)F)=CC=C1N1C2CC2)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(C1=CC(C(F)(F)F)=CC=C1N1C2CC2)N(C2=CN=CC3=CC=CC=C23)C1=O KVKJSRQTAFJQDS-UHFFFAOYSA-N 0.000 description 1
- ZYYFBPZJEYKIEY-UHFFFAOYSA-N O=C(C1=CC(C(F)(F)F)=CC=C1N1CC2=NN=NN2)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(C1=CC(C(F)(F)F)=CC=C1N1CC2=NN=NN2)N(C2=CN=CC3=CC=CC=C23)C1=O ZYYFBPZJEYKIEY-UHFFFAOYSA-N 0.000 description 1
- HSFBRPMGOBTORE-UHFFFAOYSA-N O=C(C1=CC(C(F)(F)F)=CC=C1N1CC2OC2)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(C1=CC(C(F)(F)F)=CC=C1N1CC2OC2)N(C2=CN=CC3=CC=CC=C23)C1=O HSFBRPMGOBTORE-UHFFFAOYSA-N 0.000 description 1
- AFAGNPZCIKMEND-UHFFFAOYSA-N O=C(C1=CC(C(F)(F)F)=CC=C1N1CCF)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(C1=CC(C(F)(F)F)=CC=C1N1CCF)N(C2=CN=CC3=CC=CC=C23)C1=O AFAGNPZCIKMEND-UHFFFAOYSA-N 0.000 description 1
- MNSVDHPWMUBAMR-UHFFFAOYSA-N O=C(C1=CC(C(F)(F)F)=CC=C1N1CCN(CC2)CCC2(F)F)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(C1=CC(C(F)(F)F)=CC=C1N1CCN(CC2)CCC2(F)F)N(C2=CN=CC3=CC=CC=C23)C1=O MNSVDHPWMUBAMR-UHFFFAOYSA-N 0.000 description 1
- JVLPYXJUTDTXHE-UHFFFAOYSA-N O=C(C1=CC(C(F)(F)F)=CC=C1N1CCN(CCC2)CC2(F)F)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(C1=CC(C(F)(F)F)=CC=C1N1CCN(CCC2)CC2(F)F)N(C2=CN=CC3=CC=CC=C23)C1=O JVLPYXJUTDTXHE-UHFFFAOYSA-N 0.000 description 1
- OZFNPIAHTVJAMZ-UHFFFAOYSA-N O=C(C1=CC(C(F)(F)F)=CC=C1N1CCN2CCNCC2)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(C1=CC(C(F)(F)F)=CC=C1N1CCN2CCNCC2)N(C2=CN=CC3=CC=CC=C23)C1=O OZFNPIAHTVJAMZ-UHFFFAOYSA-N 0.000 description 1
- PGRKAUQHXDLOGS-UHFFFAOYSA-N O=C(C1=CC(C(F)(F)F)=CC=C1N1CCN2CCOCC2)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(C1=CC(C(F)(F)F)=CC=C1N1CCN2CCOCC2)N(C2=CN=CC3=CC=CC=C23)C1=O PGRKAUQHXDLOGS-UHFFFAOYSA-N 0.000 description 1
- QJIMHZACUQGSEU-UHFFFAOYSA-N O=C(C1=CC(C(F)F)=CC=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(C1=CC(C(F)F)=CC=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O QJIMHZACUQGSEU-UHFFFAOYSA-N 0.000 description 1
- XKYPTVAULPNHIQ-UHFFFAOYSA-N O=C(C1=CC(C2CC2)=CC=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(C1=CC(C2CC2)=CC=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O XKYPTVAULPNHIQ-UHFFFAOYSA-N 0.000 description 1
- CERWYVCLUAZITP-UHFFFAOYSA-N O=C(C1=CC(Cl)=CC(F)=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(C1=CC(Cl)=CC(F)=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O CERWYVCLUAZITP-UHFFFAOYSA-N 0.000 description 1
- XEXLXEYPXSKOFC-UHFFFAOYSA-N O=C(C1=CC(Cl)=CC=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(C1=CC(Cl)=CC=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O XEXLXEYPXSKOFC-UHFFFAOYSA-N 0.000 description 1
- GTBWUOOVNBDETB-UHFFFAOYSA-N O=C(C1=CC(OC(F)(F)Cl)=CC=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(C1=CC(OC(F)(F)Cl)=CC=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O GTBWUOOVNBDETB-UHFFFAOYSA-N 0.000 description 1
- JXHXZLBIMPLLIF-UHFFFAOYSA-N O=C(C1=CC(OC(F)F)=CC=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O Chemical compound O=C(C1=CC(OC(F)F)=CC=C1N1)N(C2=CN=CC3=CC=CC=C23)C1=O JXHXZLBIMPLLIF-UHFFFAOYSA-N 0.000 description 1
- KOJCEHCOLCMTIR-UHFFFAOYSA-N OC(C1(CC1)C(C=C1C(N2C3=CN=CC4=CC=CC=C34)=O)=CC=C1NC2=O)=O Chemical compound OC(C1(CC1)C(C=C1C(N2C3=CN=CC4=CC=CC=C34)=O)=CC=C1NC2=O)=O KOJCEHCOLCMTIR-UHFFFAOYSA-N 0.000 description 1
- HQHQZWYSCVXEDS-UHFFFAOYSA-N OC(C1(CN(C2=CC=C(C(F)(F)F)C=C2C(N2C3=CN=CC4=CC=CC=C34)=O)C2=O)CC1)=O Chemical compound OC(C1(CN(C2=CC=C(C(F)(F)F)C=C2C(N2C3=CN=CC4=CC=CC=C34)=O)C2=O)CC1)=O HQHQZWYSCVXEDS-UHFFFAOYSA-N 0.000 description 1
- UNQFFPXMJCACDE-UHFFFAOYSA-N OC(CN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O)=O Chemical compound OC(CN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O)=O UNQFFPXMJCACDE-UHFFFAOYSA-N 0.000 description 1
- VXYIFHYTVCTEBL-UHFFFAOYSA-N OCC1(CC1)C(C=C1C(N2C3=CN=CC4=CC=CC=C34)=O)=CC=C1NC2=O Chemical compound OCC1(CC1)C(C=C1C(N2C3=CN=CC4=CC=CC=C34)=O)=CC=C1NC2=O VXYIFHYTVCTEBL-UHFFFAOYSA-N 0.000 description 1
- FRLBAVUVDWHSHG-UHFFFAOYSA-N OCCN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O Chemical compound OCCN(C1=CC=C(C(F)(F)F)C=C1C(N1C2=CN=CC3=CC=CC=C23)=O)C1=O FRLBAVUVDWHSHG-UHFFFAOYSA-N 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 101800001016 Picornain 3C-like protease Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101800000596 Probable picornain 3C-like protease Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 101000933967 Pseudomonas phage KPP25 Major capsid protein Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 101710153041 Replicase polyprotein 1a Proteins 0.000 description 1
- 101710151619 Replicase polyprotein 1ab Proteins 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 238000010976 amide bond formation reaction Methods 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- VJBCNMFKFZIXHC-UHFFFAOYSA-N azanium;2-(4-methyl-5-oxo-4-propan-2-yl-1h-imidazol-2-yl)quinoline-3-carboxylate Chemical compound N.N1C(=O)C(C(C)C)(C)N=C1C1=NC2=CC=CC=C2C=C1C(O)=O VJBCNMFKFZIXHC-UHFFFAOYSA-N 0.000 description 1
- 125000003725 azepanyl group Chemical group 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- OJKZEZMAPKWHTG-UHFFFAOYSA-N bis(2h-triazol-4-yl)methanone Chemical compound C=1NN=NC=1C(=O)C1=CNN=N1 OJKZEZMAPKWHTG-UHFFFAOYSA-N 0.000 description 1
- 229960000517 boceprevir Drugs 0.000 description 1
- LHHCSNFAOIFYRV-DOVBMPENSA-N boceprevir Chemical compound O=C([C@@H]1[C@@H]2[C@@H](C2(C)C)CN1C(=O)[C@@H](NC(=O)NC(C)(C)C)C(C)(C)C)NC(C(=O)C(N)=O)CC1CCC1 LHHCSNFAOIFYRV-DOVBMPENSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 108010079785 calpain inhibitors Proteins 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000012069 chiral reagent Substances 0.000 description 1
- FZFAMSAMCHXGEF-UHFFFAOYSA-N chloro formate Chemical compound ClOC=O FZFAMSAMCHXGEF-UHFFFAOYSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- GHVNFZFCNZKVNT-UHFFFAOYSA-M decanoate Chemical compound CCCCCCCCCC([O-])=O GHVNFZFCNZKVNT-UHFFFAOYSA-M 0.000 description 1
- JHAYEQICABJSTP-UHFFFAOYSA-N decoquinate Chemical group N1C=C(C(=O)OCC)C(=O)C2=C1C=C(OCC)C(OCCCCCCCCCC)=C2 JHAYEQICABJSTP-UHFFFAOYSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 125000005959 diazepanyl group Chemical group 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- CETRZFQIITUQQL-UHFFFAOYSA-N dmso dimethylsulfoxide Chemical compound CS(C)=O.CS(C)=O CETRZFQIITUQQL-UHFFFAOYSA-N 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical compound [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-N ethanedisulfonic acid Chemical compound OS(=O)(=O)CCS(O)(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-N 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 229960000443 hydrochloric acid Drugs 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 229940045996 isethionic acid Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- ISIUXVGHQFJYHM-UHFFFAOYSA-N isoquinolin-4-amine Chemical compound C1=CC=C2C(N)=CN=CC2=C1 ISIUXVGHQFJYHM-UHFFFAOYSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 229960003646 lysine Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000004452 microanalysis Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- LLYKPZOWCPVRPD-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine;n,n-dimethylpyridin-4-amine Chemical compound CN(C)C1=CC=NC=C1.CN(C)C1=CC=CC=N1 LLYKPZOWCPVRPD-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004370 n-butenyl group Chemical group [H]\C([H])=C(/[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000008518 non respiratory effect Effects 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-M octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000019371 penicillin G benzathine Nutrition 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229960005141 piperazine Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- 235000011181 potassium carbonates Nutrition 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- MOODSJOROWROTO-UHFFFAOYSA-N salicylsulfuric acid Chemical compound OC(=O)C1=CC=CC=C1OS(O)(=O)=O MOODSJOROWROTO-UHFFFAOYSA-N 0.000 description 1
- 229940116351 sebacate Drugs 0.000 description 1
- CXMXRPHRNRROMY-UHFFFAOYSA-L sebacate(2-) Chemical compound [O-]C(=O)CCCCCCCCC([O-])=O CXMXRPHRNRROMY-UHFFFAOYSA-L 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910001467 sodium calcium phosphate Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- BSPJDKCMFIPBAW-JPBGFCRCSA-M sodium;(2s)-1-hydroxy-2-[[(2s)-4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]-3-(2-oxopyrrolidin-3-yl)propane-1-sulfonate Chemical compound [Na+].N([C@@H](CC(C)C)C(=O)N[C@@H](CC1C(NCC1)=O)C(O)S([O-])(=O)=O)C(=O)OCC1=CC=CC=C1 BSPJDKCMFIPBAW-JPBGFCRCSA-M 0.000 description 1
- WGRULTCAYDOGQK-UHFFFAOYSA-M sodium;sodium;hydroxide Chemical compound [OH-].[Na].[Na+] WGRULTCAYDOGQK-UHFFFAOYSA-M 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940114926 stearate Drugs 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229940071103 sulfosalicylate Drugs 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- WHRNULOCNSKMGB-UHFFFAOYSA-N tetrahydrofuran thf Chemical compound C1CCOC1.C1CCOC1 WHRNULOCNSKMGB-UHFFFAOYSA-N 0.000 description 1
- PHCBRBWANGJMHS-UHFFFAOYSA-J tetrasodium;disulfate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O PHCBRBWANGJMHS-UHFFFAOYSA-J 0.000 description 1
- 125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001583 thiepanyl group Chemical group 0.000 description 1
- 238000003354 tissue distribution assay Methods 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000004385 trihaloalkyl group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 229950000339 xinafoate Drugs 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the present invention relates to compounds and compositions for the treatment, management and/or prevention of coronaviral related diseases.
- the present invention relates to compounds which are inhibitors of SARS-CoV-2 main protease (M pro ), to pharmaceutical compositions comprising such compounds, to methods for synthesizing such compounds and to methods of using such compounds and compositions for the treatment, management or prevention of coronaviral related diseases.
- M pro main protease
- SARS-CoV-2 is a single positive-stranded RNA virus belonging to the genus Coronavirus ⁇ .
- the SARS-CoV-2 genome is about 30 kb in length, has untranslated regions (UTR) at both ends, and at least 6 complete open reading frame genes (ORF).
- ORF 1a/b directly encodes two polyproteins: polyprotein 1a (pp1a) and polyprotein 1ab (pp1ab). These polypeptides are cleaved by the main protease (M pro ), also known as 3C-like protease (3CLpro), and the papain-like protease (PLpro) into 16 non-structural proteins (nsps).
- M pro main protease
- 3CLpro 3C-like protease
- PLpro papain-like protease
- M pro plays a vital role in the replication cycle of SARS-CoV-2. Therefore, inhibiting the activity of M pro would block viral replication and may provide an effective therapeutic approach for the treatment of COVID-19, the disease caused by SARS-CoV-2, or for diseases caused by other beta-coronaviruses.
- S surface spike glycoprotein
- E envelope protein
- M membrane protein
- N Nucleocapsid protein
- Another aspect of the present invention is a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.
- Another aspect of the present invention is a pharmaceutical composition comprising a compound of the invention, or a pharmaceutically acceptable salt, and one or more pharmaceutically acceptable carriers.
- the invention provides a method ⁇ s for treating, preventing and/or managing a coronaviral-related disease or disorder, wherein the method comprises administering to a subject in need of such treatment, prevention or management a therapeutically or prophylactically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof.
- the coronaviral-related disease are COVID-19, other acute respiratory syndromes, non-respiratory coronavirus syndromes and post-infectious coronavirus syndromes.
- the invention provides a method ⁇ s for treating, preventing and/or managing a coronaviral-related disease or disorder, wherein the method comprises administering to a subject in need of such treatment, prevention or management a compound of the invention, or a pharmaceutically acceptable salt thereof.
- the coronaviral-related disease is COVID-19.
- the invention provides use of a compound of of the invention, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment, prevention and/or management of a coronalviral-related disease or disorder.
- the invention provides use of a compound of the invention, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment, prevention and/or management of COVID-19.
- the invention provides the use of a compound of the invention, or a pharmaceutically acceptable salt thereof, in the treatment, prevention and/or management of a coronalviral-related disease or disorder.
- the invention provides the use of a compound of the invention, or a pharmaceutically acceptable salt thereof, in the treatment, prevention and/or management of COVID-19.
- the invention provides a compound of the invention, or a pharmaceutically acceptable salt thereof, for use in the treatment, prevention and/or management of a coronalviral-related disease or disorder.
- the invention provides a compound of the invention, or a pharmaceutically acceptable salt thereof, for use in the treatment, prevention and/or management of COVID-19.
- the invention provides kits comprising a compound of the invention for treating, preventing and/or managing a coronaviral-related disease.
- the invention provides kits comprising a compound of the invention for treating, preventing and/or managing COVID-19.
- the invention provides combinations for the treatment, prevention and/or management of a coronaviral related disease, wherein a compound of the invention is used in combination with one or more other active agents.
- the active agent(s) is selected froma neutralizing antibody and an antiviral agent.
- the active agent(s) is selected from a neutralizing antibody, an antiviral agent and other agents selected from alvelestat, Lenzilumab, Octagam, Remestemcel-L, RPH-104 + olokizumab, Bucillamine, CD24FC (MK-7110), Tradipitant, Ifenprodil, Tocilizumab, Leronlimab, Fenretinide, ATYR-1923, CYTO-205, APN-01, and Ampion.
- the neutralizing antibody is selected from Bamlanivimab, bamlanivimab + etesevimab, bamlanivimab + VIR-7831, REGN-COV2, VIR-7831, AZD7442, Regdanvimab/CT-P59, ABP-300, , COVI-AM/STI-2020, VIR-7832, SAB- 185, JS016/etesevimab, C-135LS/C-144LS, BRII-196, BRII-198, SCTA-01, MW-33, DXP593, HFB-30132A, ADG20, COVI-GUARD (STI-1499) and convalescent plasma, and the antiviral agents is selected from remdesivir, Avigan/favipiravir, EIDD-2801/molnupiravir, AT-527, PF- 00835231, PF-07321332, Ensovibep/DARPins, galides
- the invention provides combinations for the treatment, prevention and/or management of a coronaviral related disease, wherein a compound of the invention is used in combination with remdesivir (also known as 2-ethylbutyl ((((2R,3S,4R,5R)-5-(4- aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2- yl)methoxy)(phenoxy)phosphoryl)-L-alaninate).
- remdesivir also known as 2-ethylbutyl ((((2R,3S,4R,5R)-5-(4- aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2- yl)methoxy
- the invention provides combinations for the treatment, prevention and/or management of a coronaviral related disease, wherein a compound of the invention is used in combination with an antibody selected from ABBV 47D11, ABP-300, ADG20, Bamlanivimab + VIR-7831, Bamlanivimab+etesevimab, BRII196 + BRII198, C-135LS/C-144LS, Convalescent Plasma, COR-101, CT-P63, DXP593, Etesevimab (JS016), Evusheld/AZD-7442, HFB-30132A, IBIO123, IN-006, JMB2002, LY-CoV1404, Ly-CovMab, MAD0004J08, MW-33, REGEN- COV/Ronapreve, Regkirona/Regdanvimab, SAB-185, SCTA-01, STI-2099/COVIDROPS, TY027, VIR-7832 (GS)-S
- the invention provides combinations for the treatment, prevention and/or management of a coronaviral related disease, wherein a compound of the invention is used in combination with an antiviral agent selected from ABX-464, alisporivir, alvelestat, ANA-001, Apabetalone, Arakoda (Tafenoquine), ASC-09 + ritonavir, ASC11, AT-100, AT-301, AT-527 (Bemnifosubuvir), AT-H201, ATR-002, boceprivir, brequinar, Bucillamine, Camostat (DWJ1248), Camostat mesylate, Carrimycin, DC-402234 (FB2001), Ebeselen (SPI-1005), EDP-235, Elsulfavirine, Ensitrelvir/S-217622, Ensovibep, Favipiravir, FP-025, Galidesivir, Gamunex-C, Lüvrio/Molnupira
- the invention provides combinations for the treatment, prevention and/or management of a coronaviral related disease, wherein a compound of the invention is used in combination with Actemra/RoActemra, Ampion, APN-01 (alunacedase alfa), ATR-002, ATYR- 1923, CYTO-205, Fenretinide (LAU-7b), Lenzilumab, Leronlimab, Octagam, Olumiant +/- Veklury , Remestemcel-L, RPH-104 + olokizumab, sarilumab , tocilizumab or Tradipitant.
- alkyl refers to a fully saturated branched or straight hydrocarbon chain.
- an alkyl group is a "C 1 -C 2 alkyl", “C 1 -C 3 alkyl", “C 1 -C 4 alkyl", “C 1 - C 5 alkyl", “C 1 -C 6 alkyl”, “C 1 -C 7 alkyl", “C 1 -C 8 alkyl", “C 1 -C 9 alkyl” or "C 1 -C 10 alkyl", wherein the terms "C1-C2alkyl", “C1-C3alkyl", “C1-C4alkyl", “C1-C5alkyl", “C1-C6alkyl”, “C1-C7alkyl", “C1-C8alkyl”, “C1- C 9 alkyl” and “C 1 -C 10 alkyl”, as used herein, refer to an alkyl
- alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2- dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n- octyl, n-nonyl and n-decyl.
- alkenyl refers to a partially saturated branched or straight hydrocarbon chain having one more double bonds.
- an alkenyl group is a "C 2 -C 3 alkenyl", “C 2 -C 4 alkenyl", “C 2 -C 5 alkenyl”, “C 2 -C 6 alkenyl”, “C 2 -C 7 alkenyl”, “C 2 -C 8 alkenyl”, “C 2 -C 9 alkenyl” or “C 2 -C 10 alkenyl”, wherein the terms “C 2 -C 3 alkenyl”, “C 2 -C 4 alkenyl”, “C 2 - C 5 alkenyl", “C 2 -C 6 alkenyl”, “C 2 -C 7 alkenyl”, “C 2 -C 8 alkenyl”, “C 2 -C 9 alkenyl” and “C 2 -C 10 alkenyl”, as used herein, refer to an alkenyl group containing at least 2, and at most 3, 4, 5, 6, 7, 8, 9 or 10 carbon atoms, respectively.
- alkenyl groups include ethenyl, n- propenyl, isopropenyl, n-butenyl, isobutenyl, sec-butenyl, tert-butenyl, n-pentenyl, isopentenyl, n-hexenyl, n-heptenyl, n-octenyl, n-nonenyl and n-decenyl.
- alkoxy refers to -O-alkyl or-alkyl-O-, wherein "alkyl" is as defined herein.
- an alkoxy group is a "C 1 -C 2 alkoxy", “C 1 -C 3 alkoxy", “C 1 - C 4 alkoxy", “C 1 -C 5 alkoxy", “C 1 -C 6 alkoxy”, “C 1 -C 7 alkoxy”, “C 1 -C 8 alkoxy”, “C 1 -C 9 alkoxy” or “C 1 - C10alkoxy”, wherein the terms "C1-C3alkoxy", “C1-C4alkoxy”, “C1-C5alkoxy”, “C1-C6alkoxy", “C1- C 7 alkoxy", “C 1 -C 8 alkoxy", “C 1 -C 9 alkoxy” and "C 1 -C 10 alkoxy”, as used herein refer to -O-C 1 - C 2 alkyl, -O-C 1 -C 3 alkyl, -O-C 1 -C 4 alkyl, -O-C 1 -C 1
- alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, sec-butoxy, tert-butoxy, n- pentoxy, isopentoxy, hexoxy, heptoxy, octoxy, nonoxy and decoxy.
- C 3 -C 8 cycloalkyl refers to a fully saturated, monocyclic hydrocarbon ring system having 3 to 8 carbon atoms as ring members.
- C 3 -C 8 cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.
- C 5 -C 6 cycloalkenyl refers to a partially saturated (but not aromatic), monocyclic hydrocarbon ring system having 5 to 6 carbon atoms as ring members.
- C 5 -C 6 cycloalkenyl include cyclopent-1-enyl, cyclopenta-1,3-dienyl, cyclohex-1-enyl and cyclohexa-1,3-dienyl.
- C 1 -C 6 alkyl-phenyl refer to a C 1 -C 6 alkyl as defined above which is substituted with a phenyl group.
- Non-limiting example of a C 1 -C 6 alkyl-phenyl is benzyl.
- haloalkyl refers to an alkyl group as defined herein, wherein at least one of the hydrogen atoms of the alkyl is replaced by a halo group (as defined herein).
- the haloalkyl can be monohaloalkyl, dihaloalkyl, trihaloalkyl, or polyhaloalkyl including perhaloalkyl.
- a monohaloalkyl can have one iodo, bromo, chloro or fluoro within the alkyl group.
- Dihaloalkyl and polyhaloalkyl groups can have two or more of the same halo atoms or a combination of different halo groups within the alkyl.
- the polyhaloalkyl contains up to 6, or 4, or 3, or 2 halo groups.
- haloalkyl include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, difluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl.
- a perhalo-alkyl refers to an alkyl having all hydrogen atoms replaced with halo atoms, e.g., trifluoromethyl.
- haloalkyl groups include monofluoro-, difluoro- and trifluoro- substituted methyl and ethyl groups, e.g. CF 3 , CHF 2 , CH 2 F, CH 2 CHF 2 and CH 2 CF 3 .
- C 1 -C 6 haloalkyl refers to the respective "C 1 -C 6 alkyl", as defined herein, wherein at least one of the hydrogen atoms of the "C 1 -C 6 alkyl" is replaced by a halo group (as defined herein).
- the C1-C6haloalkyl groups can be monoC1-C6haloalkyl, wherein such C 1 -C 6 haloalkyl groups have one iodo, one bromo, one chloro or one fluoro. Additionally, the C 1 - C 6 haloalkyl groups can be diC 1 -C 6 haloalkyl wherein such C 1 -C 6 haloalkyl groups can have two halo atoms independently selected from iodo, bromo, chloro or fluoro.
- the C 1 - C 6 haloalkyl groups can be polyC 1 -C 6 haloalkyl wherein such C 1 -C 6 haloalkyl groups can have two or more of the same halo atoms or a combination of two or more different halo atoms.
- Such polyC 1 -C 6 haloalkyl can be perhaloC 1 -C 6 haloalkyl where all the hydrogen atoms of the respective C1-C6alkyl have been replaced with halo atoms and the halo atoms can be the same or a combination of different halo atoms.
- C 1 -C 6 haloalkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl, chloromethyl, dichloromethyl, trichloromethyl, pentafluoroethyl, heptafluoropropyl, difluorochloromethyl, dichlorofluoromethyl, fluoroethyl, difluoroethyl, trifluoroethyl, difluoropropyl, dichloroethyl and dichloropropyl.
- haloalkoxy refers to the group –O-haloalkyl wherein the term "haloalkyl" is as defined herein.
- Non-limiting examples of haloalkoxy include fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, trichloromethoxy, pentafluoroethoxy, heptafluoropropoxy, difluorochloromethoxy, dichlorofluoromethoxy, difluoroethoxy, difluoropropoxy, dichloroethoxy and dichloropropoxy.
- a perhalo-alkoxy refers to an alkoxy having all hydrogen atoms replaced with halo atoms, e.g., trifluoromethoxy.
- haloalkoxy groups include monofluoro-, difluoro- and trifluoro- substituted methoxy and ethoxygroups, e.g. -OCF 3 , -OCHF 2 , -OCH 2 F, -OCH 2 CHF 2 and - OCH 2 CF 3 .
- C 1 -C 6 haloalkoxy refers to the group –O-C 1 -C 6 haloalkyl, wherein the term C 1 -C 6 haloalkyl is as defined herein.
- Non-limiting examples of "C 1 - C 6 haloalkoxy” groups include fluoromethoxy, difluoromethoxy, trifluoromethoxy, chloromethoxy, dichloromethoxy, trichloromethoxy, pentafluoroethoxy, heptafluoropropoxy, difluorochloromethoxy, dichlorofluoromethoxy, fluoroethoxy, difluoroethoxy, trifluoroethoxy, difluoropropoxy, dichloroethoxy and dichloropropoxy.
- halogen or “halo” as used herein, refer to fluoro (F), chloro (Cl), bromo (Br) and iodo (I).
- heteroatoms refers to nitrogen (N), oxygen (O) or sulfur (S) atoms.
- heteroaryl refers to an aromatic ring system containing one or more heteroatoms which may be the same or different.
- heteroaryl also refers to an aromatic ring system having one or more ring members which are each independently selected from N, NR 6 , O and S, where R 6 is as defined herein.
- Heteroaryl groups may be monocyclic ring systems or fused bicyclic ring systems. Monocyclic heteroaryl rings have from 5 to 6 ring atoms. Bicyclic heteroaryl rings have from 7 to 12 ring member atoms.
- Bicyclic heteroaryl rings include those ring systems wherein a heteroaryl ring is fused to a phenyl ring.
- heteroaryl groups include benzofuranyl, benzo[c]thiophenyl, benzothiophenyl, benzoxazolyl, benzothiazolyl, benzimidazolyl, cinnolinyl, furazanyl, furyl, imidazolyl, indolyl, indolizinyl, indazolyl, isoindolyl, isoquinolinyl, isoxazolyl, isothiazolyl, oxazolyl, oxaindolyl, oxadiazolyl (including 1,3,4-oxadiazolyl and 1,2,4-oxadiazolyl), purinyl, pyrazolyl, pyrrolyl, phthalazinyl, pyridyl (including 2-, 3-, and 4-
- 5 or 6 membered heteroaryl refers to an aromatic, 5 or 6 membered monocyclic ring system wherein 1, 2, 3 or 4 ring members are each independently selected from N, NR 6 , O and S, where R 6 is as defined herein.
- Non-limiting examples of such 5 or 6 membered heteroaryl groups include furyl, imidazolyl, isoxazolyl, isothiazolyl, oxazolyl, pyrrolyl, pyrazolyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, tetrazolyl, pyridyl (including 2-, 3-, and 4-pyridyl), pyridazinyl, pyrazinyl and pyrimidinyl.
- the term "5 or 6 membered heteroaryl”, as used herein, also refers to an aromatic, 5 or 6 membered monocyclic ring system wherein 1, 2, or 3 ring members are each independently selected from N, NR 6 , O and S, where R 6 is as defined herein.
- Non-limiting examples of such 5 or 6 membered heteroaryl groups include furyl, imidazolyl, isoxazolyl, isothiazolyl, oxazolyl, pyrrolyl, pyrazolyl, thiadiazolyl, thiazolyl, thienyl, triazolyl, pyridyl (including 2-, 3-, and 4-pyridyl), pyridazinyl, pyrazinyl and pyrimidinyl.
- Non-limiting examples of such 6 membered heteroaryl groups include pyridyl (including 2-, 3-, and 4-pyridyl), pyridazinyl, pyrazinyl and pyrimidinyl.
- pyridyl including 2-, 3-, and 4-pyridyl
- pyridazinyl pyrazinyl
- pyrazinyl pyrazinyl
- pyrimidinyl pyridyl
- 5 membered heteroaryl refers to an aromatic, 5 membered monocyclic ring system wherein 1, 2, 3 or 4 ring members are each independently selected from N, NR 6 , O and S, where R 6 is as defined herein.
- Non-limiting examples of such 5 membered heteroaryl groups include furyl, imidazolyl, isoxazolyl, isothiazolyl, oxazolyl, pyrrolyl, pyrazolyl, thiadiazolyl, thiazolyl, thienyl, triazolyl and tetrazolyl.
- the term "5 membered heteroaryl”, as used herein, also refers to an aromatic, 5 membered monocyclic ring system wherein 1, 2, or 3 ring members are each independently selected from N, NR 6 , O and S, where R 6 is as defined herein.
- Non-limiting examples of such 5 membered heteroaryl groups include furyl, imidazolyl, isoxazolyl, isothiazolyl, oxazolyl, pyrrolyl, pyrazolyl, thiadiazolyl, thiazolyl, thienyl and triazolyl.
- the term "9 or 10 membered bicyclic heteroaryl”, as used herein, refers to a 9 or 10 membered fused, bicyclic aromatic ring system wherein 1, 2, 3, 4 or 5 ring members are each independently selected from N, NR 6 , O and S, where R 6 is as defined herein.
- Non-limiting examples of such bicyclic heteroaryl groups include indolyl, quinolinyl, isoquinolinyl, indazolyl, purinyl, phthalazinyl, naphthyridinyl, quinazolinyl, cinnolinyl, thieno[2,3- b]furanyl, 1H-pyrazolo[4,3-d]-oxazolyl, imidazo[2,1-b] thiazolyl, imidazo[1,2-c]pyrimidinyl, imidazo[1,2-a]pyrazinyl, imidazo[1,2-a]pyridinyl, pyrazolo[1,5-a]pyrazinyl, pyrazino[2,3- d]pyridazinyl, imidazo[1,2-b][1,2,4]triazinyl, benzoxazolyl, benzimidazolyl, imidazopyridinyl,
- 4 to 7 membered heterocycloalkyl refers to a 4 to 7 membered, saturated hydrocarbon ring wherein 1, 2, 3 or 4 ring members are each independently selected from N, NR 6 , O or S, where R 6 is as defined herein.
- the heterocycloalkyl group can be attached to another group at a nitrogen or a carbon atom.
- Non-limiting examples of 4 to 6 membered heterocycloalkyl groups include azetadinyl (which includes azetadin-1-yl, azetadin-2-yl and azetadin-3-yl), oxetanyl (which includes oxetan-2-yl, oxetan-3-yl and oxetan- 4-yl), thietanyl (which includes thietan-2-yl, thietan-3-yl and thietan-4-yl), pyrrolidinyl (which includes pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, pyrrolidin-4-yl and pyrrolidin-5-yl), tetrahydrofuranyl (which includes tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrofuran-3-y
- 3 to 6 membered heterocycloalkyl refers to a 3 to 6 membered, saturated hydrocarbon ring wherein 1, 2 or 3 ring members are each independently selected from N, NR 6 , O or S, where R 6 is as defined herein.
- the heterocycloalkyl group can be attached to another group at a nitrogen or a carbon atom.
- Non-limiting examples of 3 to 6 membered heterocycloalkyl groups include oxiranyl, aziridinyl, thiiranyl, azetadinyl (which includes azetadin-1-yl, azetadin-2-yl and azetadin-3-yl), oxetanyl (which includes oxetan-2-yl, oxetan-3-yl and oxetan-4-yl), thietanyl (which includes thietan-2-yl, thietan-3-yl and thietan-4-yl), pyrrolidinyl (which includes pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, pyrrolidin-4-yl and pyrrolidin-5-yl), tetrahydrofuranyl (which includes tetrahydrofuran-2-yl,
- 4 to 6 membered heterocycloalkyl refers to a 4 to 6 membered, saturated hydrocarbon ring wherein 1, 2, 3 or 4 ring members are each independently selected from N, NR 6 , O or S, where R 6 is as defined herein.
- the heterocycloalkyl group can be attached to another group at a nitrogen or a carbon atom.
- Non-limiting examples of 4 to 6 membered heterocycloalkyl groups include azetadinyl (which includes azetadin-1-yl, azetadin-2-yl and azetadin-3-yl), oxetanyl (which includes oxetan-2-yl, oxetan-3-yl and oxetan- 4-yl), thietanyl (which includes thietan-2-yl, thietan-3-yl and thietan-4-yl), pyrrolidinyl (which includes pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, pyrrolidin-4-yl and pyrrolidin-5-yl), tetrahydrofuranyl (which includes tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrofuran-3-y
- heterocycloalkyl refers to a 5 or 6 membered, saturated hydrocarbon ring wherein 1, 2, 3 or 4 ring members are each independently selected from N, NR 6 , O or S, where R 6 is as defined herein.
- the heterocycloalkyl group can be attached to another group at a nitrogen or a carbon atom.
- Non-limiting examples of 5 or 6 membered heterocycloalkyl groups include pyrrolidinyl (which includes pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, pyrrolidin-4-yl and pyrrolidin-5-yl), tetrahydrofuranyl (which includes tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydrofuran-4-yl and tetrahydrofuran-5- yl), tetrahydrothienyl (which includes tetrahydrothien-2-yl, tetrahydrothien-3-yl, tetrahydrothien- 4-yl and tetrahydrothien-5-yl), piperidinyl (which includes piperidin-1-yl, piperidin-2-yl, piperidin- 3-yl, piperidin-4-yl,
- 6 membered heterocycloalkyl refers to a 6 membered, saturated hydrocarbon ring wherein 1, 2, 3 or 4 ring members are each independently selected from N, NR 6 , O or S, where R 6 is as defined herein.
- the heterocycloalkyl group can be attached to another group at a nitrogen or a carbon atom.
- Non-limiting examples of 6 membered heterocycloalkyl groups include piperidinyl (which includes piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, piperidin-5-yl and piperidin-6-yl), tetrahydropyranyl (which includes tetrahydropyran-2-yl, tetrahydropyran-3-yl, tetrahydropyran-4-yl, tetrahydropyran-5-yl and tetrahydropyran-6-yl), tetrahydrothiopyranyl (which includes tetrahydrothiopyran-2-yl, tetrahydrothiopyran-3-yl, tetrahydrothiopyran-4-yl, tetrahydrothiopyran- 5-yl and tetrahydrothiopyran-6-yl), piperazinyl (which includes piperazinyl (which
- 3 membered heterocycloalkyl refers to a 3 membered, saturated hydrocarbon ring wherein 1or 2 ring members are each independently selected from N, NR 6 , O or S, where R 6 is as defined herein.
- the heterocycloalkyl group can be attached to another group at a nitrogen or a carbon atom.
- Non-limiting examples of 3 membered heterocycloalkyl groups, as used herein, include oxiranyl, aziridinyl and thiiranyl.
- 5 or 6 membered heterocyclyl refers to a partially saturated (but not aromatic) 5 or 6 membered monocyclic ring system wherein 1, 2 or 3 ring members are each independently selected from N, NR 6 , O or S, where R 6 is as defined herein.
- the 5 or 6 membered heterocyclyl group can be attached to another group at a nitrogen or a carbon atom.
- Non-limiting examples of 5 or 6 membered heterocyclyl groups include 1,2-dihydropyridinyl and 2,3-dihydro- 1H-pyrrolyl.
- the 6 membered heterocyclyl group can be attached to another group at a nitrogen or a carbon atom.
- Non-limiting examples of membered heterocyclyl groups include 1,2-dihydropyridinyl.
- the 5 membered heterocyclyl group can be attached to another group at a nitrogen or a carbon atom.
- Non-limiting examples of 5 membered heterocyclyl groups include 2,3-dihydro-1H-pyrrolyl.
- the C 5 -C 6 heterocycloalkenyl group can be attached to another group at a nitrogen or a carbon atom.
- Non-limiting examples of 9 or 10 membered bicyclic heterocyclyl groups include isochromanyl, 1,2-dihydroquinolinyl, 3a,7a-dihydro-1H-pyrrolo[2,3-c]pyridinyl and 3a,7a- dihydro-1H-indazolyl.
- spiro attached refers to the attachment of one ring system to another ring system via one carbon aton common to both rings.
- the beta ( ⁇ ) position relative to the attachment point indicated by the asterix (*) is located at the beta ( ⁇ ) position relative to the attachment point indicated by the asterix (*) .
- isomers refers to different compounds that have the same molecular formula but differ in arrangement and configuration of the atoms.
- an optical isomer or “a stereoisomer” refers to any of the various stereo isomeric configurations which may exist for a given compound of the present invention and includes geometric isomers. It is understood that a substituent may be attached at a chiral center of a carbon atom.
- the term “chiral” refers to molecules which have the property of non- superimposability on their mirror image partner, while the term “achiral” refers to molecules which are superimposable on their mirror image partner. Therefore, the invention includes enantiomers, diastereomers or racemates of the compound. “Enantiomers” are a pair of stereoisomers that are non- superimposable mirror images of each other.
- a 1:1 mixture of a pair of enantiomers is a "racemic” mixture.
- the term is used to designate a racemic mixture where appropriate.
- "Diastereoisomers” are stereoisomers that have at least two asymmetric atoms, but which are not mirror-images of each other.
- the absolute stereochemistry can be specified according to the Cahn- lngold- Prelog R-S system. When a compound is a pure enantiomer the stereochemistry at each chiral carbon may be specified by either R or S.
- Resolved compounds whose absolute configuration is unknown can be designated (+) or (-) depending on the direction (dextro- or levorotatory) which they rotate plane polarized light at the wavelength of the sodium D line.
- Certain compounds described herein contain one or more asymmetric centers or axes and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)-.
- the absolute stereochemistry of atropisomers can be assigned either as M or P according to the “helicity” rule of Prelog and Helmchen.
- pharmaceutically acceptable carrier includes any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drug stabilizers, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, and the like and combinations thereof, as would be known to those skilled in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp.1289- 1329).
- coronaviral related disease means a disease caused by a member of the Coronavirus family (i.e., may belong to the Coronaviridae family).
- Coronaviruses are positive-stranded RNA viruses with a crown-like appearance under an electron microscope due to the presence of spike glycoproteins on the envelope.
- Any member of the coronavirus family e.g., those belonging to the alphacoronavirus, betacoronavirus, deltacoronavirus, or gammacoronavirus genuses
- coronavirus family e.g., those belonging to the alphacoronavirus, betacoronavirus, deltacoronavirus, or gammacoronavirus genuses
- the respiratory virus could be a betacoronavirus such as severe acute respiratory syndrome-related coronavirus (SARS-CoV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome related coronavirus (MERS-CoV), OC43 and HKU1, or an alphacoronavirus such as 229E and NL63.
- the respiratory virus could also be a coronavirus other than SARS-CoV, SARS-CoV-2, MERS-CoV, OC43, HKU1, 229E or NL63.
- SARS-CoV-2 Patients infected with SARS-CoV-2 present with a wide range of clinical severity varying from asymptomatic to a severe form of interstitial pneumonia, which may progress towards acute respiratory distress syndrome (ARDS), a severe form of acute lung injury (ALI), a form of diffuse alveolar injury, and is a serious lung condition that causes low blood oxygenation and respiratory failure and/or multi organ failure (MOF), associated symptoms and death.
- ARDS acute respiratory distress syndrome
- ALI severe form of acute lung injury
- MOF multi organ failure
- SARS-CoV-2 uses the same receptor as SARS-CoV, angiotensin-converting enzyme 2 (ACE2), and mainly spreads through the respiratory tract.
- ACE2 angiotensin-converting enzyme 2
- Cytokine profiling of patients with severe COVID-19 demonstrates elevated levels of interleukin (IL)-2, IL-7, IL-6, IL-1, granulocyte-colony stimulating factor, interferon- ⁇ inducible protein 10, monocyte chemoattractant protein 1, macrophage inflammatory protein 1- ⁇ and tumor necrosis factor- ⁇ .
- IL interleukin
- IL-7 interleukin-7
- IL-6 IL-1
- granulocyte-colony stimulating factor interferon- ⁇ inducible protein 10
- monocyte chemoattractant protein 1 ⁇ macrophage inflammatory protein 1- ⁇
- tumor necrosis factor- ⁇ tumor necrosis factor- ⁇ .
- the terms “inhibit”, “inhibition” or “inhibiting”, as used herein, refers to the reduction or suppression of a given condition, symptom, or disorder, or disease, or a significant decrease in the baseline activity of a biological activity or process.
- subject as used herein may refer to an animal. The animal
- a subject also refers to for example, primates (e.g., humans, male or female), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice, fish, birds and the like.
- the subject is a primate.
- the subject is a human.
- the terms “patient” or “subject” are used herein interchangeably.
- the terms “treat,” “treating,” or “treatment” of any disease or disorder refers in one embodiment, to ameliorating the disease or disorder (i.e., slowing or arresting or reducing the development of the disease or at least one of the clinical symptoms thereof).
- “treat,” “treating,” or “treatment” refers to alleviating or ameliorating at least one physical parameter including those which may not be discernible by the patient.
- “treat,” “treating,” or “treatment” refers to modulating the disease or disorder, either physically, (e.g., stabilization of a discernible symptom), physiologically, (e.g., stabilization of a physical parameter), or both.
- the term “prevent”, “preventing” or “prevention” of any disease or disorder refers to the prophylactic treatment of the disease or disorder; or delaying the onset or progression of the disease or disorder.
- the expression “substituted with 1, 2, 3 or 4 R 4 and optionally substituted with 1 or 2 oxo” means the group is substituted with 1, 2, 3 or 4 R 4 or the group is substituted with 1, 2, 3 or 4 R 4 and is substituted with 1 or 2 oxo.
- the expression “optionally substituted with oxo” means the group is unsubstituted or is substituted oxo.
- the terms “manage,” “managing,” and “management” encompass preventing the recurrence of the specified disease or disorder in a patient who has already suffered from the disease or disorder, and/or lengthening the time that a patient who has suffered from the disease or disorder remains in remission.
- the terms encompass modulating the threshold, development and/or duration of the disease or disorder, or changing the way that a patient responds to the disease or disorder.
- a therapeutically effective amount of a compound of the present invention refers to an amount of the compound of the present invention that will elicit the biological or medical response of a subject, for example, reduction or inhibition of an enzyme or a protein activity, or ameliorate symptoms, manage a condition, alleviate conditions, slow or delay disease progression, or prevent a disease.
- a therapeutically effective amount refers to the amount of the compound of the present invention that, when administered to a subject, is effective to (1) at least partially alleviating, inhibiting, preventing managing and/or ameliorating a condition, or a disorder or a disease (i) mediated by SARS- CoV-2 main protease (M pro ), or (ii) associated with or mediated by SARS-CoV-2 main protease (M pro ) activity, or (iii) characterized by activity (normal or abnormal) of SARS-CoV-2 main protease (M pro ); or (2) reducing or inhibiting the activity of SARS-CoV-2 main protease (M pro ).
- a therapeutically effective amount refers to the amount of the compound of the present invention that, when administered to a cell, or a tissue, or a non-cellular biological material, or a medium, is effective to at least partially reducing or inhibiting the activity of SARS-CoV-2 main protease (Mpro).
- co-administer refers to the presence of two active agents in the blood of an individual. Active agents that are co-administered can be concurrently or sequentially delivered.
- the terms “compound of the invention”, “compounds of the invention”, “compound of the present invention” or “compounds of the present invention” refers to a compound or compounds of Formula (I), or subformulae thereof such as Formula (I-a), (Formula (I-a), Formula (I-b), Formula (I-c), Formula (I-d), Formula (I-e), Formula (I-f), Formula (I-g), Formula (I-h), Formula (I-i), Formula (I-j), Formula (I-k), Formula (I-l), Formula (I-m), Formula (I-n), Formula (I-o), Formula (I-p), Formula (I-q), Formula (I-r), Formula (I-s), Formula (I-t), Formula (I-u), Formula (I-v), Formula (I-w), Formula (I-x), Formula (I-y), Formula (I-z), Formula (I-aa), Formula (I-ab), Formula (I-ac), Formula (I-ad),
- Embodiment 1 A compound of Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, as described above in the Summary of the Invention.
- a compound of Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof wherein: the dashed line between X 1 and X 2 is a single bond or a double bond;
- X 2 is N, C or CH;
- X 3 is N, C or CH;
- X 4 is C(R 2a ) 2 or
- Embodiment 3 The compound of Embodiment 1 or Embodiment 2, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein p is 0 and the compound of Formula (I) has the structure of Formula (IA): X 1 , X 2 , X 3 , R 3 where Ring A, , R 5 , n and the dashed line between X 1 and X 2 are as defined in Embodiment 1.
- Embodiment 11 The compound of any one of Embodiments 1 to 10, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: the dashed line between X 1 and X 2 is a single bond; X 1 is NR 1 , C(R 2a ) 2 or O; X 2 is C or CH; X 3 is C or CH; R 1 is H, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, a C 1 -C 6 alkyl substituted with one or more R 12 , or a C 1 -C 6 alkenyl substituted with one or more R 12 , and wherein the cycloalkyl is unsubstituted or the cycloalkyl is substituted with 1 substituent selected from the group consisting of C 1 -C 6 alkyl substituted with CN; each R 2a is independently selected from the group consisting of H, and C 1 -C 6 alkyl; R 3 is selected from the group consisting of:
- Embodiment 12 The compound of any one of Embodiments 1 to 11, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: X 1 is NR 1 ; R 1 is H, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, a C 1 -C 6 alkyl substituted with one or more R 12 , or a C 1 -C 6 alkenyl substituted with one or more R 12 , and wherein the cycloalkyl is unsubstituted or the cycloalkyl is substituted with 1 substituent selected from the group consisting of C 1 -C 6 alkyl substituted with CN; each R 2a is independently selected from the group consisting of H, and C 1 -C 6 alkyl; R 3 is selected from the group consisting of: i) a 6 membered heteroaryl with an attachment point at a carbon atom ring member and a N heteroatom as a ring member which is located at a beta ( ⁇ )
- Embodiment 16 The compound of any one of Embodiments 1 to 15, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: X 1 is NR 1 ; R 1 is H or C 1 -C 6 alkyl substituted with one or more R 12 ; R 3 is selected from the group consisting of: i) -CHR 13 R 14 ; ii) benzyl which is unsubstituted or is substituted with 1 R 4 ; iii) a 6 membered heteroaryl wherein 1 ring member is selected from N, and wherein the 6 membered heteroaryl is unsubstituted or is substituted with 1 or 2 R 4 ; iv) a 10 membered bicyclic heteroaryl with an attachment point at a carbon atom ring member and a N heteroatom as a ring member which is located at a beta ( ⁇ ) position relative to the attachment point, wherein the 10 membered bicyclic heteroaryl has 0, 1, 2 or 3 additional N heteroatoms
- Embodiment 17 The compound of any one of Embodiments 1 to 16, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 1 is H or C 1 -C 6 alkyl substituted with one or more R 12 ; R 3 is selected from the group consisting of: i) a 9 or 10 membered bicyclic heteroaryl wherein 1, 2 or 3 ring members are each independently selected from N, NR 6 and O, wherein the 9 or 10 membered bicyclic heteroaryl is unsubstituted or is substituted with 1 or 2 R 4 ; and ii) a 10 membered bicyclic heteroaryl with an attachment point at a carbon atom ring member and a N heteroatom as a ring member which is located at a beta ( ⁇ ) position relative to the attachment point, wherein the 10 membered bicyclic heteroaryl has 0, 1, 2 or 3 additional N heteroatoms as ring members, and wherein the 10 membered bicyclic heteroaryl is unsubstituted or is
- Embodiment 22 The compound of any one of Embodiments 1 to 21, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the dashed line between X 1 and X 2 is a single bond.
- Embodiment 23 The compound of any one of Embodiments 1 to 21, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the dashed line between X 1 and X 2 is a double bond.
- Embodiment 24. The compound of any one of Embodiments 1 to 23, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Ring A is phenyl.
- Embodiment 25 The compound of any one of Embodiments 1 to 23, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Ring A is .
- Embodiment 26 The compound of any one of Embodiments 1 to 23, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Ring A is a 5 or 6 membered heteroaryl wherein 1, 2, 3 or 4 ring members are each independently selected from N, NR 6 , O and S.
- Embodiment 27 The compound of any one of Embodiments 1 to 23, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Ring A is a 5 or 6 membered heteroaryl wherein 1 or 2 ring members are each independently selected from N, NR 6 , O and S.
- Embodiment 28 The compound of any one of Embodiments 1 to 23, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Ring A is a 5 or 6 membered heteroaryl wherein 1 or 2 ring members are each independently selected from N, NR 6 , O and S.
- Embodiment 40 is
- Embodiment 42 The compound of any one of Embodiments 1 to 23, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Ring A is a 9 or 10 membered bicyclic heterocyclyl wherein 1, 2, 3, 4 or 5 ring members are each independently selected from N, NR 6 , O and S.
- Embodiment 43 The compound of any one of Embodiments 1 to 23, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Ring A is a 9 or 10 membered bicyclic heterocyclyl wherein 1 ring member is selected from N, NR 6 , O and S.
- Embodiment 44 Embodiment 44.
- Embodiment 50 The compound of any one of Embodiments 1 to 23, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein Ring A is Embodiment 51.
- Embodiment 53 The compound of any one of Embodiments 1 to 51, or a pharmaceutically acceptable salt or stereoisomer thereof, selected from a compound having the structure of the following sub-formulae: Formula (I-aaa), Formula (I-aab) and Formula (I-aac)): (I-aaa) (I-aab) (I-aac).
- Embodiment 54 The compound of any one of Embodiments 1 to 52, or a pharmaceutically acceptable salt or stereoisomer thereof, selected from a compound having the structure of Formula (I-a), (I-a).
- Embodiment 55 The compound of any one of Embodiments 1 to 51, or a pharmaceutically acceptable salt or stereoisomer thereof, selected from a compound having the structure of Formula (I-a), (I-a).
- Embodiment 56 The compound of any one of Embodiments 1 to 51, or a pharmaceutically acceptable salt or stereoisomer thereof, selected from a compound having the structure of Formula (I-ay), (I-ay).
- Embodiment 56 The compound of any one of Embodiments 1 to 51, or a pharmaceutically acceptable salt or stereoisomer thereof, selected from a compound having the structure of Formula (I-az), Formula (I-ba) or Formula (I-bb), or a pharmaceutically acceptable salt or stereoisomer thereof, (I-az) (I-ba) (I-bb).
- Embodiment 57 Embodiment 57.
- Embodiment 58 The compound of any one of Embodiments 1 to 51, or a pharmaceutically acceptable salt or stereoisomer thereof, selected from a compound having the structure of Formula (I-az), Formula (I-ba), Formula (I-bc) or Formula (I-bd), or a pharmaceutically acceptable salt or stereoisomer thereof, (I-az) (I-ba) (I-bc) (I-bd).
- Embodiment 60 The compound of any one of Embodiments 1 to 51, or a pharmaceutically acceptable salt or stereoisomer thereof, selected from a compound having the structure of the Formula (I-be), or a pharmaceutically acceptable salt or stereoisomer thereof, (I-be).
- Embodiment 62 The compound of any one of Embodiments 1 to 51, or a pharmaceutically acceptable salt or stereoisomer thereof, selected from a compound having the structure of Formula (I-bk), Formula (I-bl) or Formula (I-bm), or a pharmaceutically acceptable salt or stereoisomer thereof, (I-bk) (I-bl) (I-bm).
- Embodiment 63 The compound of any one of Embodiments 1 to 51, or a pharmaceutically acceptable salt or stereoisomer thereof, selected from a compound having the structure of Formula (I-k) or Formula (I-l), or a pharmaceutically acceptable salt or stereoisomer thereof, (I-k) (I-l).
- Embodiment 64 The compound of any one of Embodiments 1 to 51, or a pharmaceutically acceptable salt or stereoisomer thereof, selected from a compound having the structure of Formula (I-k) or Formula (I-l), or a pharmaceutically acceptable salt or stereoisomer thereof, (I-k
- Embodiment 65 The compound of any one of Embodiments 1 to 51, or a pharmaceutically acceptable salt or stereoisomer thereof, selected from a compound having the structure of Formula (I-bn), Formula (I-bo) or Formula (I-bp), or a pharmaceutically acceptable salt or stereoisomer thereof, (I-bn) (I-bo) (I-bp).
- Embodiment 65 The compound of any one of Embodiments 1 to 51, or a pharmaceutically acceptable salt or stereoisomer thereof, selected from a compound having the structure of Formula (I-bq), Formula (I-br) or Formula (I-bs), or a pharmaceutically acceptable salt or stereoisomer thereof, (I-bq) (I-br) (I-bs).
- Embodiment 71 The compound of any one of Embodiment 52 to 65, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: X 1 is NR 1 , C(R 2a ) 2 or O; R 1 is H, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, a C 1 -C 6 alkyl substituted with one or more R 12 , or a C 1 -C 6 alkenyl substituted with one or more R 12 , and wherein the cycloalkyl is unsubstituted or the cycloalkyl is substituted with 1 substituent selected from the group consisting of C 1 -C 6 alkyl substituted with CN; each R 2a is independently selected from the group consisting of H, and C 1 -C 6 alkyl; R 3 is selected from the group consisting of: i) a 6 membered heteroaryl with an attachment point at a carbon atom ring member and a N heteroatom as a
- Embodiment 72 The compound of any one of Embodiment 52 to 65, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: X1 is NR 1 ; R 1 is H, C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, a C 1 -C 6 alkyl substituted with one or more R 12 , or a C 1 -C 6 alkenyl substituted with one or more R 12 , and wherein the cycloalkyl is unsubstituted or the cycloalkyl is substituted with 1 substituent selected from the group consisting of C 1 -C 6 alkyl substituted with CN; R 3 is selected from the group consisting of: i) a 6 membered heteroaryl with an attachment point at a carbon atom ring member and a N heteroatom as a ring member which is located at a beta ( ⁇ ) position relative to the attachment point, wherein the 6 membered heteroaryl has 0, 1 or 2 additional N hetero
- Embodiment 76 The compound of any one of Embodiments 52 to 65, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: X 1 is NR 1 ; R 1 is H or C 1 -C 6 alkyl substituted with one or more R 12 ; R 3 is selected from the group consisting of: i) -CHR 13 R 14 ; ii) benzyl which is unsubstituted or is substituted with 1 R 4 ; iii) a 6 membered heteroaryl wherein 1 ring member is selected from N, and wherein the 6 membered heteroaryl is unsubstituted or is substituted with 1 or 2 R 4 ; iv) a 10 membered bicyclic heteroaryl with an attachment point at a carbon atom ring member and a N heteroatom as a ring member which is located at a beta ( ⁇ ) position relative to the attachment point, wherein the 10 membered bicyclic heteroaryl has 0, 1, 2 or 3 additional N hetero
- Embodiment 77 The compound of any one of Embodiments 52 to 65, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein: R 1 is H or C 1 -C 6 alkyl substituted with one or more R 12 ; R 3 is selected from the group consisting of: i) a 9 or 10 membered bicyclic heteroaryl wherein 1, 2 or 3 ring members are each independently selected from N, NR 6 and O, wherein the 9 or 10 membered bicyclic heteroaryl is unsubstituted or is substituted with 1 or 2 R 4 ; and ii) a 10 membered bicyclic heteroaryl with an attachment point at a carbon atom ring member and a N heteroatom as a ring member which is located at a beta ( ⁇ ) position relative to the attachment point, wherein the 10 membered bicyclic heteroaryl has 0, 1, 2 or 3 additional N heteroatoms as ring members, and wherein the 10 membered bicyclic heteroaryl is unsubstituted
- Embodiment 83 The compound of any one of Embodiments 1 to 81, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X 1 is NR 1 .
- Embodiment 84 The compound of any one of Embodiments 1 to 81, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X 1 is N.
- Embodiment 85 The compound of any one of Embodiments 1 to 81, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X 1 is N.
- Embodiment 85 The compound of any one of Embodiments 1 to 81, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein
- Embodiment 86 The compound of any one of Embodiments 1 to 81, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X1 is C(R 2a )2.
- Embodiment 86 The compound of any one of Embodiments 1 to 81, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X 1 is CR 2a .
- Embodiment 87 The compound of any one of Embodiments 1 to 81, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X 1 is O.
- Embodiment 89 The compound of any one of Embodiments 1 to 81, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X 1 is CR 2a R 2b .
- Embodiment 91 The compound of any one of Embodiments 1 to 90, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X 2 is N.
- Embodiment 92 The compound of any one of Embodiments 1 to 90, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X 2 is C.
- Embodiment 93 The compound of any one of Embodiments 1 to 90, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X 2 is CH.
- Embodiment 94 The compound of any one of Embodiments 1 to 93, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X 3 is N.
- Embodiment 95 The compound of any one of Embodiments 1 to 93, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X 3 is N.
- Embodiment 96 The compound of any one of Embodiments 1 to 93, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X 3 is C.
- Embodiment 96 The compound of any one of Embodiments 1 to 93, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X 3 is CH.
- Embodiment 97 The compound of any one of Embodiments 1 to 96, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein X 4 is C(R 2a ) 2 .
- Embodiment 1 The compound of any one of Embodiments 1 to 98, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 is H.
- Embodiment 100 The compound of any one of Embodiments 1 to 98, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 is C 1 -C 6 alkyl substituted with one or more R 12 .
- Embodiment 101 The compound of any one of Embodiments 1 to 98, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 is –CH2R 12 .
- Embodiment 102 The compound of any one of Embodiments 1 to 98, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 is –CH2R 12 .
- Embodiment 104 The compound of any one of Embodiments 1 to 98, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 is C 1 -C 6 alkenyl substituted with one or more R 12 .
- Embodiment 104 Embodiment 104.
- Embodiment 107 The compound of any one of Embodiments 1 to 103, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 12 is CN.
- Embodiment 105 The compound of any one of Embodiments 1 to 100, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 12 is C 1 -C 6 alkyl substituted with CN.
- Embodiment 106 The compound of any one of Embodiments 1 to 98, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 is –CH 2 CN.
- Embodiment 107 The compound of any one of Embodiments 1 to 103, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 12 is CN.
- Embodiment 108 Embodiment 108.
- Embodiment 110 The compound of any one of Embodiments 1 to 101, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 12 is a 3 membered heterocycloalkyl wherein 1 ring member is N, NR 6 , O and S, and wherein the heterocycloalkyl is unsubstituted.
- Embodiment 109 The compound of any one of Embodiments 1 to 101, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 12 is oxiranyl.
- Embodiment 110 The compound of any one of Embodiments 1 to 101, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 12 is oxiranyl.
- Embodiment 113 The compound of any one of Embodiments 1 to 98, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 is C1-C6alkyl.
- Embodiment 114 The compound of any one of Embodiments 1 to 98, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 1 is methyl, ethyl, propyl or isopropyl.
- Embodiment 117 Embodiment 117.
- Embodiment 119 The compound of any one of Embodiments 1 to 117, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each R 2a is independently selected from the group consisting of H, C 1 -C 6 alkyl and C 1 -C 6 alkyl substituted with CN.
- Embodiment 120 The compound of any one of Embodiments 1 to 117, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each R 2a is independently selected from the group consisting of H, C 1 -C 6 alkyl and C 1 -C 6 alkyl substituted with CN.
- each R 2a is independently selected from the group consisting of H and C 1 -C 6 alkyl.
- Embodiment 121 The compound of any one of Embodiments 1 to 117, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 2b is H.
- Embodiment 122 The compound of any one of Embodiments 1 to 117, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 2b is C 1 -C 6 alkyl.
- Embodiment 123 is
- Embodiment 128 The compound of any one of Embodiments 1 to 117, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each R 2a is independently selected from the group consisting of H and -CH 3 .
- Embodiment 126 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is -(CH 2 ) 0-6 CHR 13 R 14 .
- Embodiment 127 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is -CHR 13 R 14 .
- Embodiment 128 The compound of any one of Embodiments 1 to 117, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each R 2a is independently selected from the group consisting of H and -CH 3 .
- Embodiment 126 The compound of any one of Embodiments 1 to 125, or a
- Embodiment 130 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is benzyl which is unsubstituted or is substituted with 1, 2, 3 or 4 R 4 .
- Embodiment 129 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is benzyl which is unsubstituted or is substituted with 1 R 4 .
- Embodiment 130 Embodiment 130.
- Embodiment 131 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is a 6 membered heteroaryl wherein 1, 2 or 3 ring members are each independently selected from N, O and S, and wherein the 6 membered heteroaryl is unsubstituted or is substituted with 1, 2, 3 or 4 R 4 .
- Embodiment 131 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is a 6 membered heteroaryl wherein 1, ring member is selected from N, and wherein the 6 membered heteroaryl is unsubstituted or is substituted with 1 or 2 R 4 .
- Embodiment 132 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is pyridyl which is unsubstituted or is substituted with 1, 2, 3 or 4 R 4 .
- Embodiment 133 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is pyrid-3-yl which is unsubstituted or is substituted with 1 or 2 R 4 .
- Embodiment 134 Embodiment 134.
- Embodiment 136 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is a 9 or 10 membered bicyclic heteroaryl wherein 1, 2 or 3 ring members are each independently selected from N, NR 6 andO and S, and wherein the 9 or 10 membered bicyclic heteroaryl is unsubstituted or is substituted with 1 or 2 R 4 .
- Embodiment 136 Embodiment 136.
- Embodiment 137 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is isoquinolinyl, phthalazinyl, cinnolinyl, imidazo[1,2-c]pyrimidinyl, pyrazolo[1,5-a]pyrazinyl, benzo[c]isoxazolyl, imidazo[1,2-a]pyrazinyl, imidazo[1,2-a]pyridinyl or naphthyridinyl, each of which is unsubstituted or substituted with 1, 2, 3 or 4 R 4 .
- Embodiment 137 Embodiment 137.
- Embodiment 138 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is isoquinolin-4-yl, phthalazin-4-yl, cinnolin-4-yl, imidazo[1,2-c]pyrimidin-8-yl, pyrazolo[1,5-a]pyrazin-7-yl, benzo[c]isoxazol-3-yl, imidazo[1,2-a]pyrazine-5-yl, imidazo[1,2-a]pyridine-3-yl or naphthyridin-4-yl, each of which is unsubstituted or substituted with 1, 2, 3 or 4 R 4 .
- Embodiment 138 Embodiment 138.
- Embodiment 140 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is , , , , , N N N , or , each of which is unsubstituted or substituted with 1 or 2 R 4 .
- Embodiment 139 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is isoquinolinyl which is unsubstituted or substituted with 1 or 2 R 4 .
- Embodiment 140 Embodiment 140.
- Embodiment 141 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is isoquinolin-4-yl which is unsubstituted or substituted with 1 or 2 R 4 .
- Embodiment 141 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is isoquinolin-4-yl which is unsubstituted.
- Embodiment 142 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is phthalazinyl which is unsubstituted or substituted with 1 or 2 R 4 .
- Embodiment 143 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is phthalaziny-4-yl which is unsubstituted or substituted with 1 or 2 R 4 .
- Embodiment 144 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is phthalaziny-4-yl which is unsubstituted.
- Embodiment 145 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is phthalaziny-4-yl which is unsubstituted.
- Embodiment 148 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is a 6 membered heterocyclyl wherein 1 ring member is selected from NR 6 , and wherein the 6 membered heterocyclyl substituted with an oxo.
- Embodiment 148 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is pyridinyl-2(1H)-one which is unsubstituted or substituted with 1, 2, 3 or 4 R 4 .
- Embodiment 149 Embodiment 149.
- Embodiment 150 he compound of any one of Embodiments 1 to 125, or a pharmaceutically Embodiment 151.
- Embodiment 156 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is , , or , each of which is unsubstituted or substituted with 1 or 2 R 4 .
- Embodiment 156 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is , , or , each of which is unsubstituted or substituted with 1 or 2 R 4 .
- R 3 is isoquinolinyl, isochromanyl, pyridyl, phthalazinyl, cinnolinyl, imidazo[1,2-c]pyrimidinyl, pyrazolo[1,5- a]pyrazinyl, 3a,7a-dihydro-1H-pyrrolo[2,3-c]pyridinyl, benzo[c]isoxazolyl, imidazo[1,2- a]pyrazinyl, pyridinyl-2(1H)-one, quinolinyl-2(1H)-one, imidazo[1,2-a]pyridinyl, naphthyridinyl or 3a,7a-dihydro-1H-indazolyl, each of which is unsubstituted or substituted with 1 or 2 R 4 .
- Embodiment 157 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is Embodiment 158.
- Embodiment 159 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is a 10 membered bicyclic heteroaryl with an attachment point at a carbon atom ring member and a N heteroatom as a ring member which is located at a beta ( ⁇ ) position relative to the attachment point, wherein the 10 membered bicyclic heteroaryl has 0, 1, 2 or 3 additional N heteroatoms as ring members, and wherein the 10 membered bicyclic heteroaryl is unsubstituted or is substituted with 1, 2, 3 or 4 R 4 .
- Embodiment 160 Embodiment 160.
- R 3 is a 9 membered bicyclic heteroaryl with an attachment point at a carbon atom ring member and a N heteroatom as a ring member which is located at a beta ( ⁇ ) position relative to the attachment point, wherein the 9 membered bicyclic heteroaryl further has 0, 1, 2, 3, or 4 ring members each independently selected from N, NR 6 , O and S, and wherein the 9 membered bicyclic heteroaryl is unsubstituted or is substituted with 1, 2, 3 or 4 R 4 .
- Embodiment 163 is a 9 membered bicyclic heteroaryl with an attachment point at a carbon atom ring member and a N heteroatom as a ring member which is located at a beta ( ⁇ ) position relative to the attachment point, wherein the 9 membered bicyclic heteroaryl further has 0, 1, 2, 3, or 4 ring members each independently selected from N, NR 6 , O and S, and wherein the 9 membered bicyclic heteroaryl is unsubstituted
- R 3 is a 5 or 6 membered heterocycloalkyl with an attachment point at a carbon atom ring member and a NR 6 as a ring member which is located at a beta ( ⁇ ) position relative to the attachment point, wherein the 5 or 6 membered heterocycloalkyl further has 0, 1, or 2 ring members each independently selected from N, NR 6 , O and S, and wherein the 5 or 6 membered heterocycloalkyl is unsubstituted, substituted with 1 or 2 oxo, or is substituted with 1, 2, 3 or 4 R 4 and optionally substituted with 1 or 2 oxo.
- Embodiment 164 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is a 5 or 6 membered heterocyclyl with an attachment point at a carbon atom ring member and a NR 6 as a ring member which is located at a beta ( ⁇ ) position relative to the attachment point, wherein the 5 or 6 membered heterocyclyl further has 0, 1, or 2 ring members each independently selected from N, NR 6 , O and S, and wherein the 5 or 6 membered heterocyclyl is unsubstituted, substituted with 1 or 2 oxo, or is substituted with 1, 2, 3 or 4 R 4 and optionally substituted with 1 or 2 oxo.
- Embodiment 165 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is a 9 or 10 membered bicyclic heterocyclyl with an attachment point at a carbon atom ring member and a NR 6 as a ring member which is located at a beta ( ⁇ ) position relative to the attachment point, wherein the 9 or 10 membered heterocyclyl further has 0, 1, 2, 3, or 4 ring members each independently selected from N, NR 6 , O and S, and wherein the 9 or 10 membered heterocyclyl is unsubstituted, substituted with 1 or 2 oxo, or is substituted with 1, 2, 3 or 4 R 4 and optionally substituted with 1 or 2 oxo.
- R 3 is a 9 or 10 membered bicyclic heterocyclyl with an attachment point at a carbon atom ring member and a NR 6 as a ring member which is located at a beta ( ⁇ ) position relative to the
- Embodiment 166 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is a 9 or 10 membered bicyclic heterocyclyl with an attachment point at a carbon atom ring member and a O heteroatom as a ring member which is located at a beta ( ⁇ ) position relative to the attachment point, wherein the 9 or 10 membered heterocyclyl further has 0, 1, 2, 3, or 4 ring members each independently selected from N, NR 6 , O and S, and wherein the 9 or 10 membered heterocyclyl is unsubstituted, substituted with 1 or 2 oxo, or is substituted with 1, 2, 3 or 4 R 4 and optionally substituted with 1 or 2 oxo.
- R 3 is a 9 or 10 membered bicyclic heterocyclyl with an attachment point at a carbon atom ring member and a O heteroatom as a ring member which is located at a beta ( ⁇ ) position relative to the
- Embodiment 167 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is a 6 membered heterocyclyl with an attachment point at a carbon atom ring member and a carbon atom as a ring member which is substituted with oxo and located at a beta ( ⁇ ) position relative to the attachment point, wherein the 6 membered heterocyclyl further has 1 or 2 ring members each independently selected from N, NR 6 , O and S, and wherein the 6 membered heterocyclyl is unsubstituted or is substituted with 1, 2, 3 or 4 R 4 and optionally substituted with an oxo.
- Embodiment 168 Embodiment 168.
- Embodiment 171 The compound of any one of Embodiments 1 to 125, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 3 is isoquinolin-4-yl which is unsubstituted or is substituted with 1 or 2 R 4 .
- Embodiment 176 Embodiment 176.
- Embodiment 177 Embodiment 177.
- Embodiment 180 The compound of any one of Embodiments 1 to 174, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 5 is C 1 -C 6 haloalkyl, halo or C 1 -C 6 haloalkoxy.
- Embodiment 181. The compound of any one of Embodiments 1 to 174, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 5 is -CF 3 , F, Cl, - OCHF 2 or -OCF 3 .
- each R 5 is independently selected from the group consisting of F, Br, Cl, -CF 3 , -CHF 2 , -CH 2 F, -C(CH 3 )F 2 , -CH 3 , isopropyl, -OCHF 2 , -OCClF 2 , -OCF 3 , -OCH 3 , SF 5 , -C(CH 3 ) 2 OH, -CH 2 CF 3 , -CH(CH 3 )CF 3 , an unsubstituted cyclopropyl, a cyclopropyl substituted with 1 R 9 , and a cyclobutyl substituted with 1 or 2 R 9 .
- Embodiment 183 The compound of any one of Embodiments 1 to 181, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each R 6 is independently selected from the group consisting of H and C 1 -C 6 alkyl.
- Embodiment 185 Embodiment 185.
- Embodiment 186 The compound of any one of Embodiments 1 to 185, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each R 7 is H.
- Embodiment 187 The compound of any one of Embodiments 1 to 185, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each R 7 is C 1 -C 6 alkyl.
- Embodiment 188 The compound of any one of Embodiments 1 to 181, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each R 6 is independently selected from the group consisting of H, -CH 3 , and -CH 2 CH 2 OR 7 .
- Embodiment 191 The compound of any one of Embodiments 1 to 185, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein each R 7 is independently selected from the group consisting of H and -CH 3 .
- Embodiment 189 The compound of any one of Embodiments 1 to 188, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 8 is H.
- Embodiment 190 The compound of any one of Embodiments 1 to 188, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 8 is C 1 -C 6 alkyl.
- Embodiment 193 The compound of any one of Embodiments 1 to 188, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 8 is C 3 -C 8 cycloalkyl, wherein the cycloalkyl is unsubstituted or is substituted with 1, 2, 3 or 4 R 9 .
- Embodiment 192 The compound of any one of Embodiments 1 to 188, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 8 is C 3 -C 8 cycloalkyl, wherein the cycloalkyl is unsubstituted or is substituted with 1 or 2 R 9 .
- Embodiment 195 The compound of any one of Embodiments 1 to 194, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 9 is NR 10 R 11 .
- Embodiment 196 The compound of any one of Embodiments 1 to 188, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 8 is a 4 to 6 membered heterocycloalkyl wherein 1, 2, 3 or 4 ring members are each independently selected from N, NR 6 , O and S, and wherein the heterocycloalkyl is unsubstituted or is substituted with 1, or 2 R 9 .
- Embodiment 195 The compound of any one of Embodiments 1 to 194, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 9 is NR 10 R 11 .
- Embodiment 196 The compound of any one of Embodiments 1 to 188, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 8 is a 4 to 6 membere
- Embodiment 197 The compound of any one of Embodiments 1 to 194, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 9 is C 1 -C 6 alkyl substituted with -OH or -N(R 7 ) 2 .
- Embodiment 200 The compound of any one of Embodiments 1 to 198, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 10 is H.
- Embodiment 200 The compound of any one of Embodiments 1 to 198, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 10 is C 1 -C 6 alkyl.
- Embodiment 201 The compound of any one of Embodiments 1 to 198, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 10 is H or -CH 3 ;
- Embodiment 202 The compound of any one of Embodiments 1 to 201, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 11 is H.
- Embodiment 203 The compound of any one of Embodiments 1 to 198, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 11 is H.
- Embodiment 203 The compound of any one of Embodiments 1 to 198, or
- Embodiment 204 The compound of any one of Embodiments 1 to 201, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 11 is C 1 -C 6 alkyl.
- Embodiment 205 The compound of any one of Embodiments 1 to 204, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 13 is H.
- Embodiment 206 The compound of any one of Embodiments 1 to 204, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 13 is H.
- Embodiment 207 The compound of any one of Embodiments 1 to 204, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 13 is a 5 or 6 membered heteroaryl wherein 1, 23 or 4 ring members are each independently selected from N, NR 6 , O and S.
- Embodiment 208 The compound of any one of Embodiments 1 to 204, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 13 is a 5 or 6 membered heteroaryl wherein 1, 23 or 4 ring members are each independently selected from N, NR 6 , O and S.
- Embodiment 211 The compound of any one of Embodiments 1 to 207, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 14 is 6 membered heterocyclyl wherein 1 ring member is selected from N, NR 6 , O and S, and wherein the 6 membered heterocyclyl is substituted with an oxo.
- Embodiment 211 The compound of any one of Embodiments 1 to 207, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 14 is 6 membered heterocyclyl wherein 1 ring member is selected from NR 6 , and wherein the 6 membered heterocyclyl is substituted with an oxo.
- Embodiment 212 The compound of any one of Embodiments 1 to 207 or a pharmaceutically acceptable salt or stereoisomer thereof, wherein R 14 is 6 membered heterocyclyl wherein 1 ring member is selected from NR 6 , and wherein the 6 membered heterocyclyl is substituted
- Embodiment 215. The compound of Embodiment 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound is selected from: 7-fluoro-3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione; 3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione; 2-(3-(isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4-dihydroquinazolin-1(2H)- yl)acetonitrile; 3-(isoquinolin-4-yl)-6-(trifluoromethoxy)quinazoline-2,4(1H,3H)-dione; 3-(isoquinolin-4-yl)-6-(trifluoromethyl)pyrido[2,3-
- Embodiment 217 The compound of Embodiment 1, or a pharmaceutically acceptable salt or stereoisomer thereof, wherein the compound is selected from:
- the compounds can be present in the form of one of the possible isomers or as mixtures thereof, for example as pure optical isomers, or as isomer mixtures, such as racemates and diastereoisomer mixtures, depending on the number of asymmetric carbon atoms.
- the present invention is meant to include all such possible isomers, including racemic mixtures, diasteriomeric mixtures and optically pure forms.
- Optically active (R)- and (S)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituent may be E or Z configuration.
- the cycloalkyl substituent may have a cis- or trans-configuration. All tautomeric forms are also intended to be included.
- the terms “salt” or “salts” refers to an acid addition or base addition salt of a compound of the invention. “Salts” include in particular “pharmaceutical acceptable salts”.
- pharmaceutically acceptable salt or “pharmaceutically acceptable salts”, as used herein, refers to a salt or salts that retain the biological effectiveness and properties of the compounds of this invention and, which typically are not biologically or otherwise undesirable.
- the compounds of the present invention are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
- Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids.
- the organic acid or inorganic acids used to form pharmaceutically acceptable acid addition salts of compounds of the present invention include, but are not limited to, acetic acid, adipic acid, ascorbic acid, aspartic acid, benzoic acid, benzenesulfonic acid, carbonic acid, camphor sulfonic acid, capric acid, chlorotheophyllinate, citric acid, ethanedisulfonic acid, fumaric acid, D-glycero-D-gulo-Heptonicacid, galactaric aid, galactaric acid/mucic acid, gluceptic acid, glucoheptonoic acid, gluconic acid, glucuronic acid, glutamatic acid, glutaric acid, glycolic acid, hippuric acid,
- Salt forms of the compounds of the present invention can be converted into the free compounds by treatment with a suitable basic agent.
- Pharmaceutically acceptable acid addition salts of compounds of the present invention include, but are not limited to, a acetate, adipate, ascorbate, aspartate, benzoate, besylatye, benzenesulfonate, bicarbonate/carbonate, bisulfate/sulfate, bromide/hydrobromide, camphor sulfonate, camsylate, caprate, chloride/hydrochloride, chlorotheophyllinate, citrate, edisylate, ethanedisulfonate, fumarate, gluceptate, glucoheptonate, gluconate, glucuronate, glutamate, glutarate, glycolate, hippurate, hydroiodide/iodide, isethionate, lactate, lactobionate, laurylsulphate, malate, maleate, malon
- Organic bases used to form pharmaceutically acceptable base addition salts of compounds of the present invention include, but are not limited to, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like. Certain organic amines include isopropylamine, benzathine, cholinate, diethanolamine, diethylamine, lysine, meglumine, piperazine and tromethamine.
- Inorganic bases used to form pharmaceutically acceptable base addition salts of compounds of the present invention include, but are not limited to, sodium hydroxide, potassium hydroxide, ammonium hydroxide, ammonium salts and metals from columns I to XII of the periodic table.
- Pharmaceutically acceptable base addition salts of compounds of the present invention include, but are not limited to, sodium, potassium, ammonium, calcium, magnesium, iron, silver, zinc, and copper salts; particularly suitable salts include ammonium, potassium, sodium, calcium and magnesium salts.
- the pharmaceutically acceptable salts of the present invention can be synthesized from a basic or acidic moiety, by conventional chemical methods.
- such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid.
- a stoichiometric amount of the appropriate base such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate or the like
- Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two.
- non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is desirable, where practicable.
- Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds.
- lsotopically labeled compounds have structures depicted by the formulae given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number.
- Isotopes that can be incorporated into compounds of the present invention include, for example, isotopes of hydrogen. Further, incorporation of certain isotopes, particularly deuterium (i.e., 2 H or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased in vivo half-life or reduced dosage requirements or an improvement in therapeutic index or tolerability. It is understood that deuterium in this context is regarded as a substituent of a compound of the present invention. The concentration of deuterium, may be defined by the isotopic enrichment factor.
- isotopic enrichment factor means the ratio between the isotopic abundance and the natural abundance of a specified isotope. If a substituent in a compound of this invention is denoted as being deuterium, such compound has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium incorporation), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
- isotopic enrichment factor can be applied to any isotope in the same manner as described for deuterium.
- isotopes that can be incorporated into compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, and chlorine, such as 3 H, 11 C, 13 C, 14 C, 15 N, 18 F 31 P, 32 P, 35 S, 36 Cl, 123 I, 124 I, 125 I respectively.
- the invention includes compounds that incorporate one or more of any of the aforementioned isotopes, including for example, radioactive isotopes, such as 3 H and 14 C, or those into which non-radioactive isotopes, such as 2 H and 13 C are present.
- isotopically labelled compounds are useful in metabolic studies (with 14 C), reaction kinetic studies (with, for example 2 H or 3 H), detection or imaging techniques, such as positron emission tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays, or in radioactive treatment of patients.
- PET positron emission tomography
- SPECT single-photon emission computed tomography
- an 18 F or labeled compound may be particularly desirable for PET or SPECT studies.
- Isotopically- labeled compounds of the present invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagents in place of the non-labeled reagent previously employed.).
- compounds of the present invention can exist in a deuterated form as shown below: Any asymmetric atom (e.g., carbon or the like) of the compound(s) of the present invention can be present in racemic or enantiomerically enriched, for example the (R)-, (S)- or (R,S)- configuration.
- each asymmetric atom has at least 50 % enantiomeric excess, at least 60 % enantiomeric excess, at least 70 % enantiomeric excess, at least 80 % enantiomeric excess, at least 90 % enantiomeric excess, at least 95 % enantiomeric excess, or at least 99 % enantiomeric excess in the (R)- or (S)- configuration.
- Substituents at atoms with unsaturated double bonds may, if possible, be present in cis- (Z)- or trans- (E)- form.
- a compound of the present invention can be in the form of one of the possible isomers, rotamers, atropisomers, tautomers or mixtures thereof, for example, as substantially pure geometric (cis or trans) isomers, diastereomers, optical isomers (antipodes), racemates or mixtures thereof. Any resulting mixtures of isomers can be separated on the basis of the physicochemical differences of the constituents, into the pure or substantially pure geometric or optical isomers, diastereomers, racemates, for example, by chromatography and/or fractional crystallization.
- any resulting racemates of final products or intermediates can be resolved into the optical antipodes by known methods, e.g., by separation of the diastereomeric salts thereof, obtained with an optically active acid or base, and liberating the optically active acidic or basic compound.
- a basic moiety may thus be employed to resolve the compounds of the present invention into their optical antipodes, e.g., by fractional crystallization of a salt formed with an optically active acid, e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-O,O'-p- toluoyl tartaric acid, mandelic acid, malic acid or camphor-10-sulfonic acid.
- an optically active acid e.g., tartaric acid, dibenzoyl tartaric acid, diacetyl tartaric acid, di-O,O'-p- toluoyl tartaric acid, mandelic acid, malic acid
- Racemic products can also be resolved by chiral chromatography, e.g., high pressure liquid chromatography (HPLC) using a chiral adsorbent.
- HPLC high pressure liquid chromatography
- Scheme 2 In scheme 2, starting from an amino-acid, e.g. substituted anthranilic acids, amide bond formation with a commercially available amine, e.g. isoquilonine-4-amine, mediated by a coupling agent, e.g. HATU gives an amide. The amide undergoes cyclization in the presence of a carbonyl donor such as triphosgene, CDI or a mixture of CDI and CDT.
- Scheme 3 In scheme 3, the product is obtained by addition of an amino-ester to an isocyanate in the presence of a base, e.g. pyridine. The isocyanate is commercially available or can be prepared from the corresponding amine and triphosgene.
- Scheme 4 The isocyanate is commercially available or can be prepared from the corresponding amine and triphosgene.
- an amino-ester e.g. an ethyl ester of substituted anthranilic acid is reacted with a chloroformate, e.g. phenylchloroformate or p-nitrophenylchloroformate in the presence of a base. e.g. pyridine, to give a carbamate.
- a base e.g. pyridine
- the product is then obtained by addition of an amine, e.g. isoquinoline-4-amine, in the presence of a base, e.g. DBU.
- Scheme 5 5
- a urea is formed by first reacting an amino-ester with triphosgene and a base, e.g. triethylamine, to form the corresponding isocyanate, which is trapped by amine to form a urea. Treating the urea with a base, such as potassium carbonate, gives the product.
- a base such as potassium carbonate
- Administration and Pharmaceutical Compositions For the therapeutic uses of compounds of the present invention, such compounds are administered either alone or as part of a pharmaceutical composition. Accordingly, in another aspect of the present invention provides a pharmaceutical composition, which comprises a compound of the present invention, or pharmaceutically acceptable salt or stereoisomer thereof, and one or more pharmaceutically acceptable carriers. In a further embodiment, the composition comprises at least two pharmaceutically acceptable carriers, such as those described herein.
- the pharmaceutical composition can be formulated for particular routes of administration such as oral administration, parenteral administration (e.g. by injection, infusion, transdermal or topical administration), and rectal administration. Topical administration may also pertain to inhalation or intranasal application.
- the pharmaceutical composition comprising a compound of the present invention can be formulated for intramuscularly, intravenously, subcutaneously, orally, pulmonary, intrathecally, topically or intranasally administration.
- the pharmaceutical compositions of the present invention can be made up in a solid form (including without limitation capsules, tablets, pills, granules, powders or suppositories), or in a liquid form (including without limitation solutions, suspensions or emulsions).
- Tablets may be either film coated or enteric coated according to methods known in the art.
- the pharmaceutical compositions are tablets or gelatin capsules comprising the active ingredient together with a) diluents, e.g., lactose, dextrose, sucrose, mannitol, sorbitol, cellulose and/or glycine; b) lubricants, e.g., silica, talcum, stearic acid, its magnesium or calcium salt and/or polyethyleneglycol; for tablets also c) binders, e.g., magnesium aluminum silicate, starch paste, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose and/or polyvinylpyrrolidone; if desired d) disintegrants, e.g., starches, agar, alginic acid or its sodium salt, or effervescent mixtures; and/or e) absorbents, colorants, flavors and sweeteners.
- compositions for oral administration include a compound of the present invention in the form of tablets, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsion, hard or soft capsules, or syrups or elixirs.
- Compositions intended for oral use are prepared according to any method known in the art for the manufacture of pharmaceutical compositions and such compositions can contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets may contain the active ingredient in admixture with nontoxic pharmaceutically acceptable carriers/excipients which are suitable for the manufacture of tablets.
- carriers/excipients are, for example, inert diluents, such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example magnesium stearate, stearic acid or talc.
- the tablets are uncoated or coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
- a time delay material such as glyceryl monostearate or glyceryl distearate can be employed.
- Formulations for oral use can be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example, peanut oil, liquid paraffin or olive oil.
- the parenteral compositions e.g, intravenous (IV) formulation
- IV intravenous
- the parenteral compositions are aqueous isotonic solutions or suspensions.
- the parenteral compositions may be sterilized and/or contain adjuvants, such as preserving, stabilizing, wetting or emulsifying agents, solution promoters, salts for regulating the osmotic pressure and/or buffers. In addition, they may also contain other therapeutically valuable substances.
- compositions are generally prepared according to conventional mixing, granulating or coating methods, respectively, and contain about 0.1-75%, or contain about 1-50%, of the active ingredient.
- the compound of the present invention or pharmaceutical composition thereof for use in a subject e.g., human
- the dosage may depend upon the infusion rate at which an iv formulation is administered.
- the therapeutically effective dosage of a compound, the pharmaceutical composition, or the combinations thereof is dependent on the species of the subject, the body weight, age and individual condition, the disorder or disease or the severity thereof being treated.
- the above-cited dosage properties are demonstrable in vitro and in vivo tests using advantageously mammals, e.g., mice, rats, dogs, monkeys or isolated organs, tissues and preparations thereof.
- the compounds of the present invention can be applied in vitro in the form of solutions, e.g., aqueous solutions, and in vivo either enterally, parenterally, advantageously intravenously, e.g., as a suspension or in aqueous solution.
- Certain aspects and examples of the pharmaceutical compositions of the present invention are provided in the following listing of enumerated embodiments. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of the present invention. Embodiment 218.
- a pharmaceutical composition comprising a compound of Formula (I) or any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt or stereoisomer thereof, and one or more pharmaceutically acceptable carriers.
- a pharmaceutical composition comprising a compound of Embodiment 218, or a pharmaceutically acceptable salt or stereoisomer thereof, and one or more pharmaceutically acceptable carriers.
- the pharmaceutical composition of Embodiment 218 or Embodiment 219 comprising one or more additional therapeutic agents.
- Pharmacology and Utility The compounds of the invention, in free form or in pharmaceutically acceptable salt form, exhibit valuable pharmacological properties, e.g.
- the compounds of the invention may generally be useful in the treatment, management and/or prevention of a coronaviral-related disease.
- Certain aspects and examples of the use of compounds of the present invention and pharmaceutical compositions of the present invention are provided in the following listing of enumerated embodiments. It will be recognized that features specified in each embodiment may be combined with other specified features to provide further embodiments of the present invention. Embodiment 221.
- Embodiment 222. A method for treating a disease or disorder associated with the activity of SARS-CoV-2 main protease (M pro ), wherein the method comprises administering to a subject in need of such treatment a compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt.
- Embodiment 224 Use of a compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease or disorder associated with the activity of SARS-CoV-2 main protease (M pro ).
- Embodiment 224 Use of a compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt thereof, in the treatment of a disease or disorder associated with the activity of SARS-CoV-2 main protease (M pro ).
- Embodiment 225 A compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease or disorder associated with the activity of SARS-CoV-2 main protease (M pro ).
- Embodiment 226 A method for treating, managing and/or preventing a coronaviral-related disease in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt thereof.
- Embodiment 227 A method for treating, managing and/or preventing a coronaviral-related disease in a subject in need thereof, wherein the method comprises administering to the subject a compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt thereof.
- Embodiment 228 A method for treating, managing and/or preventing a coronaviral-related disease in a subject in need thereof, wherein the method comprises administering to the subject a compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt thereof.
- Embodiment 22 Use of a compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment, management and/or prevention of a coronaviral-related disease.
- Embodiment 230 A compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt thereof, for use in the treatment, management and/or prevention of a coronaviral-related disease.
- a method for treating a coronaviral-related disease in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt thereof.
- Embodiment 232 A method for treating a coronaviral-related disease in a subject in need thereof, wherein the method comprises administering to the subject a compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt thereof.
- Embodiment 233. Use of a compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment a coronaviral-related disease.
- Embodiment 217 Use of a compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt thereof, in the treatment of a coronaviral-related disease.
- Embodiment 235 A compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt thereof, for use in the treatmen of a coronaviral-related disease.
- Embodiment 236 A method for treating, managing and/or preventing COVID-19 disease in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt thereof.
- Embodiment 237 A method for treating, managing and/or preventing COVID-19 disease in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt thereof.
- a method for treating, managing and/or preventing COVID-19 disease in a subject in need thereof comprising administering to the subject a compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt thereof.
- Embodiment 238 Use of a compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment, management and/or prevention of COVID-19 disease.
- Embodiment 240 Use of a compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt thereof, in the treatment, management and/or prevention of COVID-19 disease.
- Embodiment 241 A method for treating COVID-19 disease in a subject in need thereof, wherein the method comprises administering to the subject a therapeutically effective amount of a compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt thereof.
- Embodiment 242. A method for treating COVID-19 disease in a subject in need thereof, wherein the method comprises administering to the subject a compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt thereof.
- Embodiment 243 A method for treating COVID-19 disease in a subject in need thereof, wherein the method comprises administering to the subject a compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt thereof.
- Embodiment 244 Use of a compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of COVID-19 disease.
- Embodiment 245. Use of a compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt thereof, for use in the treatment of COVID-19 disease.
- Embodiment 246. The method of any one of Embodiments 221, 222, 226, 227, 231, 232, 236, 237, 241 and 242, wherein the coronaviral-related disease is COVID-19.
- Embodiment 247 The use of a compound of any one of Embodiments 223, 224, 228, 229, 233, 234, 238, 239, 243 and 244, wherein the coronaviral-related disease is COVID-19.
- Embodiment 248 The compound for the use in treatment of any one of Embodiments 225, 230, 235, 240 and 245, wherein the coronaviral-related disease is COVID-19.
- Embodiment 249. A method for inhibiting the activity of SARS-CoV-2 main protease (M pro ), wherein the method comprises administering to a subject in need of such treatment a therapeutically effective amount of a compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt.
- Embodiment 250 A method for inhibiting the activity of SARS-CoV-2 main protease (M pro ), wherein the method comprises administering to a subject in need of such treatment a compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt.
- Embodiment 251. Use of a compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt thereof, in the inhibition of the activity of SARS-CoV-2 main protease (M pro ).
- Embodiment 252. A compound of any one of Embodiments 1 to 217, or a pharmaceutically acceptable salt thereof, for use in the inhibition of the activity of SARS-CoV-2 main protease (M pro ).
- a therapeutic agent is, for example, a chemical compound, peptide, antibody, antibody fragment or nucleic acid, which is therapeutically active or enhances the therapeutic activity when administered to a patient in combination with a compound of the present invention.
- Compounds of the invention may be administered as the sole active ingredient or together with other active agents useful against a coronaviral-related disease. Accordingly, another aspect of the invention are combination for use in the treatment, prevention and/or management of a coronaviral related disease, wherein a compound of the invention is used in combination with one or more other active agents.
- the active agent(s) is selected from a neutralizing antibody and an antiviral agent.
- the active agent(s) is selected from a neutralizing antibody, an antiviral agent and other agents selected from alvelestat, Lenzilumab, Octagam, Remestemcel-L, RPH-104 + olokizumab, Bucillamine, CD24FC (MK-7110), Tradipitant, Ifenprodil, Tocilizumab, Leronlimab, Fenretinide, ATYR-1923, CYTO-205, APN-01, and Ampion.
- the neutralizing antibody is selected from Bamlanivimab, bamlanivimab + etesevimab, bamlanivimab + VIR-7831, REGN-COV2, VIR-7831, AZD7442, Regdanvimab/CT-P59, ABP-300, , COVI-AM/STI-2020, VIR-7832, SAB- 185, JS016/etesevimab, C-135LS/C-144LS, BRII-196, BRII-198, SCTA-01, MW-33, DXP593, HFB-30132A, ADG20, COVI-GUARD (STI-1499) and convalescent plasma, and the antiviral agents is selected from remdesivir, Avigan/favipiravir, EIDD-2801/molnupiravir, AT-527, PF- 00835231, PF-07321332, Ensovibep/DARPins, galides
- a compound of the invention is used in combination with remdesivir (also known as 2-ethylbutyl ((((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5- cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate) for the treatment, prevention and/or management of a coronaviral related disease.
- remdesivir also known as 2-ethylbutyl ((((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5- cyano-3,4-dihydroxytetrahydrofuran-2-yl)methoxy
- remdesivir also known as 2-ethylbutyl ((((2R,
- a compound of the invention is used in combination with an antibody for the treatment, prevention and/or management of a coronaviral related disease, wherein the antibody selected from ABBV 47D11, ABP-300, ADG20, Bamlanivimab + VIR- 7831, Bamlanivimab+etesevimab, BRII196 + BRII198, C-135LS/C-144LS, Convalescent Plasma, COR-101, CT-P63, DXP593, Etesevimab (JS016), Evusheld/AZD-7442, HFB-30132A, IBIO123, IN-006, JMB2002, LY-CoV1404, Ly-CovMab, MAD0004J08, MW-33, REGEN- COV/Ronapreve, Regkirona/Regdanvimab, SAB-185, SCTA-01, STI-2099/COVIDROPS, TY027, VIR-7832 (GSK
- a compound of the invention is used in combination with an antiviral agent for the treatment, prevention and/or management of a coronaviral related disease, wherein the antiviral agent selected from ABX-464, alisporivir, alvelestat, ANA-001, Apabetalone, Arakoda (Tafenoquine), ASC-09 + ritonavir, ASC11, AT-100, AT-301, AT-527 (Bemnifosubuvir), AT-H201, ATR-002, boceprivir, brequinar, Bucillamine, Camostat (DWJ1248), Camostat mesylate, Carrimycin, DC-402234 (FB2001), Ebeselen (SPI-1005), EDP-235, Elsulfavirine, Ensitrelvir/S-217622, Ensovibep, Favipiravir, FP-025, Galidesivir, Gamunex-C, Lüvrio/Molnupir
- a compound of the invention is used in combination with other active agents for the treatment, prevention and/or management of a coronaviral related disease, wherein active agents is selected from Actemra/RoActemra, Ampion, APN-01 (alunacedase alfa), ATR-002, ATYR-1923, CYTO-205, Fenretinide (LAU-7b), Lenzilumab, Leronlimab, Octagam, Olumiant +/- Veklury , Remestemcel-L, RPH-104 + olokizumab, sarilumab , tocilizumab and Tradipitant.
- active agents is selected from Actemra/RoActemra, Ampion, APN-01 (alunacedase alfa), ATR-002, ATYR-1923, CYTO-205, Fenretinide (LAU-7b), Lenzilumab, Leronlimab, Octagam, Olumi
- LCMS conditions LCMS Method 1: Instrument: Agilent 1200 & 6110, ESI; Column: Kinetex C1850mmx2.1mm, 5 ⁇ m; Gradient: mobile phase A: 0.04% trifluoroacetic acid in water, B: 0.02% trifluoroacetic acid in acetonitrile; 5%B for 0.4 min, 5-95% B over 2.6 min, 95% B for 1.0 min, 95-5%B over 0.01 min; Flow rate: 1.0 mL/min; UV detection 215 nm and 254 nm; Mass detection MS
- LCMS Method 4 Instrument: Agilent 1260 & 6120, ESI; Column: Luna LC-C1850mmx2mm, 5 ⁇ m; Gradient: mobile phase A: 0.05% trifluoroacetic acid in water, B: 0.05% trifluoroacetic acid in acetonitrile; 1%B for 0.4 min, 1-90% B over 3.0 min, 90-100% B over 0.45 min, 100-1%B over 0.01 min; Flow rate: 0.8 mL/min; UV detection 215 nm and 254 nm; Mass detection MS range 100-1000 Da (ESI); Column temperature: 40 °C.
- LCMS Method 7 Instrument: Agilent 1200 & G6120B, ESI; Column: Kinetex EVO C18100A 30mm ⁇ 2.1mm, 5 ⁇ m; Gradient: mobile phase A: 0.04% trifluoroacetic acid in water, B: 0.02% trifluoroacetic acid in acetonitrile; 5-95% B over 0.69 min, 95% B for 0.45 min, 95-5%B over 0.01 min; Flow rate: 1.5 mL/min; UV detection 220 and 254 nm; Mass detection MS range 100- 1000 Da (ESI); Column temperature: 40 °C.
- LCMS Method 8 Instrument: Agilent 1260 & 6125B, ESI; Column: Kinetex EVO C18 30mm ⁇ 2.1mm, 5 ⁇ m; Gradient: mobile phase A: 0.04% trifluoroacetic acid in water, B: 0.02% trifluoroacetic acid in acetonitrile; 5-95% B over 0.8 min, 95% B for 0.4 min, 95-5%B over 0.01 min; Flow rate: 2.0 mL/min; UV detection 220 nm; Mass detection MS range 100-1000 Da (ESI); Column temperature: 40 °C.
- LCMS Method 10 Instrument: Shimadzu LC-20AD&MS 2020, ESI; Column: Kinetex EVO C18 30mm ⁇ 2.1mm, 5 ⁇ m; Gradient: mobile phase A: 0.04% trifluoroacetic acid in water, B: 0.02% trifluoroacetic acid in acetonitrile; 5-95% B over 0.69 min, 95%B for 0.46 min, 95-5% over 0.34 min; Flow rate: 1.5 mL/min; UV detection 220 and 254 nm; Mass detection MS range 100-1000 Da (ESI); Column temperature: 40 °C.
- LCMS Method 11 Instrument: Shimadzu LC-20AD&MS 2020, ESI; Column: Halo C18 30mmx3.0mm, 2.7 ⁇ m; Gradient: mobile phase A: 0.04% trifluoroacetic acid in water, B: 0.02% trifluoroacetic acid in acetonitrile; 5% B over 0.01 min., 5-95% B over 0.69 min, 95%B for 0.46 min, 95-5% over 0.34 min; Flow rate: 1.5 mL/min; UV detection 220 and 254 nm; Mass detection MS range 100-1000 Da (ESI); Column temperature: 40 °C.
- LCMS Method 12 Instrument: Shimadzu LC-20AB&MS 2010, ESI; Column: Xbridge C18 50mmx2.1mm, 5 ⁇ m; Gradient: mobile phase A: 10 mM NH 4 HCO 3 in water, B: acetonitrile; 5%B for 0.01 min., 5-95% B over 0.69 min, 95%B for 0.46 min, 95-5% over 0.34 min; Flow rate: 1.5 mL/min; UV detection 220 and 254 nm; Mass detection MS range 100-1000 Da (ESI); Column temperature: 40 °C.
- LCMS Method 13 Instrument: Agilent 1260 & 6120, ESI; Column: Luna LC-C1850mmx2mm, 5 ⁇ m; Gradient: mobile phase A: 0.04% trifluoroacetic acid in water, B: 0.02% trifluoroacetic acid in acetonitrile; 5%B for 0.4 min, 5-95% B over 2.6 min, 95% B over 1.0 min, 95-5% B over 0.01 min., 5% B over 0.49 min.; Flow rate: 1.0 mL/min; UV detection 215 nm and 254 nm; Mass detection MS range 100-1000 Da (ESI); Column temperature: 40 °C.
- LCMS Method 14 Instrument: Shimadzu LC-20AD&MS 2020, ESI; Column: InfinityLab Poroshell SB-C1830mmx3.0mm 2.7 ⁇ m; Gradient: mobile phase A: 0.04% trifluoroacetic acid in water, B: 0.02% trifluoroacetic acid in acetonitrile; 5-95% B over 0.89 min, 95%B for 0.26 min, 95-5% over 0.44 min; Flow rate: 1.5 mL/min; UV detection 220 and 254 nm; Mass detection MS range 100-1000 Da (ESI); Column temperature: 40 °C.
- LCMS Method 15 Instrument: Shimadzu LC-20ADXR&MS 2020, ESI; Column: Shim-pack Velox SP-C1830mmx2.1mm 2.7 ⁇ m; Gradient: mobile phase A: 0.04% trifluoroacetic acid in water, B: 0.02% trifluoroacetic acid in acetonitrile; 5%B for 0.01 min., 5-95% B over 0.69 min, 95%B for 0.46 min, 95-5% over 0.34 min; Flow rate: 1.5 mL/min; UV detection 220 and 254 nm; Mass detection MS range 100-1000 Da (ESI); Column temperature: 40 °C.
- LCMS Method 16 Instrument: Agilent 1260 & 6120, ESI; Column: Kinetex LC-C18 50mmx2.1mm, 5 ⁇ m; Gradient: mobile phase A: 0.04% trifluoroacetic acid in water, B: 0.02% trifluoroacetic acid in acetonitrile; 5%B for 0.4 min, 5-95% B over 3.0 min, 95% B over 1.0 min, 95-5% B over 0.5 min; Flow rate: 1.0 mL/min; UV detection 215 nm and 254 nm; Mass detection MS range 100-1000 Da (ESI); Column temperature: 40 °C.
- LCMS Method 18 Instrument: Shimadzu LC-20AB&MS 2010, ESI; Column: Xbridge C18 50mmx2.1mm, 5 ⁇ m; Gradient: mobile phase A: 10 mM NH 4 HCO 3 in water, B: acetonitrile; 5%B for 0.01 min., 5-95% B over 2.99 min, 95%B for 0.50 min, 95-5% over 0.01 min; 5%B for 0.79 min., Flow rate: 1.0 mL/min; UV detection 220 and 254 nm; Mass detection MS range 100-1000 Da (ESI); Column temperature: 40 °C.
- LCMS Method 19 Instrument: Agilent 1200 & 6130, MSD; Column: XBridge C18 50mmx2.1mm, 5 ⁇ m; Gradient: mobile phase A: 10 mM NH 4 HCO 3 in water, B: acetonitrile; 5% B for 0.4 min., 5-95% B over 3.0 min, 95% B for 0.45 min, 95-5%B over 0.01 min, 5% B for 0.64 min; Flow rate: 0.8 mL/min; UV detection 215 nm and 254 nm; Mass detection MS range 100- 1000 Da (ESI); Column temperature: 40 °C.
- LCMS Method 20 Instrument: Shimadzu LC-20AB&MS 2010, ESI; Column: Kinetex C18 50mmx2.1mm, 5 ⁇ m; Gradient: mobile phase A: 10 mM NH 4 HCO 3 in water, B: acetonitrile; 5%B for 0.01 min., 5-95% B over 0.69 min, 95%B for 0.46 min, 95-5% over 0.34 min; Flow rate: 1.5 mL/min; UV detection 220 and 254 nm; Mass detection MS range 100-1000 Da (ESI); Column temperature: 40 °C.
- LCMS Method 21 Instrument: Shimadzu LC-20AD&MS 2020, ESI; Column: Kinetex EVO C18 30mm ⁇ 2.1mm, 5 ⁇ m; Gradient: mobile phase A: 0.04% trifluoroacetic acid in water, B: 0.02% trifluoroacetic acid in acetonitrile; 5%B over 0.0.01 min., 5-95% B over 0.69 min, 95%B for 0.50 min, 95-5% over 0.01 min; 5%B for 0.29 min Flow rate: 1.5 mL/min; UV detection 220 and 254 nm; Mass detection MS range 100-1000 Da (ESI); Column temperature: 40 °C.
- LCMS Method 22 Instrument: Shimadzu LC-20AD&MS 2020, ESI; Column: Xbridge C18 50mmx2.1mm, 5 ⁇ m; Gradient: mobile phase A: 10 mM NH 4 HCO 3 in water, B: acetonitrile; 10%B for 0.01 min., 10-80% B over 3.49 min, 80%B for 0.30 min, 80-10%B over 0.01 min; 10%B for 0.49 min.; Flow rate: 0.8 mL/min; UV detection 220 and 254 nm; Mass detection MS range 100-1000 Da (ESI); Column temperature: 40 °C.
- LCMS Method 23 Instrument: Shimadzu LC-20AD&MS 2020, ESI; Column: Xbridge Shield RPC1850mmx2.1, 5 ⁇ m; Gradient: mobile phase A: 10 mM NH 4 HCO 3 in water, B: acetonitrile; 5%B for 0.01 min., 5-95% B over 0.99 min, 95-100%B over 0.80 min, 100-5%B% over 0.0.01 min; 5%B for 0.39 min.; Flow rate: 1.0 mL/min (0.01-1.8 min) and 1.2 mL/min (1.81-2.20 min); Diode array detection; Mass detection MS range 100-1000 Da (ESI); Column temperature : 40 °C.
- LCMS Method 25 Instrument: Agilent 1200 & 6120, ESI; Column: Kinetex C1830mmx2.1mm, 5 ⁇ m; Gradient: mobile phase A: 0.04% trifluoroacetic acid in water, B: 0.02% trifluoroacetic acid in acetonitrile; 5-95%B over 1.00 min, 95-100% B over 0.8 min, 100-5% B over 0.01 min, 5% B for 0.19 min; Flow rate: 1.0 mL/min(0-1.80min) and 1.2ml/min (1.81-2.00); Diode array detection; Mass detection MS range 100-1000 Da (ESI); Column temperature: 40 °C.
- LCMS Method 26 Instrument: Shimadzu LC-20AD&MS 2020, ESI; Column: Kinetix EVO C18 30mmx2.1mm, 5 ⁇ m; Gradient: mobile phase A: 0.04% trifluoroacetic acid in water, B: 0.02% trifluoroacetic acid in acetonitrile; 5% B over 0.01 min., 5-95% B over 2.99 min, 95%B for 0.50 min, 95-5% over 0.50 min, 5% B for 0.30 min; Flow rate: 1.0 mL/min; Diode array detection; Mass detection MS range 100-1000 Da (ESI); Column temperature: 40 °C.
- LCMS Method 27 Instrument: Shimadzu LC-20AB MSD: LCMS-2010, ESI; Column: Shim-pack Scepter C1833mmx3.0mm 3 ⁇ m; Gradient: mobile phase A: 10mM NH 4 HCO in water, B: ACN; 0-60%B over 3.5 min., 60% B for 0.30 min, 60-0%B over 0.01 min, 0%B for 0.49 min; Flow rate: 0.8 mL/min 0.01 to 3.8 min., and 1.0 mL/min 3.81 to 4.3 min; UV detection 220 and 254 nm; Mass detection MS range 100-1000 Da (ESI); Column temperature: 40 °C.
- LCMS Method 28 Instrument: Agilent 1200, MSD 6150; Column: Kinetex EVO C18 30mm ⁇ 2.1mm, 5 ⁇ m; Gradient: mobile phase A: 0.04% trifluoroacetic acid in water, B: 0.02% trifluoroacetic acid in acetonitrile; 5% B for 0.01 min., 5-95% B over 3.49 min, 95% B for 0.30 min, 95-5%B over 0.01 min., 5% B for 0.49 min.; Flow rate: 1.0 mL/min; UV detection 220 and 254 nm; Mass detection MS range 100-1000 Da (ESI); Column temperature: 40 °C.
- the absolute stereochemistry of representative examples of the preferred (most active) atropisomers has been determined by analysis of X-ray crystal structures of complexes in which the respective compounds are bound to the M pro protein. In all other cases where X-ray structures are not available, the stereochemistry has been assigned by analogy, assuming that, for each pair, the atropoisomer exhibiting the highest activity in the Rapid-Fire MS Biochemical Assay (i.e. lowest IC 50 value) has the same configuration as observed by X-ray crystallography for the representative examples mentioned above.
- Example 16a axial chirality analysis using Cahn–Ingold–Prelog rules for two separate views is shown below with (a) being priority 1, (b) being priority 2, (c) being priority 3 and (d) being priority 4.
- Example 16a is assigned axial R (R a ) configuration and is the most active atropisomer wherein the phenyl ring of the isoquinoline is pointing upwards.
- the corresponding compound name for Example 16a using Cahn–Ingold–Prelog rules is also shown.
- Example 16b is shown for comparison and is assigned axial S (S a ) configuration where the phenyl ring of the isoquinoline is pointing downwards.
- Such atropisomers are the more active atropisomer(s).
- the corresponding compound name for Example 16b using Cahn–Ingold–Prelog rules is also shown.
- Example 16a chirality axis is described by the stereodescriptor M and is the most active atropisomer where the phenyl ring of the isoquinoline is pointing upwards.
- the corresponding compound name for Example 16a using Prelog and Helmchen rules is also shown.
- the structure of Example 16b (the less active atropisomer), whose chirality axis is described by the stereodescriptor P, is shown for comparison where the phenyl ring of the isoquinoline is pointing downwards.
- the corresponding compound name for Example 16b using Prelog and Helmchen rules is also shown.
- Atropisomers described in the Example section below are named according the Prelog and Helmchen stereodescriptor. All other compounds, including racemates are named using ChemDraw 19.1.
- stereochemistry assigned to atropisomers in the Examples is by analogy to Example 16, wherein the chirality of the more active atropisomer(s) is assigned as (M) and subsequently the chirality of the less active atropisomer(s) is assigned as (P).
- Step 3 To a solution of methyl 2-amino-4-fluoro-5-(trifluoromethyl)benzoate (550 mg, crude, 2.32 mmol, 1.0 eq.) in THF/H 2 O (7/3, 10 mL) was added LiOH.H 2 O (292 mg, 6.96 mmol, 3.0 eq.) at 25°C under N 2 . After addition, the mixture reaction was stirred at 25°C for 12 hrs.
- Step 1 A solution of iodine monochloride (ICl) (5.4 g, 25.12 mmol, 1.5 eq.) in MeOH (15 mL) was added dropwise to a solution of 2-fluoro-4-(trifluoromethyl)aniline (3.0 g, 16.75 mmol, 1.0 eq.) in CH 2 Cl 2 (15 mL) at 0°C and the mixture was stirred at 20°C for 16 hrs. The reaction mixture was quenched with water (50 mL) and extracted with EtOAc (50 mL x 3).
- ICl iodine monochloride
- Step 2 To a solution of tert-butyl (2-bromo-5-chloro-4-(trifluoromethyl)phenyl)(tert- butoxycarbonyl)carbamate (5.0 g, 10.53 mmol, 1.0 eq.) in THF (80 mL) was added n-BuLi (5 mL, 12.64 mmol, 1.2 eq.) at -78°C. The mixture was stirred at -78°C for 1 hrs. The reaction mixture was quenched with H2O (120 mL).
- Step 4 To a solution of methyl 2-amino-4-chloro-5-(trifluoromethyl)benzoate (400 mg, 1.56 mmol, 1.0 eq.), 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (990 mg, 7.89 mmol, 5.0 eq.) and Cs 2 CO 3 (1.0 g, 3.16 mmol, 2.0 eq.) in t-AmylOH (3 mL) was added CataCXiumA Pd G2 (104 mg, 0.16 mmol, 0.1 eq.) and H 2 O (0.5 mL) at N 2 . The mixture was stirred at 80°C for 2 hrs.
- Step 2 A mixture of ethyl 2-oxo-5-(trifluoromethyl)cyclohexane-1-carboxylate (2.6 g, 10.92 mmol, 1.0 eq.) and AcONH 4 (841 mg, 10.92 mmol, 1.0 eq.) in MeOH (30 mL) was stirred at 20°C for 16 hrs. The solution was concentrated to remove the MeOH, diluted with H2O (30 mL), extracted with CH 2 Cl 2 (3x50 mL). The combined organic phase were dried over Na 2 SO 4 , filtrated and concentrated to give ethyl 2-amino-5-(trifluoromethyl)cyclohex-1-ene-1-carboxylate (Int- A7).
- Step 2 To a solution of methyl 6-bromo-2-fluoro-3-(trifluoromethyl)benzoate (600 mg, 2.01 mmol, 1.0 eq.), BocNH 2 (350 mg, 3.02 mmol, 1.5 eq.) and Cs 2 CO 3 (1620 mg, 5.02 mmol, 2.5 eq.) in dioxane (20 mL) was added Pd 2 (dba) 3 (114 mg, 0.20 mmol, 0.1 eq.) and Xphos (190 mg, 0.40 mmol, 0.2 eq.). The mixture was stirred at 100°C for 3 hrs. The reaction mixture was quenched with H 2 O (50 mL).
- Step 3 A solution of methyl 6-((tert-butoxycarbonyl)amino)-2-fluoro-3-(trifluoromethyl)benzoate (400 mg, 1.18 mmol, 1.0 eq.) in HCl (g)/MeOH (4M, 10 mL) was stirred at 20°C for 3 hrs. The mixture was concentrated under reduced pressure to afford c methyl 6-amino-2-fluoro-3- (trifluoromethyl)benzoate (Int-A8).
- LCMS (Method 7): t R 0.685 min, [M+1] + 238.0.
- Step 3 The solution of tert-butyl 5-bromo-2-nitrobenzoate (2.7 g, 8.94 mmol, 1.0 eq.) in THF (27 mL) was added Pd(t-Bu 3 P) 2 (457 mg, 0.90 mmol, 0.1 eq.) and (1- (methoxycarbonyl)cyclopropyl)zinc(II) bromide (45 mL, 44.86 mmol, 5.0 eq.) at 25°C under N 2 . The mixture was stirred at 25°C under N 2 for 16 hrs.
- Step 4 To a mixture of tert-butyl 5-(1-(methoxycarbonyl)cyclopropyl)-2-nitrobenzoate (1.0 g, 3.12 mmol, 1.0 eq.) in CH 2 Cl 2 (10 mL) was added TFA (2 mL) and the mixture was stirred at 25°C for 3 hrs. The reaction mixture was dried under nitrogen gas to give 5-(1- (methoxycarbonyl)cyclopropyl)-2-nitrobenzoic acid (Int-A11).
- Step 2 To a solution of 4-(chlorodifluoromethoxy)-2-iodoaniline (1.0 g, 3.13 mmol, 1.0 eq.) in CH 3 CN (20 mL) and MeOH (10 mL) was added K 2 CO 3 (1.3 g, 9.40 mmol, 3.0 eq.), TEA (317 mg, 3.13 mmol, 1.0 eq.), DPPF (174 mg, 0.31 mmol, 0.1 eq.) and Pd(OAc) 2 (70 mg, 0.31 mmol, 0.1 eq.) at 25°C under nitrogen. The reaction was stirred for 16 hrs at 60°C under CO (15 psi).
- Step 1 To a solution of 6-bromoisoquinoline (38.0 g, 182.65 mmol, 1.0 eq.) in DMSO (400 mL) was added MeSO 2 Na (43.0 g, 420.09 mmol, 2.3 eq.), CuI (7.0 g, 36.53 mmol, 0.2 eq.), L-proline (6.3 g, 54.79 mmol, 0.3 eq.) and NaOH (2.2 g, 54.79 mmol, 0.3 eq.) at 25°C. The mixture was stirred at 120°C for 6 hrs. The mixture was quenched with water (500 mL) and extracted with EtOAc (400 mL x 2).
- Step 2 To a suspension of 6-(methylsulfonyl)isoquinoline (34.0 g, 164.05 mmol, 1.0 eq.) in AcOH (400 mL) was added NBS (44.0 g, 246.08 mmol, 1.5 eq.) at 25°C and the reaction mixture was then heated to 80°C and stirred at 80°C for 16 hrs.
- Step 3 To a solution of 4-bromo-6-(methylsulfonyl)isoquinoline (29.0 g, 101.07 mmol, 1.0 eq.) and BocNH 2 (24.0 g, 202.13 mmol, 2.0 eq.) in dioxane (350 mL) was added Pd 2 (dba) 3 (4.1 g, 5.05 mmol, 0.05 eq.), Xantphos (6.0 g, 10.11 mmol, 0.1 eq.) and Cs 2 CO 3 (100.0 g, 303.20 mmol, 3.0 eq.) at 25
- Step 4 To a solution of 5-bromoisoquinoline-4-carboxylic acid (1.0 g, 3.98 mmol, 1.0 eq.) and Et 3 N (1.2 g, 11.94 mmol, 3.0 eq.) in DMF (15 mL) was added DPPA (2.2 g, 7.97 mmol, 2.0 eq.) at 0°C. The mixture was stirred at 25°C for 2 hrs. t-BuOH (5 mL) was dropwise added to the mixture at 25°C. The mixture was stirred at 25°C for 16 hrs. The reaction was poured into water (30 mL) and extracted with EtOAc (20 mL x 2).
- Step 2 To a mixture of methyl isoquinoline-6-carboxylate (10.0 g, 53.42 mmol, 1.0 eq.) in AcOH (200 mL) was added NBS (12.4 g, 69.45 mmol, 1.3 eq.) at 25°C under N 2 . The reaction mixture was stirred at 80°C for 16 hrs. The mixture was concentrated, added to water (500 mL) and extracted with EtOAc (200 mL x 3).
- Step 3 To a mixture of methyl 4-bromoisoquinoline-6-carboxylate (25.0 g, 93.95 mmol, 1.0 eq.) and BocNH 2 (14.3 g, 122.14 mmol, 1.3 eq.) in dioxane (1.5 L) was added Cs 2 CO 3 (60.0 g, 187.90 mmol, 2.0 eq.), Pd 2 (dba) 3 (2.5 g, cat.) and Xantphos (2.5 g, cat.) at 25°C under N 2 . The reaction mixture was stirred at 100°C for 16 hrs. The mixture was concentrated, added to water (500 mL) and extracted with EtOAc (200 mL x 3).
- Step 2 To H 2 SO 4 (75%, 400 mL) was added (E)-2-(2-ethoxyvinyl)-3-fluorobenzonitrile (33.8 g, 176.52 mmol, 1.0 eq.) at 0°C. The reaction was stirred at 85°C for 2 hrs. The mixture was poured into ice water (1.2 L) with stirring, then filtered and the filter cake was dried to give a crude product. The crude product was suspended in water (800 mL) and stirred for 0.5 hrs, then the suspension was filtered and filter cake was dried to give 5-fluoroisoquinolin-1(2H)-one.
- the mixture was poured into ice water (800 mL), extracted with EtOAc (500 mL x 2). The combined organic layers were washed with brine (600 mL), dried over Na 2 SO 4 , filtered and concentrated to give crude product.
- the crude product was suspended in MTBE/petroleum ether/EtOAc (1/3/1, 300 mL) and stirred for 0.5 hrs, the suspension was filtered and the filter cake was dried to give 5-fluoro-4-nitroisoquinolin-1(2H)- one.
- Step 4 A solution of 5-fluoro-4-nitroisoquinolin-1(2H)-one (5.0 g, 24.03 mmol, 1.0 eq.) in POCl 3 (60 mL) was stirred at 80°C for 18 hrs. The reaction was concentrated in vacuum to remove POCl 3 to give a residue. The residue was suspended in toluene (100 mL) and concentrated, repeated for three times to give crude product. The crude product was suspended in hexane (100 mL) and ultrasonicated for 5 min.
- Step 5 To a solution of 1-chloro-5-fluoro-4-nitroisoquinoline (6.0 g, 26.43 mmol, 1.0 eq.) in EtOH (200 mL) was added Pd/C (5.0 g, Cat.) at 25°C and the mixture was stirred at 25°C for 2 hrs under H 2 (15 Psi). The reaction was filtered, the filter cake was washed by EtOH (500 mL x 3), the combined filtrate was concentrated to give a crude product.
- Pd/C 5.0 g, Cat.
- Step 3 A mixture of 2-(carboxymethyl)-5-(trifluoromethyl)benzoic acid (3.7 g, 14.92 mmol, 1.0 eq.) and Ac 2 O (4.6 g, 44.76 mmol, 3.0 eq) in toluene (50 ml) was stirred at 120°C under N 2 for 3 hrs.
- Example 1 Synthesis of 7-fluoro-3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)- dione (1)
- Step 1 HATU (920 mg, 2.42 mmol, 1.2 eq.) was added to a solution of 2-amino-4-fluoro-5- (trifluoromethyl)benzoic acid (Int-A1) (450 mg, 2.02 mmol, 1.0 eq.) in DMF (5 mL) at 25°C and the reaction mixture stirred at 25°C for 1 hr.
- Int-A1 2-amino-4-fluoro-5- (trifluoromethyl)benzoic acid
- Step 2 Triphosgene (200 mg, 0.68 mmol, 1.2 eqv) was added to a mixture of 2-amino-4-fluoro- N-(isoquinolin-4-yl)-5-(trifluoromethyl)benzamide (200 mg, 0.56 mmol, 1.0 eqv) in THF (5 mL) at 0°C. After addition, the reaction mixture was stirred at 15°C for 3 hrs. The mixture was diluted with saturated NaHCO 3 aqueous (20 mL) and extracted with EtOAc (20 mL x 2).
- Example 2a Synthesis of 3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione (2)
- Step 1 HATU (1.11 g, 2.93 mmol, 1.2 eq.) and NMM (740.4 mg, 7.32 mmol, 3.0 eq.) were added to a solution of 2-amino-5-(trifluoromethyl)benzoic acid (Int-AA1) (500 mg, 2.44 mmol, 1.0 eq.) in DMF (5 mL) and the mixture was stirred at 20°C for 1 hr.
- Int-AA1 2-amino-5-(trifluoromethyl)benzoic acid
- Step 2 DIEA (467 mg, 3.6 mmol, 2 eq.) and triphosgene (804 mg, 2.71 mmol, 1.5 eq.) were added at 0°C to a solution of 2-amino-N-(isoquinolin-4-yl)-5-(trifluoromethyl)benzamide (600 mg, 1.81 mmol, 1.0 eq.) in THF (20 mL) and the mixture was stirred at 25°C for 2 hrs. The reaction was quenched by careful addition of aq.
- Example 2b Alternative synthesis of 3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline- 2,4(1H,3H)-dione (2)
- Step 1 HATU (1.11 g, 2.93 mmol, 1.2 eq.) and NMM (740.4 mg, 7.32 mmol, 3.0 eq.) were added to a solution of 2-amino-5-(trifluoromethyl)benzoic acid (Int-AA1) (500 mg, 2.44 mmol, 1.0 eq.) in DMF (5 mL) and the mixture was stirred at 20°C for 1 hr.
- Int-AA1 2-amino-5-(trifluoromethyl)benzoic acid
- Step 2 DIEA (468 mg, 3.60 mmol, 2.0 eq.) and triphosgene (801 mg, 2.70 mmol, 1.5 eq.) were added at 0°C to a solution of 2-amino-N-(isoquinolin-4-yl)-5-(trifluoromethyl)benzamide (600 mg, 1.80 mmol, 1.0 eq.) in DCE (10 mL) and the mixture stirred at 20°C for 3 hrs. The mixture was diluted with H 2 O (10 mL) and extracted with EtOAc (15 mL x 3).
- Example 3 Synthesis of 2-(3-(isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4- dihydroquinazolin-1(2H)-yl)acetonitrile (3)
- K 2 CO 3 116 mg, 0.84 mmol, 3.0 eq.
- 2-bromoacetonitrile 40 mg, 0.34 mmol, 1.2 eq.
- 3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione (2) 100 mg, 0.28 mmol, 1.0 eq.
- Example 4 Synthesis of 3-(isoquinolin-4-yl)-6-(trifluoromethoxy)quinazoline-2,4(1H,3H)-dione Step 1: HATU (1.0 g, 2.71 mmol, 1.2 eq.) was added to a solution of 2-amino-5- (trifluoromethoxy)benzoic acid (Int-AA2) (500 mg, 2.26 mmol, 1.0 eq.) in DMF (5 mL) at 20°C and the mixture was stirred at 20°C for 1 hr.
- HATU 1.0 g, 2.71 mmol, 1.2 eq.
- Int-AA2 2-amino-5- (trifluoromethoxy)benzoic acid
- Step 2 To a solution of 2-amino-N-(isoquinolin-4-yl)-5-(trifluoromethoxy)benzamide (210 mg, 0.60 mmol, 1.0 eq.) in DCE (1 mL) was added a solution of triphosgene (179 mg, 0.60 mmol, 1.0 eq.) in DCE (1 mL) and DIEA (156 mg, 1.21 mmol, 2.0 eq.) at 20°C, and the mixture was then stirred at 20°C for 6 hrs.
- triphosgene 179 mg, 0.60 mmol, 1.0 eq.
- DIEA DIEA
- Example 5 Synthesis of 3-(isoquinolin-4-yl)-6-(trifluoromethyl)pyrido[2,3-d]pyrimidine- 2,4(1H,3H)-dione (5)
- Step 1 HATU (3.8g, 9.89 mmol, 1.2 eq.) and NMM (2.5 g, 24.73 mmol, 3.0 eq.) at 20°C were added to a solution of 2-amino-5-(trifluoromethyl)nicotinic acid hydrochloride (Int-A2) (2.0 g, 8.24 mmol, 1.0 eq.) in DMF (20 mL) and the mixture stirred at 20°C for 1 hr.
- Int-A2 2-amino-5-(trifluoromethyl)nicotinic acid hydrochloride
- Step 2 DIEA (163 mg, 1.26 mmol, 3.0 eq.) and triphosgene (63 mg, 0.21 mmol, 0.5 eq.) were added to a solution of 2-amino-N-(isoquinolin-4-yl)-5-(trifluoromethyl)nicotinamide (140 mg, 0.42 mmol, 1.0 eq.) in THF (1.5 mL) at 20°C and the mixture stirred at 20°C for 16 hrs.
- Example 6 Synthesis of 3-(8-aminoisoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)- dione (6)
- Step 1 4-bromo-8-nitroisoquinoline (1.1 g, 1.38 mmol, 0.5 eq.), Pd(OAc) 2 (40 mg, 0.18 mmol, 0.06 eq.), BINAP (300 mg, 0.48 mmol, 0.17 eq.) and DPPF (300 mg, 0.54 mmol, 0.2 eq.) were added to a solution of diphenylmethanimine (500 mg, 2.76 mmol, 1.0 eq.) in TEA (0.5 mL, 2.99 mmol, 1.1 eq) at 20°C, and the mixture was then concentrated at 30°C for 15 min.
- Step 2 4N HCl (10 mL) was added to a mixture of N-(8-nitroisoquinolin-4-yl)-1,1- diphenylmethanimine (2.0 g, 2.00 mmol, 1.0 eq.) in THF (20 ml) at 25°C and the mixture stirred at 25°C for 1 hr. The mixture was poured into NaHCO 3 aq. (100 mL) and then extracted with EtOAc (50 mL x 3). The combined organic phases were washed with brine, dried over Na 2 SO 4 , filtered and concentrated to give crude product.
- Step 4 Methyl 2-amino-5-(trifluoromethyl)benzoate (Int-A6) (101 mg, 0.46 mmol, 2.0 eq.) was added to a solution of 4-isocyanato-8-nitroisoquinoline (50 mg, 0.23 mmol, 1.0 eq.) in pyridine (3 mL) at 20°C. The mixture was stirred at 100°C for 12 hrs. The mixture was poured into water (15 mL) and extracted with EtOAc (10 mL x 3).
- Step 5 NH 4 Cl (35 mg, 0.63 mmol, 5 eq.) and Fe powder (35 mg, 0.63 mmol, 5 eq.) were added to a solution of 3-(8-nitroisoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione (50 mg, 0.13 mmol, 1.0 eq.) in EtOH (5 mL) and H 2 O (5 mL) at 20°C, and the mixture stirred at 85°C for 1 hr. The mixture was filtered and the filtrate was concentrated to give crude product.
- Example 7 Synthesis of 3-(5,6,7,8-tetrahydroisoquinolin-4-yl)-6-(trifluoromethyl)quinazoline- 2,4(1H,3H)-dione (7)
- Step 1 HATU (1.1 g, 2.93 mmol, 1.2 eq.) was added to a solution of 2-amino-5- (trifluoromethyl)benzoic acid (Int-AA1) (500 mg, 2.44 mmol, 1.0 eq.) in DMF (5 mL) and the mixture stirred at 20°C for 1 hr.5,6,7,8-tetrahydroisoquinolin-4-amine (Int-B1) (397 mg, 2.44 mmol, 1.1 eq.) and NMM (740 mg, 7.32 mmol, 3.0 eq.) were added and the mixture stirred at 45°C for 15 hrs.
- Int-AA1 2-amino-5- (trifluoromethyl)benzoic acid
- Step 2 DIEA (617 mg, 4.78mmol, 2.0 eq.) and a solution of triphosgene (1.1g, 3.59 mmol, 1.5 eq.) in THF (4 mL) were added to a mixture of 2-amino-N-(5,6,7,8-tetrahydroisoquinolin-4-yl)-5- (trifluoromethyl)benzamide (800 mg, 2.39 mmol, 1.0 eq.) in THF (8 mL) and the mixture stirred at 25°C for 3 hrs. The mixture was quenched with NaHCO 3 aq. (30 mL) and extracted with EtOAc (30 mL x 2).
- Example 8 Synthesis of 7-(trifluoromethyl)-1H-[2,4'-biisoquinoline]-1,3(4H)-dione (8)
- Example 9 Synthesis of 6-bromo-3-(isoquinolin-4-yl)quinazoline-2,4(1H,3H)-dione (9)
- Step 1 A mixture of isoquinolin-4-amine (3.0 g, 13.80 mmol, 1.0 eq.), HATU (6.3 g, 16.56 mmol, 1.2 eq.) in DMF (20 mL) was stirred at 20°C for 0.5 hr.2-amino-5-bromobenzoic acid (Int-AA3) (2.2 g, 15.18 mmol, 1.1 eq.) and NMM (4.2 g, 41.40 mmol, 3.0 eq.) were then added and the mixture was stirred at 45°C for 16 hrs.
- Step 2 A solution of Triphosgene (564 mg, 1.90 mmol, 1.0 eq.) in DCE (3.5 mL) and DIEA (491 mg, 3.80 mmol, 2.0 eq.) were added to a solution of 2-amino-5-bromo-N-(isoquinolin-4- yl)benzamide (650 mg, 1.90 mmol, 1.0 eq.) in DCE (3.5 mL) at 20°C and the mixture stirred at 20°C for 16 hrs. The reaction mixture was concentrated to give a residue.
- Example 9 Alternative synthesis of 6-bromo-3-(isoquinolin-4-yl)quinazoline-2,4(1H,3H)-dione Step 1: To an oven-dried flask was added isoquinolin-4-amine (Int-B1) (6.03 g, 1.05 eq., 41.8 mmol), and 5-bromoindoline-2,3-dione (9.00 g, 1 eq., 39.8 mmol). EtOH (500 mL) was added, followed by acetic acid (239 mg, 228 ⁇ L, 0.1 Eq, 3.98 mmol). A reflux condensor was attached and the reaction was heated at 90 °C for 4 days.
- isoquinolin-4-amine Int-B1
- 5-bromoindoline-2,3-dione 9.00 g, 1 eq., 39.8 mmol
- EtOH 500 mL
- acetic acid 239 mg, 228 ⁇ L, 0.1 E
- Step 2 To a 20 mL vial was added (E)-5-bromo-3-(isoquinolin-4-ylimino)indolin-2-one (3.52 g, 1 Eq, 10.00 mmol), DCM (200.00 mL) and TFA (2.280 g, 1.54 mL, 2.0 eq., 20.0 mmol) forming a suspension which was cooled to 0 °C .
- mCPBA (4.60 g, 75% wt, 2.0 eq., 20.00 mmol) was added as a single portion and the reaction was warmed to rt and stirred overnight. The organic phase was wshed with 200 mL H 2 O.
- Example 10 Synthesis of 4,4-dimethyl-7-(trifluoromethyl)-1H-[2,4'-biisoquinoline]-1,3(4H)-dione t-BuOK (1.1 mL, 1.12 mmol, 1 M in THF, 2.0 eq.) was added to a solution of 7-(trifluoromethyl)- 1H-[2,4'-biisoquinoline]-1,3(4H)-dione (8) (200 mg, 0.56 mmol, 1.0 eq.) in THF (5 mL) at 0°C and the mixture stirred at 0°C for 0.5 hrs.
- Methyliodide (398 mg, 2.80 mmol, 5.0 eq.) was then added dropwise at 0°C and the mixture stirred at 20°C for 2 hrs. The reaction was quenched with NH 4 Cl (10 mL) and extracted with EtOAc (8 mL ⁇ 2).
- Example 11 Synthesis of 8-fluoro-3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline- 2,4(1H,3H)-dione (11)
- Step 1 A mixture of 2-amino-3-fluoro-5-(trifluoromethyl)benzoic acid (Int-A3) (790 mg, 3.54 mmol, 1.0 eq.), HATU (1.03 g, 4.25 mmol, 1.2 eq.) in DMF (10 mL) was stirred at 20°C for 1 hr.
- Step 2 A solution of triphosgene (382 mg, 1.29 mmol, 1.5 eq.) in THF (2.0 mL) was added dropwise to a solution of 2-amino-3-fluoro-N-(isoquinolin-4-yl)-5-(trifluoromethyl)benzamide (300 mg, 0.86 mmol, 1.0 eq.) and DIEA (220 mg, 1.70 mmol, 2.0 eq.) in THF (8.0 mL) at 0°C under N 2. The mixture was stirred at 25°C for 16 hrs. The reaction mixture was quenched with NaHCO 3 (20 mL) and extracted with EtOAc (20 mL x 3).
- Example 12 Synthesis of 3-(isoquinolin-4-yl)-6-methoxyquinazoline-2,4(1H,3H)-dione (12) Step 1: HATU (4.6 g, 12.17 mmol, 1.2 eq.) was added to a mixture of 5-methoxy-2-nitrobenzoic acid (Int-AA4) (2.0 g, 10.15 mmol, 1.0 eq.) in DMF (20 mL) and the mixture stirred at 20°C for 1 hr.
- Int-AA4 5-methoxy-2-nitrobenzoic acid
- Step 2 A mixture of N-(isoquinolin-4-yl)-5-methoxy-2-nitrobenzamide (1.0 g, 3.09 mmol, 1.0 eq.) and Pd/C (500 mg, 10%) in EtOAc (50 mL) was purged with H 2 (3x) and then stirred at 30°C for 5 hrs under H 2 (50 psi). The mixture was filtered and the filtrate was concentrated to give 2- amino-N-(isoquinolin-4-yl)-5-methoxybenzamide.
- Step 3 DIEA (106 mg, 0.82 mmol, 2.0 eq.) and triphosgene (181 mg, 0.61 mmol, 1.5 eq.) were added to a solution of 2-amino-N-(isoquinolin-4-yl)-5-methoxybenzamide (120 mg, 0.41 mmol, 1.0 eq.) in DCE (2 mL) and the mixture was stirred at 20°C for 3 hrs.
- Example 13 Synthesis of 3-(4-methylpyridin-3-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)- dione (13)
- Step 1 HATU (1.1 g, 2.93 mmol, 1.2 eq.) was added to a solution of 2-amino-5- (trifluoromethyl)benzoic acid (Int-AA1) (500 mg, 2.44 mmol, 1.0 eq.) in DMF (8 mL) and the mixture was stirred at 20°C for 1 hr.4-methylpyridin-3-amine (CAS No.3430-27-1) (527 mg, 4.78 mmol, 2.0 eq.) and NMM (740 mg, 7.32 mmol, 3.0 eq.) were then added and the mixture stirred at 45°C for 15 hrs.
- Int-AA1 2-amino-5- (trifluoromethyl)benzoic acid
- DMF 8 mL
- NMM 740 mg,
- Step 2 DIEA (174 mg, 1.35 mmol, 2.0 eq.) and triphosgene (302 mg, 1.02 mmol, 1.5 eq.) were added to a solution of 2-amino-N-(4-methylpyridin-3-yl)-5-(trifluoromethyl)benzamide (200 mg, 0.67 mmol, 1.0 eq.) in DCE (3 mL) at 0°C and the mixture stirred at 20°C for 3 hrs.
- DIEA 174 mg, 1.35 mmol, 2.0 eq.
- triphosgene 302 mg, 1.02 mmol, 1.5 eq.
- Example 14 Synthesis of 3-(isoquinolin-4-yl)-6-(trifluoromethyl)-2H-benzo[e][1,3]oxazine- 2,4(3H)-dione (14)
- Step 1 HATU (1.8 g, 4.80 mmol, 1.2 eq.) and DMF (10 mL) were added to a solution of 2- methoxy-5-(trifluoromethyl)benzoic acid (Int-A4) (880 mg, 4.00 mmol, 1.0 eq.) at 20°C and the mixture was stirred at 20°C for 1 hr.
- Int-A4 2- methoxy-5-(trifluoromethyl)benzoic acid
- Step 2 BBr3 (751 mg, 3.03 mmol, 1.5 eq.) was added to a solution of N-(isoquinolin-4-yl)-2- methoxy-5-(trifluoromethyl)benzamide (700 mg, 2.02 mmol, 1.0 eq.) in CH 2 Cl 2 (7 mL) at 0°C and the mixture stirred at 20°C for 3 hrs. The mixture was poured into water (50 mL) and extracted with EtOAc (50 mL x 3).
- Step 3 Triphosgene (353 mg, 1.20 mmol, 1.0 eq.) was added to a solution of 2-hydroxy-N- (isoquinolin-4-yl)-5-(trifluoromethyl)benzamide (400 mg, 1.20 mmol, 1.0 eq.) and DIEA (310 mg, 2.40 mmol, 2.0 eq.) in CH 2 Cl 2 (5mL) at 20°C and the mixture was stirred at 20°C for 4 hrs. The mixture was poured into water (20 mL) and extracted with EtOAc (25 mL x 3). The combined organic layers were washed with brine (20 mL x 2), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give a residue.
- Example 15 Synthesis of 5-(2,4-dioxo-6-(trifluoromethyl)-1,4-dihydroquinazolin-3(2H)- yl)nicotinamide (15)
- Step 1 2-amino-5-(trifluoromethyl)benzoic acid (Int-AA1) (2.0 g, 9.75 mmol, 1.0 eq.), 5- aminonicotinamide (CAS No.60524-14-3) (1.5 g, 10.72 mmol, 1.1 eq.), HATU (5.6 g, 14.63 mmol, 1.5 eq.) and NMM (1.5 g, 14.63 mmoL, 1.5 eq.) in DMF (20 mL) were stirred at 50°C for 24 hrs.
- Step 2 5-(2-amino-5-(trifluoromethyl)benzamido)nicotinamide (300 mg, 0.93 mmol, 1.0 eq.) and CDI (150 mg, 0.93 mmol, 1.0 eq.) in DMF (6 mL)were stirred at 50°C for 16 hrs.
- Example 16 Synthesis of 3-(3-(isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4- dihydroquinazolin-1(2H)-yl)propanenitrile (16), 3-[(3M)-3-(Isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4-dihydroquinazolin- 1(2H)-yl]propanenitrile (16a) and 3-[(3P)-3-(Isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4-dihydroquinazolin- 1(2H)-yl]propanenitrile (16b) To a solution of 3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione (2) (400 mg,
- racemate (16) was separated by SFC (column: DAICEL CHIRALCEL OD (250mmx30mm, 10 ⁇ m); liquid phase: [0.1%NH 3 H 2 O MeOH B%: 50%, 7 min]) to give 2 peaks.
- Example 17 Synthesis of 1-cyclopropyl-3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline- 2,4(1H,3H)-dione (16) To a solution of 2,2-bipyridine (109 mg, 0.70 mmol, 1.0 eq.) in DCE (2 mL) was added Cu(OAc) 2 (140 mg, 0.70 mmol, 1.0 eq.) and the mixture was stirred at 60°C.
- Step 2 To a mixture of 2-bromo-4-(pentafluoro- ⁇ 6 -sulfaneyl)aniline (1.9 g, 6.37 mmol, 1.0 eq.) in MeOH (60 mL) was added Pd(dppf)Cl 2 (470 mg, 0.64 mmol, 0.1 eq.) and DIEA (1.6 g, 12.74 mmol, 2.0 eq.) at 25°C. The mixture was stirred at 80°C for 16 hrs under CO (50 psi). The mixture was filtered and the filtrate was concentrated to give crude product.
- Pd(dppf)Cl 2 470 mg, 0.64 mmol, 0.1 eq.
- DIEA 1.6 g, 12.74 mmol, 2.0 eq.
- Step 3 To a mixture of NaH (222 mg, 60%, 5.56 mmol, 1.1 eq.) in DMF (16 mL) was added a solution of methyl 2-amino-5-(pentafluoro- ⁇ 6 -sulfaneyl)benzoate (1.4 g, 5.05 mmol, 1.0 eq.) in DMF (4 mL) at 0°C under N 2 . The mixture was stirred at 0°C for 0.5 hrs under N 2 .
- Phenyl isoquinolin-4-yl(phenoxycarbonyl)carbamate (Int-B7) (1.9 g, 5.05 mmol, 1.0 eq.) in DMF (4 mL) was then added to the mixture at 0°C and the mixture was stirred at 50°C for 12 hrs under N 2 . The reaction was quenched with saturated aqueous NH 4 Cl (100 mL) and extracted with EtOAc (30 mL ⁇ 2). The combined organic layers were washed with brine (120 mL ⁇ 2), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give crude product.
- Example 19 Synthesis of 3-(isoquinolin-4-yl)-7-methyl-6-(trifluoromethyl)quinazoline- 2,4(1H,3H)-dione (19)
- a mixture of 4-isocyanatoisoquinoline (Int-B8) (569 mg, 3.34 mmol, 3.0 eq.) and methyl 2- amino-4-methyl-5-(trifluoromethyl)benzoate (Int-A5) (260 mg, 1.11 mmol, 1.0 eq.) in pyridine (3 mL) was stirred at 100°C for 16 hrs.
- the reaction mixture was quenched with H2O (20 mL).
- the reaction mixture was extracted with ethyl acetate (20 mL x 3).
- Step 1 To a mixture of 5-fluoroisoquinolin-4-amine hydrochloride (Int-B6) (9.1 g, 41.47 mmol, 1.0 eq.) and Et 3 N (12.2 g, 120.96 mmol, 3.5 eq.) in DCE (80 mL) was added a mixture of triphosgen (10.2 g, 34.56 mmol, 1.0 eq.) in DCE (20 mL) at 0°C. The mixture was stirred at 25°C for 2 hrs.
- Int-B6 5-fluoroisoquinolin-4-amine hydrochloride
- Et 3 N 12.2 g, 120.96 mmol, 3.5 eq.
- Step 2 To a solution of 3-(5-fluoroisoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)- dione (500 mg, 1.33 mmol, 1.0 eq.) in DMF (2 mL) was added DBU (400 mg, 2.66 mmol, 2.0 eq.) and acrylonitrile (8 mL) at 25°C. The mixture was stirred at 80°C for 32 hrs. The mixture was poured into water (80 mL) and extracted with EtOAc (50 mL x 2). The combined organic layers were washed with brine (50 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give crude product.
- DBU 400 mg, 2.66 mmol, 2.0 eq.
- acrylonitrile 8 mL
- Step 3 The racemate (20) was separated by SFC (DAICEL CHIRALPAK AD (250mmx50mm,10um); liquid phase: 0.1%NH 3 H 2 O EtOH]B%: 10%-70%,8min]) to give 2 peaks: peak 1 and peak 2.
- Example 21 Synthesis of [(3M,6R or 6S)-3-(5-Fluoroisoquinolin-4-yl)-2,4-dioxo-6- (trifluoromethyl)-3,4,5,6,7,8-hexahydroquinazolin-1(2H)-yl]acetonitrile (21a); [(3M,6R or 6S)-3-(5-Fluoroisoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)- 3,4,5,6,7,8-hexahydroquinazolin-1(2H)-yl]acetonitrile (21b); [(3P,6R or 6S)-3-(5-Fluoroisoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)- 3,4,5,6,7,8-hexahydroquinazolin-1(2H)-yl]aceton
- Step 1 To a mixture of ethyl 2-amino-5-(trifluoromethyl)cyclohex-1-ene-1-carboxylate (Int-A7) (4.8 g, 20.14 mmol, 1.0 eq.) and Et 3 N (6.2 g, 60.42 mmol, 3.0 eq.) in DCE (200 mL) was added dropwise a solution of triphosgene (3.0 g, 10.07 mmol, 0.5 eq.) in DCE (20 mL) at 0°C. The mixture was stirred at 0°C under nitrogen for 2 hrs.
- Et-A7 ethyl 2-amino-5-(trifluoromethyl)cyclohex-1-ene-1-carboxylate
- Et 3 N 6.2 g, 60.42 mmol, 3.0 eq.
- Step 2 Racemic 3-(5-fluoroisoquinolin-4-yl)-6-(trifluoromethyl)-5,6,7,8-tetrahydroquinazoline- 2,4(1H,3H)-dione (890 mg, 2.35 mmol) was separated by chiral SFC (column: REGIS(S, S) WHELK-O1 (250mmx25mm, 10um); mobile phase: [0.1% NH 3 H 2 O EtOH]; B%: 60%-60%, 8.5min) to obtain four peaks.
- t R2 3.239 min.
- t R3 3.682 min.
- t R4 3.859 min.
- Peak 1: LCMS Method 12): t R 0.674 min, [M+1] + 380.2.
- SFC (column: DAICEL CHIRALPAK AD (150mmx4.6 mm, 3 ⁇ m); mobile phase: A: CO 2 , B: EtOH(0.1% IPAm); 10%B for 0.5 min., 10-50%B, over 3.0 min., 50%B for 1.0 min.
- Peak 2: LCMS (Method 12): t R 0.663 min, [M+1] + 380.2.
- Step 3a To a solution of the compound from Peak 1 (70 mg, 0.18 mmol, 1.0 eq.) in DMF (1 mL) was added compound 2-bromoacetonitrile (33 mg, 0.28 mmol, 1.5 eq..) and Cs 2 CO 3 (121 mg, 0.37 mmol, 2.0 eq..) at 25°C.
- the product was purified by prep-HPLC (Waters Xbridge Prep OBD C18150mmx40mm, 10 ⁇ m; liquid phase: [A:H 2 O (10mM NH 4 HCO 3 ); B:ACN] B%: 25%-60%, 20min]) to obtain [(3M,6R or 6S)-3-(5-Fluoroisoquinolin-4-yl)-2,4-dioxo-6- (trifluoromethyl)-3,4,5,6,7,8-hexahydroquinazolin-1(2H)-yl]acetonitrile (21a)-Peak 1a.
- Step 3b To a solution of the compound from Peak 2 (65 mg, 0.17 mmol, 1.0 eq.) in DMF (1 mL) was added 2-bromoacetonitrile (31 mg, 0.26 mmol, 1.5 eq.) and Cs 2 CO 3 (112 mg, 0.34 mmol, 2.0 eq.) at 25°C. The reaction was stirred at 25°C under N 2 for 3 hrs. The reaction was quenched with H 2 O (5 mL) and extracted with EtOAc (2 mL ⁇ 3). The combined organic layers were washed with brine (5 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give crude product.
- 2-bromoacetonitrile 31 mg, 0.26 mmol, 1.5 eq.
- Cs 2 CO 3 112 mg, 0.34 mmol, 2.0 eq.
- the product was purified by prep-HPLC (column: Waters Xbridge Prep OBD C18150mmx40mm, 10 ⁇ m; liquid phase: [A:H 2 O (10mM NH 4 HCO 3 ); B:ACN] B%: 25%-60%, 20min]) to obtain [(3M,6R or 6S)-3-(5-Fluoroisoquinolin-4-yl)-2,4-dioxo-6- (trifluoromethyl)-3,4,5,6,7,8-hexahydroquinazolin-1(2H)-yl]acetonitrile (21b)-Peak 2a.
- Step 3c To a solution of the compound from Peak 3 (65 mg, 0.17 mmol, 1.0 eq.) in DMF (1 mL) was added 2-bromoacetonitrile (31 mg, 0.26 mmol, 1.5 eq.) and Cs 2 CO 3 (112 mg, 0.34 mmol, 2.0 eq.) at 25°C. The reaction was stirred at 25°C under N 2 for 3 hrs. The reaction was quenched with H2O (5 mL) and extracted with EtOAc (2 mL ⁇ 3). The combined organic layers were washed with brine (5 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give crude product.
- 2-bromoacetonitrile 31 mg, 0.26 mmol, 1.5 eq.
- Cs 2 CO 3 112 mg, 0.34 mmol, 2.0 eq.
- the product was purified by prep-HPLC (column: Waters Xbridge Prep OBD C18150mmx40mm, 10 ⁇ m; liquid phase: [A:H 2 O (10mM NH 4 HCO 3 ); B:ACN] B%: 25%-60%, 20min]) to obtain [(3P,6R or 6S)-3-(5-Fluoroisoquinolin-4-yl)-2,4-dioxo-6- (trifluoromethyl)-3,4,5,6,7,8-hexahydroquinazolin-1(2H)-yl]acetonitrile (21c)-Peak 3a.
- Step 3d To a solution of the compound from Peak 4 (50 mg, 0.13 mmol, 1.0 eq.) in DMF (1 mL) was added 2-bromoacetonitrile (24 mg, 0.20 mmol, 1.5 eq.) and Cs 2 CO 3 (86 mg, 0.26 mmol, 2.0 eq.) at 25°C.
- the product was purified by prep-HPLC (column: Waters Xbridge Prep OBD C18150mmx40mm, 10 ⁇ m; liquid phase: [A:H 2 O (10mM NH 4 HCO 3 ); B:ACN] B%: 25%- 60%, 20min]) to obtain [(3P,6R or 6S)-3-(5-Fluoroisoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)- 3,4,5,6,7,8-hexahydroquinazolin-1(2H)-yl]acetonitrile (21d)-Peak 4a.
- Example 22 Synthesis of 5-fluoro-3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline- 2,4(1H,3H)-dione (21)
- a solution of methyl 6-amino-2-fluoro-3-(trifluoromethyl)benzoate (Int-A8) (220 mg, 0.93 mmol, 1.0 eq.) in pyridine (10 mL) was added 4-isocyanatoisoquinoline (Int-B8) (173 mg, 1.02 mmol, 1.5 eq.).
- the mixture was stirred at 100°C for 6 hrs.
- the mixture was concentrated under reduced pressure to give crude product.
- Example 23 Synthesis of 5-fluoro-3-(isoquinolin-4-yl)-1-methyl-6-(trifluoromethyl)quinazoline- 2,4(1H,3H)-dione (23)
- 5-fluoro-3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione (22) (40 mg, 0.10 mmol, 1.0 eq.) and K 2 CO 3 (41 mg, 0.30 mmol, 3.0 eq.) in DMF (2 mL) was added MeI (21 mg, 0.15 mmol, 1.5 eq.). The mixture was stirred at 0°C for 2 hrs.
- Example 24 Synthesis of 3-(3-(isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4- dihydroquinazolin-1(2H)-yl)propanenitrile (24), 3-[(3M)-3-[6-(Methanesulfonyl)isoquinolin-4-yl]-2,4-dioxo-6-(trifluoromethyl)-3,4- dihydroquinazolin-1(2H)-yl]propanenitrile (24a) and 3-[(3P)-3-[6-(Methanesulfonyl)isoquinolin-4-yl]-2,4-dioxo-6-(trifluoromethyl)-3,4- dihydroquinazolin-1(2H)-yl]propanenitrile (24b) Step 1: The solution of 2-amino-5-(trifluoromethyl)benzoic acid (Int
- reaction mixture was warmed up to 25°C. Then to the reaction mixture was 6- (methylsulfonyl)isoquinolin-4-amine (Int-B2) (2.0 g, 9.00 mmol, 1.0 eq.) and NMM (1.8 g, 18.00 mmol, 2.0 eq.) at 25°C.
- the reaction mixture was heated up to 80°C and stirred at 80°C for 16 hrs.
- the reaction mixture was quenched with water (50 mL) and extracted with EtOAc (20 mL x 2). The combined organic layers were washed with brine (50 mL x 2), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give a crude product.
- Step 2 To a mixture of 2-amino-N-(6-(methylsulfonyl)isoquinolin-4-yl)-5- (trifluoromethyl)benzamide (500 mg, 1.22 mmol, 1.0 eq.) and TEA (865 mg, 8.55 mmol, 7.0 eq.) in THF (3 mL) was added a solution of triphosgene (360 mg, 1.22 mmol, 1.0 eq.) in THF (2 mL) dropwise at 0°C under N 2 . The mixture was then warmed up to 25°C and stirred at 25°C under N 2 for 2 hrs.
- Step 3 To the solution of -(6-(methylsulfonyl)isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline- 2,4(1H,3H)-dione (150 mg, 0.34 mmol, 1.0 eq.) and DBU (105 mg, 0.68 mmol, 2.0 eq.) in DMF (1 mL) was added acrylonitrile (180 mg, 3.40 mmol, 10.0 eq.) at 25°C. The mixture was heated to 100°C and stirred at 100°C for 16 hrs under N 2 . The reaction mixture was poured into water (10 mL) and extracted with EtOAc (10 mL x 2).
- Step 4 Racemic 3-(3-(6-(methylsulfonyl)isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4- dihydroquinazolin-1(2H)-yl)propanenitrile (24) (60 mg, 0.12 mmol, 1.0 eq.) was separated by prep-SFC (column: DAICEL CHIRALCEL OJ (250mmx30mm,10um); liquid phase: [A:IPA; B:ACN] B%: 15%, 12 min]) to give two peaks. (peak 1 and peak 2).
- Example 25 Synthesis of 3-(isoquinolin-4-yl)-5-methyl-6-(trifluoromethyl)quinazoline- 2,4(1H,3H)-dione (25)
- Step 1 To a solution of 6-fluoro-2-methyl-3-(trifluoromethyl)benzoic acid (Int-A9) (1.1 g, 4.95 mmol, 1.0 eq.) in DMF (20 mL) was added HATU (2.8 g, 7.43 mmol, 1.5 eq.), isoquinolin-4- amine (785 mg, 5.45 mmol, 1.1 eq.) and NMM (1.5 g, 14.85 mmol, 3.0 eq.) at 25°C.
- Int-A9 6-fluoro-2-methyl-3-(trifluoromethyl)benzoic acid
- HATU 2.8 g, 7.43 mmol, 1.5 eq.
- isoquinolin-4- amine 785 mg, 5.45 mmol,
- Step 2 To a solution of 6-fluoro-N-(isoquinolin-4-yl)-2-methyl-3-(trifluoromethyl)benzamide (1.1g, 3.16 mmol, 1.0 eq.) in NMP (11 mL) was added NaN 3 (350 mg, 5.38 mmol, 1.7 eq.) at 25°C. The mixture was stirred at 100°C for 24 hrs. To the mixture was added NaN 3 (225 mg, 3.46 mmol, 1.1 eq.) at 25°C and the mixture was stirred at 100°C for 16 hrs. The reaction was quenched with H 2 O (100 mL) and extracted with EtOAc (40 mL ⁇ 2).
- Step 4 To a mixture of 6-amino-N-(isoquinolin-4-yl)-2-methyl-3-(trifluoromethyl)benzamide (350 mg, 1.01 mmol, 1.0 eq.) and TEA (410 mg, 4.04 mmol, 4.0 eq.) in THF (6 mL) was added a solution of triphosgene (300 mg, 1.01 mmol, 1.0 eq.) in THF (4 mL) at 0°C. The mixture was stirred at 25°C for 12 hrs. The reaction was quenched with H 2 O (30 mL) and extracted with EtOAc (20 mL ⁇ 2).
- Example 26 Synthesis of 3-(isoquinolin-4-yl)-1,5-dimethyl-6-(trifluoromethyl)quinazoline- 2,4(1H,3H)-dione (26)
- 3-(isoquinolin-4-yl)-5-methyl-6-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione (25) (20 mg, 0.05 mmol, 1.0 eq.) in DMF (1 mL) was added Cs 2 CO 3 (35 mg, 0.10 mmol, 2.0 eq.) and MeI (8 mg, 0.06 mmol, 1.1 eq.) at 25°C.
- the mixture was stirred at 25°C for 2 hrs.
- Example 27 Synthesis of 3-(isoquinolin-4-yl)-6-(trifluoromethyl)-5,6,7,8-tetrahydroquinazoline- 2,4(1H,3H)-dione (27); (3M,6R or 6S)-3-(Isoquinolin-4-yl)-6-(trifluoromethyl)-5,6,7,8- tetrahydroquinazoline-2,4(1H,3H)-dione (27a); (3M,6R or 6S)-3-(Isoquinolin-4-yl)-6-(trifluoromethyl)-5,6,7,8- tetrahydroquinazoline-2,4(1H,3H)-dione (27b); (3P,6R or 6S)-3-(Isoquinolin-4-yl)-6-(trifluoromethyl)-5,6,7,8- tetrahydroquinazoline-2,4(1H,3H)-d
- Step 2 To a solution of ethyl 2-(((4-nitrophenoxy)carbonyl)amino)-5-(trifluoromethyl)cyclohex-1- ene-1-carboxylate (2.0 g, 4.97 mmol, 1.0 eq) in dioxane (40 mL) was added isoquinolin-4-amine (788 mg, 5.47 mmol, 1.1 eq) and DBU (1.5 g, 9.94 mmol, 2.0 eq) at 20°C. The reaction mixture was stirred at 20°C for 14 hrs. The solution was diluted with H 2 O (40 mL) and extracted with EtOAc (3x50 mL).
- the combined organic phase was dried over Na 2 SO 4 , filtrated and concentrated to give crude product.
- the crude product was purified by prep-HPLC (Column: Waters Xbridge Prep OBD C18150mmx40mm, 10 ⁇ m; liquid phase: [A:H 2 O(10mM NH 4 HCO 3 ); B:ACN]B%: 20%-40%,20min]) to give racemic 3-(isoquinolin-4-yl)-6-(trifluoromethyl)-5,6,7,8- tetrahydroquinazoline-2,4(1H,3H)-dione.
- Example 29 Synthesis of [(3M,6R or 6S)-3-(Isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)- 3,4,5,6,7,8-hexahydroquinazolin-1(2H)-yl]acetonitrile (29a); [(3M,6R or 6S)-3-(Isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4,5,6,7,8- hexahydroquinazolin-1(2H)-yl]acetonitrile (29b); [(3P,6R or 6S)-3-(Isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4,5,6,7,8- hexahydroquinazolin-1(2H)-yl]acetonitrile (29c), and [(3P,6
- Example 30 Synthesis of 1- ⁇ [(3M)-3-(5-Fluoroisoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4- dihydroquinazolin-1(2H)-yl]methyl ⁇ cyclopropane-1-carbonitrile (30a) and 1- ⁇ [(3P)-3-(5-Fluoroisoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4- dihydroquinazolin-1(2H)-yl]methyl ⁇ cyclopropane-1-carbonitrile (30b) Step 1: To a solution of 3-(5-fluoroisoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)- dione (300 mg, 0.66 mmol, 1.0 eq.) in DMF (6 mL) was added (1-cyanocyclopropyl)methyl
- Step 2 The racemate (30) was separated by SFC (DAICEL CHIRALPAK AD (250mmx50mm,10um); liquid phase: 0.1%NH 3 H 2 O EtOH]B%: 10%-50%,10min]) to give 2 peaks: peak 1 and peak 2.
- Example 31 Synthesis of 3-(isoquinolin-4-yl)-6-(trifluoromethyl)pyrido[3,2-d]pyrimidine- 2,4(1H,3H)-dione (31)
- Step 1 To a mixture of 3-amino-6-(trifluoromethyl)picolinic acid (Int-A10) (1.0 g, crude, 4.85 mmol, 1.0 eq.), isoquinolin-4-amine (699 mg, 4.85 mmol, 1.0 eq.), NMI (1.2 g, 14.55 mmol, 3.0 eq.) in ACN (10 mL) was added TCFH (1.6 g, 5.82 mmol, 1.2 eq.) in portions at 20°C.
- Int-A10 3-amino-6-(trifluoromethyl)picolinic acid
- NMI 1.2 g, 14.55 mmol, 3.0 eq.
- TCFH 1.6 g, 5.82 mmol, 1.2 e
- Step 2 To a solution of 3-amino-N-(isoquinolin-4-yl)-6-(trifluoromethyl)picolinamide (100 mg, 0.30 mmol, 1.0 eq.) and TEA (183 mg, 1.81 mmol, 6.0 eq.) in THF (1 mL) was added a solution of triphosgene (179 mg, 0.60 mmol, 2.0 eq.) in THF (0.5 mL) dropwise at 0°C. The mixture was stirred at 20°C for 20 hrs under N 2 .
- Step 1 To a solution of 5-(1-(methoxycarbonyl)cyclopropyl)-2-nitrobenzoic acid (Int-A11) (850 mg, 3.21 mmol, 1.0 eq.) in DMF (8.5 mL) was added HATU (1.5 g, 3.85 mmol, 1.2 eq.). The mixture was stirred at 25°C for 1 hr. Then to the mixture was added isoquinolin-4-amine (508 mg, 3.53 mmol, 1.1 eq.) and NMM (972 mg, 9.62 mmol, 3.0 eq.). The mixture was stirred at 45°C for 15 hrs.
- Step 2 To a mixture of Raney Ni (1.0 g) in EtOH (10 mL) was added methyl 1-(3-(isoquinolin-4- ylcarbamoyl)-4-nitrophenyl)cyclopropane-1-carboxylate (926 g, 2.37 mmol, 1.0 eq). The suspension was degassed under vacuum and purged with H 2 several times, and the mixture was stirred under H2 (15 psi) at 35°C for 16 hrs. The mixture was filtered though a pad, the filtrate was concentrated to give methyl 1-(4-amino-3-(isoquinolin-4- ylcarbamoyl)phenyl)cyclopropane-1-carboxylate.
- Step 3 To a solution of methyl 1-(4-amino-3-(isoquinolin-4-ylcarbamoyl)phenyl)cyclopropane-1- carboxylate (679 mg, 1.88 mmol, 1.0 eq.) in THF (7 mL) was added DMAP (23 mg, 0.20 mmol, 0.1 eq.) and CDI (610 mg, 3.76 mmol, 2.0 eq.). The mixture was stirred at 80°C for 6 hrs. The mixture was quenched with H 2 O (10 mL), extracted with CH 2 Cl 2 (30 mL x 2).
- Step 4 To a solution of methyl 1-(3-(isoquinolin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6- yl)cyclopropane-1-carboxylate (150 mg, 0.39 mmol, 1.0 eq.) in dioxane (1 mL) was added 6 M HCl (1 mL) at 25°C and then the mixture was stirred at 60°C for 16 hrs.
- Example 33 Synthesis of 6-(1-(hydroxymethyl)cyclopropyl)-3-(isoquinolin-4-yl)quinazoline- 2,4(1H,3H)-dione (33)
- 1-(3-(isoquinolin-4-yl)-2,4-dioxo-1,2,3,4-tetrahydroquinazolin-6-yl)cyclopropane- 1-carboxylic acid (32) 153 mg, 0.41 mmol, 1.0 eq.
- TEA 62 mg, 0.61 mmol, 1.5 eq.
- CDI 100 mg, 0.61 mmol, 1.5 eq.
- Example 34 Synthesis of 1-isopropyl-3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline- 2,4(1H,3H)-dione (34)
- 3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione (2) 200 mg, 0.56 mmol, 1.0 eq.
- Cs 2 CO 3 364 mg, 1.12 mmol, 2.0 eq.
- 2- iodopropane 190 mg, 1.12 mmol, 2.0 eq.
- Example 35 Synthesis of 6-isopropyl-3-(isoquinolin-4-yl)quinazoline-2,4(1H,3H)-dione (35)
- a mixture of methyl 2-amino-5-isopropylbenzoate (Int-A12) 1.0 g, 5.18 mmol, 1.0 eq.
- pyridine 10 mL
- 4-isocyanatoisoquinoline Int-B8
- the mixture was stirred at 100°C for 12 hrs under N 2 .
- the mixture was quenched with H 2 O (10 mL), extracted with EtOAc (10 mL x 3).
- Example 36 Synthesis of 6-isopropyl-3-(isoquinolin-4-yl)-1-methylquinazoline-2,4(1H,3H)-dione (36) To the mixture of 6-isopropyl-3-(isoquinolin-4-yl)quinazoline-2,4(1H,3H)-dione (35) (160 mg, 0.48 mmol, 1.0 eq.) in DMF (3 mL) were added K 2 CO 3 (133 mg, 0.96 mmol, 2.0 eq.) and MeI (68 mg, 0.48 mmol, 1.0 eq.) at 0°C and the mixture was stirred at 20°C for 12 hrs.
- K 2 CO 3 133 mg, 0.96 mmol, 2.0 eq.
- MeI 68 mg, 0.48 mmol, 1.0 eq.
- Example 37 Synthesis of methyl 2-((3-(isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4- dihydroquinazolin-1(2H)-yl)methyl)acrylate (37)
- 3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione (2) 105 mg, 0.30 mmol, 1.0 eq.
- Cs 2 CO 3 196 mg, 0.60 mmol, 2.0 eq.
- methyl 2-(bromomethyl)acrylate 54 mg, 0.30 mmol, 1.0 eq.
- Example 38 Synthesis of 3-(3-(isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4- dihydroquinazolin-1(2H)-yl)-2-methylpropanoic acid (38) Step 1: To a mixture of methyl 2-((3-(isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4- dihydroquinazolin-1(2H)-yl)methyl)acrylate (37) (150 mg, 0.33 mmol, 1.0 eq.) in EtOAc (6 mL) was added Pd/C (50 mg, 10%) at 25°C.
- Step 2 To a mixture methyl 3-(3-(isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4- dihydroquinazolin-1(2H)-yl)-2-methylpropanoate (120 mg, 0.26 mmol, 1.0 eq.) in dioxane (2 mL) was added trimethylstannanol (95 mg, 0.52 mmol, 2.0 eq.) at 25°C. The mixture was stirred at 100°C for 18 hrs.
- Example 39 Synthesis of 2-((3-(isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4- dihydroquinazolin-1(2H)-yl)methyl)acrylic acid (39) To a mixture of methyl 2-((3-(isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4- dihydroquinazolin-1(2H)-yl)methyl)acrylate (37) (150 mg, 0.33 mmol, 1.0 eq.) in dioxane (2 mL) was added aq. HCl (2 mL, 6 M) at 25°C.
- Example 40 Synthesis of 2-((3-(isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4- dihydroquinazolin-1(2H)-yl)methyl)acrylamide (40) To a solution of 2-((3-(isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4-dihydroquinazolin-1(2H)- yl)methyl)acrylic acid (39) (150 mg, 0.34 mmol, 1.0 eq.) in dioxane (3 mL) was added pyridine (0.3 mL) and Boc2O (1.2 g, 5.44 mmol, 16.0 eq.) at 25°C.
- Example 41 Synthesis of 3-(5-bromoisoquinolin-4-yl)-6-(trifluoromethyl)quinazoline- 2,4(1H,3H)-dione (41)
- Example 42 Synthesis of 3-(5-methylisoquinolin-4-yl)-6-(trifluoromethyl)quinazoline- 2,4(1H,3H)-dione (42)
- 3-(5-bromoisoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione (41) 50 mg, 0.11 mmol, 1.0 eq.) in dioxane (2 mL) was added MeB(OH) 2 (35 mg, 0.55 mmol, 5.0 eq.), K 3 PO 4 (47 mg, 0.22 mmol, 2.0 eq.) and S-Phos-Pd-G 2 (10 mg, 0.01 mmol, 0.1 eq.) at 25°C under N 2 .
- Step 1 A mixture of 5-(difluoromethoxy)-2-nitrobenzoic acid (Int-A13) (800 mg, 3.43 mmol, 1.0 eq), isoquinolin-4-amine (495 mg, 3.43 mmol, 1.0 eq), TCFH (962 mg, 3.43 mmol, 1.0 eq) and NMI (985 mg, 12.01 mmol, 3.5 eq) in CH 3 CN (8 mL) was stirred at 20°C for 1 hr. The reaction mixture was quenched with H 2 O (30 mL) and extracted with ethyl acetate (30 mL x 3). The combined organic layers were dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give a residue.
- Int-A13 800 mg, 3.43 mmol, 1.0 eq
- isoquinolin-4-amine 495 mg, 3.43 mmol, 1.0 eq
- TCFH 962 mg, 3.43 mmol, 1.0
- Step 2 To the solution of 5-(difluoromethoxy)-N-(isoquinolin-4-yl)-2-nitrobenzamide (370 mg, 1.03 mmol, 1.0 eq) in EtOH (4 mL) and H 2 O (1 mL) was added Fe (288 mg, 5.15 mmol, 5.0 eq) and NH4Cl (275 mg, 5.15 mmol, 5.0 eq). The mixture was stirred at 70°C for 18 hrs. The reaction mixture was filtered and concentrated under reduced pressure to give 2-amino-5- (difluoromethoxy)-N-(isoquinolin-4-yl)benzamide which was used directly in the next step.
- Example 44 Synthesis of 1-((3-(isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4- dihydroquinazolin-1(2H)-yl)methyl)cyclopropane-1-carbonitrile (44)
- 3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione (2) 200 mg, 0.56 mmol, 1.0 eq.
- DMF 4 mL
- Cs 2 CO 3 364 mg, 1.12 mmol, 2.0 eq.
- (1- cyanocyclopropyl)methyl 4-methylbenzenesulfonate 212 mg, 0.84 mmol, 1.5 eq.
- NaI 84 mg, 0.56 mmol, 1.0 eq.
- (1-cyanocyclopropyl)methyl 4-methylbenzenesulfonate was obtained using the following procedure: To a solution of 1-(hydroxymethyl)cyclopropane-1-carbonitrile (700 mg, 7.21 mmol, 1.0 eq.) in CH 2 Cl 2 (4 mL) was added Et 3 N (1.3 g, 9.01 mmol, 1.3 eq.) at 25°C. A solution of TsCl (1.6 g, 8.65 mmol, 1.2 eq.) in CH 2 Cl 2 (2 mL) was added dropwise at 0°C and the reaction was stirred at 25°C for 16 hrs.
- Example 45 Synthesis of 1-(2-hydroxyethyl)-3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline- 2,4(1H,3H)-dione (45)
- Step 1 A mixture of 3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione (2) (500 mg, 1.51 mmol, 1.0 eq.), 2-((tert-butyldimethylsilyl)oxy)ethyl 4-methylbenzenesulfonate (540 mg, 1.51 mmol, 1.0 eq.), Cs 2 CO 3 (985 mg, 3.02 mmol, 2.0 eq.) and NaI (230 mg, 1.51 mmol, 1.0 eq.) in DMF (5 mL) was stirred at 50°C for 16 hrs.
- Step 2 To a solution of 1-(2-((tert-butyldimethylsilyl)oxy)ethyl)-3-(isoquinolin-4-yl)-6- (trifluoromethyl)quinazoline-2,4(1H,3H)-dione (520 mg, 0.19 mmol, 1.0 eq.) in dioxane (5 mL) was added 6 M HCl (5 mL) dropwise at 0°C and the mixture then stirred at 20°C for 1 hr. The reaction mixture was quenched with water (10 mL) and extracted with MTBE (10 mL).
- reaction mixture was quenched with water (20 mL) and extracted with CH 2 Cl 2 (20 mL x 3). The combined organic layers were washed with brine (50 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give crude product.
- Example 46 Synthesis of 1-(2-fluoroethyl)-3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline- 2,4(1H,3H)-dione (46) To a mixture of 1-(2-hydroxyethyl)-3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)- dione (45) (300 mg, 0.73 mmol, 1.0 eq.) in MeCN (5 mL) was added Et 3 N (660 mg, 6.57 mmol, 9.0 eq.) and 1,1,2,2,3,3,4,4,4-nonafluorobutane-1-sulfonyl fluoride (660 mg, 2.19 mmol, 3.0 eq.) followed by the addition of HF .
- Et 3 N 660 mg, 6.57 mmol, 9.0 eq.
- Example 47 Synthesis of 4-(2,4-dioxo-6-(trifluoromethyl)-1,4-dihydroquinazolin-3(2H)-yl)-N-(2- methoxyethyl)isoquinoline-6-carboxamide (47)
- Step 1 To a mixture of methyl 4-aminoisoquinoline-6-carboxylate hydrochloride (Int-B4) (2.8 g, 13.58 mmol, 1.2 eq.) in DMF (30 mL) was added HATU (6.5 g, 16.97 mmol, 1.5 eq.) at 45°C. The reaction mixture was stirred at 45°C for 2 hrs.
- Int-B4 4-aminoisoquinoline-6-carboxylate hydrochloride
- HATU 6.5 g, 16.97 mmol, 1.5 eq.
- Step 2 To a mixture of methyl 4-(2-amino-5-(trifluoromethyl)benzamido)isoquinoline-6- carboxylate (400 mg, 1.03 mmol, 1.0 eq.) in DMF (5 mL) was added CDI (334 mg, 2.06 mmol, 2.0 eq.), CDT (338 mg, 2.06 mmol, 2.0 eq.) and DMAP (26 mg, 0.21 mmol, 0.2 eq.) at 20°C. The reaction mixture was stirred at 80°C for 16 hrs. The reaction was poured into water (50 mL) and extracted with EtOAc (20 mL x 3).
- Step 4 To a mixture of 4-(2,4-dioxo-6-(trifluoromethyl)-1,4-dihydroquinazolin-3(2H)- yl)isoquinoline-6-carboxylic acid, (200 mg, 0.50 mmol, 1.0 eq.), 2-methoxyethan-1-amine (45 mg, 0.60 mmol, 1.2 eq.) and Et 3 N (253 mg, 2.50 mmol, 5.0 eq.) in CH 2 Cl 2 (5 mL) was added T3P (477 mg, 0.75 mmol, 1.5 eq.) at 25°C. The reaction mixture was stirred at 25°C for 16 hrs.
- Example 48 Synthesis of 8-bromo-3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline- 2,4(1H,3H)-dione (48) To a solution of methyl 2-amino-3-bromo-5-(trifluoromethyl)benzoate (Int-A14) (217 mg, 0.73mmol, 1.4 eq.) in DMF (2 mL) was added NaH (19 mg, 0.78 mmol, 1.5 eq.) at 0°C and the mixture was stirred at 0°C for 1 hr.
- phenyl isoquinolin-4-yl(phenoxycarbonyl)carbamate (Int-B7) (200 mg, 0.52 mmol, 1.0 eq.) was added to the above mixture at 0°C and the mixture was stirred 25°C for 15 hrs.
- the aqueous phase was extracted with EtOAc (20 mL x 2).
- the combined organic layers were washed with brine (50 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give crude product.
- Example 49 Synthesis of 8-(2-hydroxypropan-2-yl)-3-(isoquinolin-4-yl)-6- (trifluoromethyl)quinazoline-2,4(1H,3H)-dione (49)
- Step 1 To a mixture of 8-bromo-3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)- dione (48) (200 mg, 0.46 mmol, 1.0 eq.) in MeOH (10 mL) was added K 2 CO 3 (159 mg, 1.15 mmol, 2.5 eq.) and Pd(dppf)Cl 2 (37 mg, 0.05 mmol, 0.1 eq.) at 20°C under CO (50 psi).
- Step 2 To a mixture of methyl 3-(isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-1,2,3,4- tetrahydroquinazoline-8-carboxylate (50 mg, 0.12 mmol, 1.0 eq.) in THF (2 mL) was added MeMgBr (0.2 mL, 0.60 mmol, 5.0 eq.) at 0°C under N 2 . The reaction was stirred at 0°C for 2 hrs. The reaction mixture was quenched with NH 4 Cl (5 mL), extracted with CH 2 Cl 2 (10 mL x 2).
- Example 50 Synthesis of 3-(isoquinolin-4-yl)-1-methyl-6-(trifluoromethyl)quinazoline- 2,4(1H,3H)-dione (50)
- Step 1 To a mixture of 3-bromoisoquinolin-4-amine (Int-B5) (3.5 g, 15.76 mmol, 1.0 eq.) and pyridine (5 g, 63.07 mmol, 4.0 eq.) in CH 2 Cl 2 (40 mL) was added ClCOOPh (6.1 g, 39.40 mmol, 2.5 eq.) at 0°C. The mixture was stirred at 20°C for 4 hrs. The reaction solution was poured into water (80 mL) and extracted with CH 2 Cl 2 (50 mL x 3), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give a residue.
- ClCOOPh 6.1 g, 39.40 mmol, 2.5 eq.
- Step 2 To a solution of methyl 2-amino-5-(trifluoromethyl)benzoate (Int-A6) (1.7 g, 7.80 mmol, 1.5 eq.) in DMF (30 mL) was added NaH (292 mg, 7.30 mmol, 1.4 eq.) at 0°C under N 2 . The mixture was stirred at 0°C for 30 mins. Phenyl (3-bromoisoquinolin-4-yl)carbamate (2.4 g, 5.20 mmol, 1.0 eq.) in DMF (20 mL) was added dropwise at 0°C under N2. The mixture was stirred at 20°C for 15.5 hrs.
- Int-A6 methyl 2-amino-5-(trifluoromethyl)benzoate
- Step 3 To a solution of 3-(3-bromoisoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)- dione (300 mg, 0.69 mmol, 1.0 eq.) and ZnCN 2 (143 mg, 1.38 mmol, 2.0 eq.) in DMF (5 mL) was added Pd 2 (dba) 3 (30mg) and DPPF (45 mg) at 20°C. The mixture was stirred at 130°C for 16 hrs under N 2 . The reaction solution was poured into H 2 O (10 mL) and extracted with EtOAc (15 mL x 3).
- Example 52 Synthesis of 3-(3-ethynylisoquinolin-4-yl)-6-(trifluoromethyl)quinazoline- 2,4(1H,3H)-dione (52)
- Step 1 To the solution of 3-(3-bromoisoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)- dione (400 mg, 0.92 mmol, 1.0 eq.) in TEA/MeCN (4/1mL) was added ethynyltrimethylsilane (451 mg, 4.60 mmol, 5.0 eq.) and Pd(pph 3 ) 2 Cl 2 (40 mg) at 20°C.
- Step 2 To a solution of 6-(trifluoromethyl)-3-(3-((trimethylsilyl)ethynyl)isoquinolin-4- yl)quinazoline-2,4(1H,3H)-dione (300 mg, 0.66 mmol, 1.0 eq.) in MeOH (6 mL) was added K 2 CO 3 (183 mg, 1.32 mmol, 2.0 eq.) at 0°C. The mixture was stirred at 20°C for 2 hrs. The reaction solution was poured into H 2 O (10 mL) and extracted with EtOAc (20 mL x 3), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give the residue.
- Example 54 Synthesis of 3-(isoquinolin-4-yl)-6-(trifluoromethyl)pyrido[3,4-d]pyrimidine- 2,4(1H,3H)-dione (54)
- a solution of methyl 5-amino-2-(trifluoromethyl)isonicotinate (Int-A15) 500 mg, 2.27 mmol, 1.0 eq.) in pyridine (5 mL) was added to 4-isocyanatoisoquinoline (Int-B8) (600 mg crude, 2.27 mmol, 1.0 eq.) at 25°C and the mixture was stirred for 12 hrs at 100°C under N 2 .
- the reaction mixture was concentrated to give a residue.
- Step 2 To a solution of methyl (E)-4-(3-(isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4- dihydroquinazolin-1(2H)-yl)but-2-enoate (450 mg, 0.99 mmol, 1.0 eq.) in dioxane (6 mL) was added Me 3 SnOH (358 mg, 1.98 mmol, 2.0 eq.) at 0°C under nitrogen. The reaction was stirred for 12 hrs at 80°C. The reaction was slowly quenched with water (10 mL), adjusted to pH ⁇ 5 with 1N HCl and extracted with EtOAc (10 ⁇ 3 mL).
- Step 1 To a solution of racemic (E)-4-(3-(isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4- dihydroquinazolin-1(2H)-yl)but-2-enoic acid (350 mg, 0.79 mmol, 1.0 eq.) in THF (4 mL) was added Boc 2 O (346 mg, 1.58 mmol, 2.0 eq.), NH 4 HCO 3 (125 mg, 1.58 mmol, 2.0 eq.) and pyridine (125 mg, 1.58 mmol, 2.0 eq.) at 20°C under nitrogen. The reaction was stirred for 12 hrs at 20°C.
- Example 57 Synthesis of 3-(isoquinolin-4-yl)-1-(2-morpholinoethyl)-6- (trifluoromethyl)quinazoline-2,4(1H,3H)-dione (57)
- 2-morpholinoethyl 4-methylbenzenesulfonate 300 mg, 0.84 mmol, 1.0 eq.
- Cs 2 CO 3 547 mg, 1.68 mmol, 2.0 eq.
- NaI 30 mg
- the reaction mixture was quenched into water (40 mL) and extracted with EtOAc (40 mL x 2). The combined organic layers were dried over Na 2 SO 4 , filtered and concentrated in vacuum to give crude product.
- the crude product was purified by prep-HPLC (column: Waters Xbridge BEH C18100mmx30mm, 10 ⁇ m; liquid phase: [A:10mM NH 4 HCO 3 in H 2 O; B:ACN] B%: 30%- 50%, 8min]) to give3-(isoquinolin-4-yl)-1-(2-morpholinoethyl)-6-(trifluoromethyl)quinazoline- 2,4(1H,3H)-dione (57).
- 2-morpholinoethyl 4-methylbenzenesulfonate was obtained using the following procedure: To a solution of 2-morpholinoethan-1-ol (2.0 g, 15.24 mmol, 1.0 eq.), Et 3 N (3.1 g, 62.24 mmol, 2.0 eq.) in CH 2 Cl 2 (20 mL) was added TsCl (2.9 g, 15.24 mmol, 1.0 eq.) at 20°C, the mixture was stirred at 20°C for 5 hrs. The reaction mixture was quenched with water (20 mL) and extracted with CH 2 Cl 2 (20 mL x 3).
- Example 58 Synthesis of 3-(isoquinolin-4-yl)-8-methyl-6-(trifluoromethyl)quinazoline- 2,4(1H,3H)-dione (58)
- Step 1 To a solution of 8-bromo-3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)- dione (48) (200 mg, 0.46 mmol, 1.0 eq.) in THF (5 mL) was added methylboronic acid (120 mg, 1.83 mmol, 4.0 eq.), Pd(dppf)Cl 2 (40 mg, 0.05 mmol, 0.1 eq.) and Na 2 CO 3 (100 mg, 0.92 mmol, 2.0 eq.) at 25°C and the mixture was stirred 80°C for 16 hrs.
- methylboronic acid 120 mg, 1.83 mmol, 4.0 eq.
- reaction mixture was quenched with saturated aqueous NH 4 Cl (5 mL) and extracted with ethyl acetate (10 mL x 2). The combined organic layers were washed with brine (20 mL), dried over Na 2 SO 4 , filtered and concentrated to give crude product.
- Example 59 Synthesis of 1-(2-(4,4-difluoropiperidin-1-yl)ethyl)-3-(isoquinolin-4-yl)-6- (trifluoromethyl)quinazoline-2,4(1H,3H)-dione (59)
- Step 1 To a mixture of 1-(2-hydroxyethyl)-3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline- 2,4(1H,3H)-dione (45) (400mg, 1.00 mmol, 1.0 eq.) and Et 3 N (202 mg, 2.00 mmol, 2.0 eq.) in CH 2 Cl 2 (5 mL) was added TsCl (210 mg, 1.10 mmol, 1.1 eq.) at 20°C, the mixture was stirred at 20°C for 16 hrs.
- the reaction mixture was quenched into water (20 mL) and extracted with CH 2 Cl 2 (20 mL x 3). The combined organic layers were washed by brine (50 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give the crude product.
- Step 2 To a mixture of 2-(3-(isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4- dihydroquinazolin-1(2H)-yl)ethyl 4-methylbenzenesulfonate (300 mg, 0.54 mmol, 1.0 eq.) in DMF (3 mL) was added 4,4-difluoropiperidine (131 mg, 1.08 mmol, 2.0 eq.) and DIEA (210 mg, 1.62 mmol, 3.0 eq.) at 20°C and the mixture was stirred at 50°C for 16 hrs.
- Example 60 Synthesis of 1-(2-(3,3-difluoropiperidin-1-yl)ethyl)-3-(isoquinolin-4-yl)-6- (trifluoromethyl)quinazoline-2,4(1H,3H)-dione (60)
- DMF dimethyl methyl
- alkaline resin a mixture of 3,3-difluoropiperidine hydrochloride (282 mg, 1.80 mmol, 5.0 eq.) in DMF (4 mL) was added alkaline resin to adjust pH to 8, the mixture was stirred 1 hr at 20°C and filtered.
- Example 61 Synthesis of 3-(isoquinolin-4-yl)-1-(2-(piperazin-1-yl)ethyl)-6- (trifluoromethyl)quinazoline-2,4(1H,3H)-dione (61)
- Step 1 A mixture of 2-(3-(isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4-dihydroquinazolin- 1(2H)-yl)ethyl 4-methylbenzenesulfonate (300 mg, 0.54 mmol, 1.0 eq.), tert-butyl piperazine-1- carboxylate (150 mg, 0.81 mmol, 1.5 eq.) and DIEA (135 mg, 1.08 mmol, 2.0 eq.) in DMF (5 mL) was stirred at 50°C for 16 hrs.
- Step 2 A mixture of tert-butyl 4-(2-(3-(isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4- dihydroquinazolin-1(2H)-yl)ethyl)piperazine-1-carboxylate (160 mg, 0.28 mmol, 1.0 eq.) in HCl (g)/EtOAc (5 mL) was stirred at 20°C for 1 hr. The reaction mixture was poured into water (5 mL) and the precipitate filtered.
- Example 62 Synthesis of 3-(isoquinolin-4-yl)-1-(2-methoxyethyl)-6-(trifluoromethyl)quinazoline- 2,4(1H,3H)-dione (62)
- Example 63 Synthesis of 1-ethyl-3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)- dione (63)
- 3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione (2) 200 mg, 0.56 mmol, 1.0 eq.
- DMF 2 mL
- Cs 2 CO 3 364 mg, 1.12 mmol, 2.0 eq.
- iodoethane 113 mg, 0.72 mmol, 1.3 eq.
- Example 64 Synthesis of 1-((R)-3-hydroxybutyl)-3-(isoquinolin-4-yl)-6- (trifluoromethyl)quinazoline-2,4(1H,3H)-dione (64)
- (R)-3-hydroxybutyl 4-methylbenzenesulfonate was obtained using the following procedure: A mixture of (R)-butane-1,3-diol (CAS No.6290-03-5) (1.0 g, 11.10 mmol, 1.0 eq.) and TsOH (2.2 g, 11.65 mmol, 1.1 eq.) in pyridine (10 mL) was stirred at 50°C for 16 hrs. The reaction was quenched with saturated aqueous NH 4 Cl (80 mL) and extracted with EtOAc (30 mL ⁇ 2). The combined organic layers were washed with brine (80 mL ⁇ 2), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give crude product.
- Example 65 Synthesis of 1-((S)-4-hydroxybutan-2-yl)-3-(isoquinolin-4-yl)-6- (trifluoromethyl)quinazoline-2,4(1H,3H)-dione (65)
- Step 1 To a solution of 3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione (2) (140 mg, 0.39 mmol, 1.0 eq.) in DMF (3 mL) was added Cs 2 CO 3 (383 mg, 1.18 mmol, 3.0 eq.) at 25°C.
- Step 2 To a solution of 1-((S)-4-((tert-butyldiphenylsilyl)oxy)butan-2-yl)-3-(isoquinolin-4-yl)-6- (trifluoromethyl)quinazoline-2,4(1H,3H)-dione (230 mg, 0.34 mmol, 1.0 eq.) in dioxane (2 mL) was added HCl (2 mL, 6M) at 25°C. The reaction was stirred at 25°C for 1 hr under N 2 . The reaction was concentrated to give a residue.
- Step 1 A mixture of (R)-butane-1,3-diol (CAS No.6290-03-5) (2.0 g, 22.19 mmol, 1.0 eq.) in CH 2 Cl 2 (20 mL) was added Imidizole (3.0 g, 44.38 mmol, 2.0 eq.) at 25°C.
- Step 2 To a solution of (R)-4-((tert-butyldiphenylsilyl)oxy)butan-2-ol (2.0 g, 6.09 mmol, 1.0 eq.) in CH 2 Cl 2 (20 mL) was added Et 3 N (1.2 g, 12.18 mmol, 2.0 eq.) and DMAP (75 mg, 0.61 mmol, 0.1 eq.) at 25°C. A solution of TsCl (1.5 g, 7.92 mmol, 1.3 eq.) in CH 2 Cl 2 (5 mL) was added into the reaction at 0°C. The mixture was stirred at 25°C for 16 hrs under N 2 .
- Example 66 Synthesis of 1-((3-(isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4- dihydroquinazolin-1(2H)-yl)methyl)cyclopropane-1-carboxylic acid (66) Step 1: To a solution of 3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione (2) (300 mg, 0.84 mmol, 1.0 eq.) in DMF (4 mL) was added Cs 2 CO 3 (546 mg, 1.68 mmol, 2.0 eq.), ethyl 1-((tosyloxy)methyl)cyclopropane-1-carboxylate (375 mg, 1.26 mmol, 1.5 eq.) and NaI (126 mg, 0.84 mmol, 1.0 eq.) at 25°C.
- Step 2 To a solution of thyl 1-((3-(isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4- dihydroquinazolin-1(2H)-yl)methyl)cyclopropane-1-carboxylate (360 mg, 0.74 mmol, 1.0 eq.) in dioxane (5 mL) was added SnMe 3 OH (270 mg, 1.49 mmol, 2.0 eq.) at 25°C. The mixture was stirred at 100°C for 16 hrs under N 2 . The mixture was concentrated to give a residue. The residue was dissolved in DMF (3 mL) and filtered off.
- the filtrate was purified by prep-HPLC (column: Phenomenex Luna C18200mmx40mm, 10 ⁇ m; liquid phase: [A:H 2 O (0.1% FA); B:ACN] B%: 50%-90%, 20 min]) to give 1-((3-(isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4- dihydroquinazolin-1(2H)-yl)methyl)cyclopropane-1-carboxylic acid (66).
- Ethyl 1-((tosyloxy)methyl)cyclopropane-1-carboxylate was obtained using the following procedure: To a solution of ethyl 1-(hydroxymethyl)cyclopropane-1-carboxylate (400 mg, 2.77 mmol, 1.0 eq.) in CH 2 Cl 2 (4 mL) was added Et 3 N (561 mg, 5.55 mmol, 2.0 eq.) and DMAP (34 mg, 0.28 mmol, 0.1 eq.) at 25°C. A solution of TsCl (635 mg, 3.33 mmol, 1.2 eq.) in CH 2 Cl 2 (2 mL) was added dropwise at 0°C and the reaction was stirred at 25°C for 16 hrs.
- Example 67 Synthesis of 6-(1,1-difluoroethyl)-3-(isoquinolin-4-yl)quinazoline-2,4(1H,3H)-dione
- Step 1 To a solution of 5-acetyl-2-aminobenzoic acid (CAS No.53589-27-8) (2.4 g, 13.41 mmol, 1.0 eq.) in DMF (23 mL) was added HATU (6.1 g, 16.09 mmol, 1.2 eq.) and the mixture was stirred at 25°C for 1 hr.
- 5-acetyl-2-aminobenzoic acid CAS No.53589-27-8
- HATU 6.1 g, 16.09 mmol, 1.2 eq.
- Step 2 To a mixture of 5-acetyl-2-amino-N-(isoquinolin-4-yl)benzamide (375 mg, 1.23 mmol, 1.0 eq.) in THF (4 mL) was added DIEA (952 mg, 7.38 mmol, 6.0 eq.) and triphosgene (365 mg, 1.23 mmol, 1.0 eq.). The mixture was stirred at 25°C for 16 hrs. The mixture was quenched with saturated NaHCO 3 aqueous (15 mL), extracted with EtOAc (15 mL x 2).
- Step 3 A solution of 6-acetyl-3-(isoquinolin-4-yl)quinazoline-2,4(1H,3H)-dione (106 mg, 0.35 mmol, 1.0 eq.) in BAST (2 mL) was stirred at 60°C for 16 hrs. The reaction was quenched with saturated NaHCO 3 aqueous (20 mL) and extracted with EtOAc (15 mL x 2).
- Step 1 To a mixture of 5-bromo-N-(isoquinolin-4-yl)-2-nitrobenzamide (1.4 g, 3.76 mmol, 3.0 eq.), cyclopropylboronic acid (387 mg, 4.51 mmol, 1.2 eq.) and Cs 2 CO 3 (3.1 g, 9.40 mmol, 2.5 eq) in 1, 4-dioxane (8 mL) and H 2 O (2 mL) was added Pd(dppf)Cl 2 -CH 2 Cl 2 (307 mg, 376 ⁇ mol. 0.1 eq) under N 2 . The homogeneous reaction mixture was heated to 100°C for 16 h.
- Step 2 To a mixture of 5-cyclopropyl-N-(isoquinolin-4-yl)-2-nitrobenzamide (400 mg, 1.20 mmol, 1 eq) in H 2 O (1 mL) and EtOH (5 mL) was added NH 4 Cl (321 mg, 6.00 mmol, 5.0 eq) at 25°C. The mixture was heated to 65°C, Fe powder (201 mg, 3.60 mmol, 3.0 eq) was added and the mixture stirred at 65°C for 4 hours. The mixture was poured into water (30 mL) and extracted with EtOAc (10 mL x 3).
- Step 3 To a mixture of 2-amino-5-cyclopropyl-N-(isoquinolin-4-yl)benzamide (200 mg, 0.06 mmol, 1.0 eq) in 1,2-dichloroethane (2 mL) was added triphosgene (65 mg, 0.02 mmol, 0.3 eq) and DIEA (85 mg, 0.06 mmol, 3.0 eq) at 25°C and the mixture at 25°C for 12 hours. The reaction mixture was diluted with sat. NaHCO 3 (10 mL) and extracted with CH 2 Cl 2 (5 mL x 3). The combined organic layers were dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give the crude product.
- triphosgene 65 mg, 0.02 mmol, 0.3 eq
- DIEA 85 mg, 0.06 mmol, 3.0 eq
- Example 69 Synthesis of 1-((1H-tetrazol-5-yl)methyl)-3-(isoquinolin-4-yl)-6- (trifluoromethyl)quinazoline-2,4(1H,3H)-dione (69)
- Step 1 A mixture of 3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione (2) (150 mg, 0.42 mmol, 1.0 eq.) and K 2 CO 3 (116 mg, 0.84 mmol, 2.0 eq.) in DMF (2 mL) was cooled to 0°C, then 2-bromoacetonitrile (76 mg, 0.63 mmol, 1.5 eq) was added and the reaction mixture was stirred at 20°C for 2 hrs.
- Step 2 To a mixture of 2-(3-(isoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4- dihydroquinazolin-1(2H)-yl)acetonitrile (130 mg, 0.33 mmol, 1.0 eq.) and NaN 3 (21 mg, 0.33 mmol, 1.0 eq.) in DMF (1 mL) was added NH 4 Cl (1 mL) at 20°C. The result mixture was stirred at 120°C for 3 hrs. The solution was diluted with H 2 O (10 mL) and extracted with EtOAc (3x20 mL).
- Example 70 Synthesis of 3-(1-aminoisoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)- dione (70)
- Step 1 A mixture of 3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione (2) (200 mg, 0.56 mmol, 1.0 eq.) in CH 2 Cl 2 (5 mL) was added m-CPBA (228 mg 1.12 mmol, 2.0 eq.) at 0°C. The mixture was stirred at 40°C for 16 hrs.
- Step 2 To a mixture of 4-(2,4-dioxo-6-(trifluoromethyl)-1,4-dihydroquinazolin-3(2H)- yl)isoquinoline 2-oxide (160 mg, 0.43 mmol, 1.0 eq.) in pyridine (5 mL) was added TsCl (171 mg, 0.52 mmol, 1.2 eq.) at 0°C and stirred at 25°C for 30 min. NH2CH2CH2OH (657 mg, 10.75 mmol, 25.0 eq.) was added to the mixture at 25°C and the mixture stirred at 25°C for 16 hrs.
- Example 71 Synthesis of 1-(3-hydroxy-3-methylbutyl)-3-(isoquinolin-4-yl)-6- (trifluoromethyl)quinazoline-2,4(1H,3H)-dione (71)
- 3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione (2) 200 mg, 0.55 mmol, 1.0 eq.
- 3-hydroxy-3-methylbutyl 4- methylbenzenesulfonate (723 mg, 2.79 mmol, 5.0 eq.) and Cs 2 CO 3 (358 mg, 1.10 mmol, 2.0 eq.) and NaI (24 mg, 0.16 mmol, 0.3 eq.) at 25°C under N 2 .
- 3-hydroxy-3-methylbutyl 4-methylbenzenesulfonate was obtained using the following procedure: To a mixture of 3-methylbutane-1,3-diol (2.0 g, 19.20 mmol, 1.0 eq.) in Pyridine (20 mL) was added 4-methylbenzenesulfonyl chloride (3.6 g, 19.20 mmol, 1.0 eq.) at 0°C under N 2 . The reaction mixture was stirred at 25°C for 16 hrs. The mixture was diluted with saturated NH 4 Cl aqueous (30 mL) and extracted with CH 2 CI 2 (20 mL x 2).
- Example 72 Synthesis of 3-(isoquinolin-4-yl)-1-(oxiran-2-ylmethyl)-6- (trifluoromethyl)quinazoline-2,4(1H,3H)-dione (72)
- 3-(isoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione (2) 200 mg, 0.56 mmol, 1.0 eq
- Cs 2 CO 3 365 mg, 1.12 mmol, 2.0 eq
- 2- (bromomethyl)oxirane 77 mg, 0.56 mmol, 1.0 eq.
- reaction mixture was stirred for 12 hrs at 20°C.
- the reaction was poured into water (20 mL) and extracted with EtOAc (20 mL x 2). The organic phases were washed with brine (20 mL), dried over Na 2 SO 4 , filtered and concentrated to give crude product.
- Step 1 To a mixture of 4-chloro-2-nitrobenzoic acid (Int-AA5) (2.00 g, 9.92 mmol, 1.3 eq) and (COCl) 2 (1.64 g, 12.90 mmol, 1.13 mL, 1.7 eq) in CH 2 Cl 2 (12 mL) was added DMF (0.1 mL) at 0 °C under N 2 . The mixture was stirred at 20°C for 1 h.
- Int-AA5 4-chloro-2-nitrobenzoic acid
- (COCl) 2 1.64 g, 12.90 mmol, 1.13 mL, 1.7 eq
- reaction mixture was concentrated to get crude product which was dissolved with THF (12 mL), K2CO3 (1.15 g, 8.33 mmol, 1.2eq), DMAP (896 mg, 694.11 ⁇ mol, 0.1eq) and then isoquinolin-4-amine (1.00 g, 6.94 mmol, 1eq) was added.
- the mixture was stirred at 65°C for 2 hrs.
- the mixture was cooled to 25 °C, poured into ice-water (20 mL) and stirred for 3 min.
- the aqueous phase was extracted with ethyl acetate (20 mL x 3).
- Step 2 To a mixture of 4-chloro-N-(isoquinolin-4-yl)-2-nitrobenzamide (1 g, 3.05 mmol, 1 eq) in H 2 O (2 mL) and EtOH (10 mL) was added NH 4 Cl (816 mg, 15.26 mmol, 5 eq) in one portion at 25°C. The mixture was heated to 65°C and Fe powder (511 mg, 9.15 mmol, 3 eq) was added. Then the mixture was stirred at 65°C for 4 hours. The mixture was poured into water (30 mL) and extracted with EtOAc (10 mL x 3). The combined organic phases were washed with brine, dried over Na 2 SO 4 , filtered and concentrated to give crude product.
- Example 74 Synthesis of 6-chloro-3-(isoquinolin-4-yl)quinazoline-2,4(1H,3H)-dione (74)
- Step 1 To a mixture of triphosgene (576 mg, 0.02 mmol, 3.0 eq.) was added to a suspension of 2-amino-5-chlorobenzoic acid (Int-AA6) (1 g, 0.06 mmol, 3.0 eq.) in 1,4- dioxane (10 mL) at 0°C. The homogeneous reaction mixture was heated to 90°C for 2 hrs.
- Triphosgene 576 mg, 0.02 mmol, 3.0 eq.
- 1,4- dioxane 10 mL
- Step 2 A mixture of 6-chloro-2H-benzo[d][1,3]oxazine-2,4(1H)-dione (1.0 g, 5.06 mmol, 1.0 eq.) and isoquinolin-4-amine (700 mg, 5.06 mmol, 1.0 eq.) in H 2 O (20 mL) was stirred at 80°C for 6 hrs. The solution was poured into water (30 mL) and extracted with EtOAc (40 mL x 2).
- Step 3 A mixture of 2-amino-5-chloro-N-(isoquinolin-4-yl)benzamide (100 mg, 0.33mmol, 3.0 eq.), triphosgene (34 mg, 0.11 mmol, 1.0 eq.) and DIEA (15 mg, 0.11 mmoL, 1.0 eq) in CH 2 Cl 2 (5 mL) was stirred at 25°C for 10 hrs. The solution was poured into water (40 mL) and extracted with EtOAc (40 mL x 2). The organic phase was washed with water (40 mL), brine (40 mL), dried over Na 2 SO 4 , filtered and concentrated to give crude product.
- Step 1 To a stirred solution of methyl 3-oxocyclopentane-1-carboxylate (5.0 g, 35.17 mmol, 1.0 eq.) in toluene (50 mL) was added ethane-1,2-diol (4.4 g, 70.35 mmol, 2.0 eq.) and TsOH (0.3 g, 1.76 mmol, 0.05 eq.) at 25°C. The mixture was stirred at 140°C for 4 hrs (water removal by Dean–Stark). The reaction mixture was evaporated under reduced pressure to give a residue.
- ethane-1,2-diol 4.4 g, 70.35 mmol, 2.0 eq.
- TsOH 0.3 g, 1.76 mmol, 0.05 eq.
- Step 2 LiAlH 4 (0.9 g, 22.56 mmol, 1.2 eq.) was added dropwise to a stirred solution of methyl 1,4-dioxaspiro[4.4]nonane-7-carboxylate (3.5 g, 18.80 mmol, 1.0 eq.) in THF (50 mL) at 0°C under a N 2 atmosphere and the mixture stirred at 25°C for 3 hrs. The reaction mixture was cooled to 0°C, quenched with H 2 O (2 mL), aqueous NaOH (10%, 10 mL) and stirred at 25°C for 10 mins.
- Step 3 Under N2 flow and at 0°C, Tf2O (3.2 g, 11.38 mmol, 1.2 eq.) was added to a solution of (1,4-dioxaspiro[4.4]nonan-7-yl)methanol (1.5 g, 9.48 mmol, 1.0 eq.) and pyridine (1.5 g, 18.96 mmol, 1.2 eq.) in CH 2 Cl 2 (30 mL). The reaction mixture was stirred for 0.5 hrs at 0°C. The mixture was quenched with water (30 mL). The aqueous layer was separated from the organic and extracted with CH 2 Cl 2 (5 mL x 2).
- Step 4 At -30°C, TMAF (1.1 g, 11.38 mmol, 1.2 eq.) was added to a solution of (1,4- dioxaspiro[4.4]nonan-7-yl)methyl trifluoromethanesulfonate (1.5 g, 9.48 mmol, 1.0 eq.) and TMSCF 3 (4.0 g, 28.45 mmol, 3.0 eq.) in DME (50 mL). The reaction mixture was stirred for 0.5 hrs at -30°C and then at 0°C for 1.5 hrs. The mixture was then stirred for 16 hrs at 25°C. The mixture was quenched with water (100 mL).
- Step 5 At 25°C, HCl (0.5 mL, 2 M) was added to a solution of 7-(2,2,2-trifluoroethyl)-1,4- dioxaspiro[4.4]nonane (100 mg, 0.47 mmol, 1.0 eq.) in EtOAc (1.5 mL). The reaction mixture was stirred at 25°C for 16 hrs. The mixture was quenched with NaHCO3 (10 mL). The aqueous layer was separated from the organic phase and extracted with EtOAc (2 mL x 3). The combined organic solutions were dried (Na 2 SO 4 ), filtered, and concentrated under reduced pressure to give 3-(2,2,2-trifluoroethyl)cyclopentan-1-one.
- Step 6 To a solution of 3-(2,2,2-trifluoroethyl)cyclopentan-1-one (150 mg, 0.90 mmol, 1.0 eq.) in THF (2 mL) was added LiHMDS (1.08 mL, 1.08 mmol, 1.2 eq.) at -70°C under N 2 . The mixture was stirred at -70°C for 0.5 hrs under N 2 . NCCOOEt (99 mg, 0.99 mmol, 1.1 eq.) was added to at -70°C under N 2 and the mixture stirred at -70°C for 1 hr under N 2 .
- Step 7 To a solution of the mixture of ethyl 2-oxo-4-(2,2,2-trifluoroethyl)cyclopentane-1- carboxylate and ethyl 2-oxo-5-(2,2,2-trifluoroethyl)cyclopentane-1-carboxylate (100 mg, 0.42 mmol, 1.0 eq.) in MeOH (2 mL) was added NH 4 OAc (324 mg, 4.20 mmol, 10.0 eq.) at 25°C and the mixture stirred at 50°C for 2 hrs. The mixture was concentrated to give a residue which was suspended in saturated NaHCO 3 solution (10 mL) and extracted with EtOAc (5 mL ⁇ 3).
- Step 8 To a mixture of ethyl 2-amino-4-(2,2,2-trifluoroethyl)cyclopent-1-ene-1-carboxylate and ethyl 2-amino-5-(2,2,2-trifluoroethyl)cyclopent-1-ene-1-carboxylate (50 mg, 0.21 mmol, 1.0 eq.) and TEA (64 mg, 0.63 mmol, 3.0 eq.) in DCE (0.5 mL) was added drop-wise a solution of triphosgene (31 mg, 0.11 mmol, 0.5 eq.) in DCE (0.5 mL) at 0°C. The mixture was stirred at 25°C for 2 hrs.
- Step 9 To a mixture of ethyl 2-(3-(isoquinolin-4-yl)ureido)-4-(2,2,2-trifluoroethyl)cyclopent-1- ene-1-carboxylate and ethyl 2-(3-(isoquinolin-4-yl)ureido)-5-(2,2,2-trifluoroethyl)cyclopent-1-ene- 1-carboxylate (100 mg, crude) in MeOH (2 mL) was added K 2 CO 3 (100 mg, 0.49 mmol, 2.0 eq.) at 0°C. The mixture was stirred at 25°C for 16 hrs.
- Peak 1 3-(isoquinolin-4-yl)-6-(2,2,2-trifluoroethyl)-1,5,6,7-tetrahydro-2H- cyclopenta[d]pyrimidine-2,4(3H)-dione.
- Peak 2 3-(isoquinolin-4-yl)-5-(2,2,2-trifluoroethyl)-1,5,6,7-tetrahydro-2H- cyclopenta[d]pyrimidine-2,4(3H)-dione.
- Step 10 To a mixture of 3-(isoquinolin-4-yl)-5-(2,2,2-trifluoroethyl)-1,5,6,7-tetrahydro-2H- cyclopenta[d]pyrimidine-2,4(3H)-dione (30 mg, 0.08 mmmol, 1.0 eq.) and Cs 2 CO 3 (54 mg, 0.16 mmmol, 2.0 eq.) in DMF (1 mL) was added 2-bromoacetonitrile (15 mg, 0.12 mmmol, 1.5 eq.). The reaction mixture was stirred at 25°C for 16 hrs.
- Step 1 To a solution of methyl 2-fluoro-5-(trifluoromethyl)benzoate (Int-AA8) (1.0 g, 4.50 mmol, 1.0 eq.), (1-aminocyclopropyl)methanol (508 mg, 5.86 mmol, 1.5 eq.) in NMP (10 mL) was added K 2 CO 3 (1.2 g, 0.90 mmol, 2.0 eq.). The mixture was stirred at 100 °C for 2 hrs under N 2 . The reaction mixture was diluted with H 2 O (20 mL) and extracted with ethyl acetate (15 mL ⁇ 3).
- Step 4 The solution of 2-((1-(cyanomethyl)cyclopropyl)amino)-5-(trifluoromethyl)benzoic acid (210 mg, 0.74 mmol, 1.0 eq.) and isoquinolin-4-amine (127mg, 0.88 mmol, 1.2 eq.) in MeCN (5 mL) was added TCFH (250 mg, 0.88 mmol, 1.2 eq.) and NMI (240 mg, 2.22 mmol, 3.0 eq.) at 25°C under N 2 . The solution was stirred at 45°C for 1.5 hrs. The reaction was quenched with H 2 O (10 mL) and extracted with EtOAc (20 mL ⁇ 2).
- Step 5 To a solution of 2-((1-(cyanomethyl)cyclopropyl)amino)-N-(isoquinolin-4-yl)-5- (trifluoromethyl)benzamide (100 mg, 0.50 mmol, 1.0 eq.) in DMF (2 mL) was added CDI (80 mg, 1.01 mmol, 2.0 eq.) and CDT (80 mg, 1.01 mmol, 2.0 eq.). The mixture was stirred at 120°C for 0.5 hr. The reaction mixture was concentrated to dryness to give a residue.
- CDI 80 mg, 1.01 mmol, 2.0 eq.
- CDT 80 mg, 1.01 mmol, 2.0 eq.
- Example 77 Synthesis of ⁇ (1M or 1P)-[(3M)-3-(5-Fluoroisoquinolin-4-yl)-2,4-dioxo-6- (trifluoromethyl)-3,4-dihydroquinazolin-1(2H)-yl]cyclopropyl ⁇ acetonitrile (77a) and ⁇ (1M or 1P)-[(3P)-3-(5-Fluoroisoquinolin-4-yl)-2,4-dioxo-6-(trifluoromethyl)-3,4- dihydroquinazolin-1(2H)-yl]cyclopropyl ⁇ acetonitrile (77b) Step 1: To a solution of 2-((1-(cyanomethyl)cyclopropyl)amino)-5-(trifluoromethyl)benzoic acid (500 mg, 1.76 mmol, 1.0 eq.) and 5-fluoroisoquinolin-4-amine
- Step 2 To a solution of 2-((1-(cyanomethyl)cyclopropyl)amino)-N-(5-fluoroisoquinolin-4-yl)-5- (trifluoromethyl)benzamide (150 mg, 0.35 mmol, 1.0 eq.), CDI (142 mg, 0.88 mmol, 2.5 eq.) and CDT (144 mg, 0.88 mmol, 2.5 eq.) in NMP (10 mL) was added DBU (160 mg, 1.05 mmol, 3.0 eq.) at 25°C. The mixture was stirred at 25°C for 16 hrs under N 2 .
- Step 1 To a mixture of ethyl 2-amino-5-(trifluoromethyl)cyclohex-1-ene-1-carboxylate (Int-A7) (3.6 g, 15.10 mmol, 1.0 eq.) and Et 3 N (4.6 g, 45.30 mmol, 3.0 eq.) in DCE (150 mL) was added dropwise a solution of triphosgene (2.2 g, 7.55 mmol, 0.5 eq.) in DCE (15 mL) at 0°C. The mixture was stirred at 0°C for 2 hrs.
- Int-A7 ethyl 2-amino-5-(trifluoromethyl)cyclohex-1-ene-1-carboxylate
- Et 3 N 4.6 g, 45.30 mmol, 3.0 eq.
- Step 2 Racemic 3-(5-fluoroisoquinolin-4-yl)-6-(trifluoromethyl)-5,6,7,8-tetrahydroquinazoline- 2,4(1H,3H)-dione (5.5 g, 14.50 mmol) was separated by chiral SFC (DAICEL CHIRALPAK AD (250mmx50mm, 10 ⁇ m); mobile phase: [0.1% NH 3 H 2 O EtOH]; B%: 30%-30%, 8 min) to obtain four peaks.
- t R2 3.239 min.
- t R3 3.682 min.
- t R4 3.859 min.
- Peak 1: LCMS Method 12): t R 0.664 min, [M+1] + 380.1.
- SFC (column: DAICEL CHIRALPAK AD (150mmx4.6mm, 3 ⁇ m); mobile phase: A: CO 2 , B: EtOH(0.1% IPAm); 10%B for 0.5 min., 10- 50%B, over 3.0 min., 50%B for 1.0 min.
- Peak 2: LCMS (Method 12): t R 0.657 min, [M+1] + 380.1.
- Step 3a To a solution of the compound from Peak 1 (127 mg, 0.33 mmol, 1.0 eq.) in DMF (8 mL) was added Cs 2 CO 3 (109 mg, 0.33 mmol, 1.0 eq.), NaI (5 mg, 0.03 mmol, 0.1 eq.) and (1- cyanocyclopropyl)methyl 4-methylbenzenesulfonate (127 mg, 0.50 mmol, 1.5 eq.) at 20°C. The reaction was stirred at 40°C under N 2 for 8 hrs.
- reaction mixture was quenched with saturated aqueous HCl (0.5 M, 80 mL) and extracted with ethyl acetate (30 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na 2 SO 4 , filtered and concentrated to give crude product.
- the crude was purified by prep-HPLC (column: Waters Xbridge BEH C18100mmx30mm, 10 ⁇ m; liquid phase: [A:10 mM NH 4 HCO 3 in H 2 O; B:ACN] B%: 35%-55%, 8 min]) to obtain 1- ⁇ [(3M,6R or 6S)-3-(5-Fluoroisoquinolin-4-yl)-2,4-dioxo-6- (trifluoromethyl)-3,4,5,6,7,8-hexahydroquinazolin-1(2H)-yl]methyl ⁇ cyclopropane-1-carbonitrile (78a)-Peak 1a.
- Step 3b To a solution of the compound from Peak 2 (150 mg, 0.40 mmol, 1.0 eq.) in DMF (8 mL) was added Cs 2 CO 3 (130 mg, 0.40 mmol, 1.0 eq.), NaI (6 mg, 0.04 mmol, 0.1 eq.) and (1- cyanocyclopropyl)methyl 4-methylbenzenesulfonate (127 mg, 0.50 mmol, 1.5 eq.) at 20°C. The reaction was stirred at 40°C under N 2 for 7 hrs. The reaction mixture was quenched with saturated aqueous HCl (0.5 M, 80 mL), extracted with ethyl acetate (30 mL x 3).
- Step 3c To a solution of the compound from Peak 3 (150 mg, 0.40 mmol, 1.0 eq.) in DMF (8 mL) was added Cs 2 CO 3 (130 mg, 0.40 mmol, 1.0 eq.), NaI (6 mg, 0.04 mmol, 0.1 eq.) and (1- cyanocyclopropyl)methyl 4-methylbenzenesulfonate (150 mg, 0.60 mmol, 1.5 eq.) at 20°C. The reaction was stirred at 40°C under N 2 for 7 hrs. The mixture was quenched with saturated aqueous HCl (0.5 M, 80 mL), extracted with ethyl acetate (30 mL x 3).
- Step 3d To a solution of the compound from Peak 4150 mg, 0.40 mmol, 1.0 eq.) in DMF (8 mL) was added Cs 2 CO 3 (130 mg, 0.40 mmol, 1.0 eq.), NaI (6 mg, 0.04 mmol, 0.1 eq.) and (1- cyanocyclopropyl)methyl 4-methylbenzenesulfonate (150 mg, 0.60 mmol, 1.5 eq.) at 20°C. The reaction was stirred at 40°C under N 2 for 7 hrs. The mixture was quenched with saturated aqueous HCl (0.5 M, 80 mL), extracted with ethyl acetate (30 mL x 3).
- Example 79 Synthesis of (3M)-3-(5-Fluoroisoquinolin-4-yl)-6-(trifluoromethyl)quinazoline- 2,4(1H,3H)-dione (79a) and (3P)-3-(5-Fluoroisoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione
- Step 1 To a solution of 5-fluoroisoquinolin-4-amine (Int-B6) (400 mg, 2.47 mmol, 1.0 eq.) and pyridine (598 mg, 7.41 mmol, 3.0 eq.) in CH 2 Cl 2 (10 mL) was added dropwise phenyl carbonochloridate (966 mg, 6.17 mmmol, 2.5 eq.) at 0°C under N 2 .
- Step 2 To a mixture of NaH (74 mg, 1.86 mmol, 1.5 eq.) in DMF (5 mL) was added dropwise a solution of methyl 2-amino-5-(trifluoromethyl)benzoate (int-A6) (544 mg, 2.48 mmol, 2.5 eq.) in DMF (2 mL) at 0°C under N 2 . The mixture was stirred at 25°C for 1 hr. Then a solution of phenyl (5-fluoroisoquinolin-4-yl)(phenoxycarbonyl)carbamate (400 mg, 0.10 mmol, 1.0 eq.) in DMF (5 mL) was added dropwise to the system at 0°C under N 2 .
- int-A6 methyl 2-amino-5-(trifluoromethyl)benzoate
- the reaction was stirred at 25°C under N 2 for 15 hrs.
- the reaction mixture was diluted with aq. NH 4 Cl (60 mL) and extracted with EtOAc (30 mL x 3). The organic layers were washed with brine (50 mL), dried over Na 2 SO 4 and concentrated to give a residue.
- Step 3 Racemic 3-(5-fluoroisoquinolin-4-yl)-6-(trifluoromethyl)quinazoline-2,4(1H,3H)-dione was separated by chiral SFC (column: DAICEL CHIRALPAK AD (250mmx30mm,10 ⁇ m); IPA (0.1%NH 3 .
- SFC (column: DAICEL CHIRALPAK AD (150mmx4.6mm, 3 ⁇ m); mobile phase: A: CO 2 , B: IPA(0.1% IPAm); 10%B for 0.5 min., 10- 50%B, over 3.0 min., 50%B for 1.0 min.
- Step 2 A mixture of methyl 2-amino-5-bromo-4-fluorobenzoate (2.0 g, 8.06 mmol, 1.0 eq.) and 4-isocyanatoisoquinoline (Int-B8) (1.37g, 8.06 mmol, 1.0 eq.) in pyridine (20 mL) was stirred at 100°C for 16 hrs. The reaction mixture was quenched with H 2 O (20 mL) and extracted with ethyl acetate (20 mL x 3).
- Step 3 To a mixture of 6-bromo-7-fluoro-3-(isoquinolin-4-yl)quinazoline-2,4(1H,3H)-dione (400 mg, 0.36 mmol, 1.0 eq.), cyclopropylboronic acid(48 mg, 1.55 mmol, 1.5 eq.) and K 2 PO 4 (158 mg, 0.04 mmol, 0.1 eq.) in toluene (5 mL) and H 2 O (0.5 mL) was added Sphos (16 mg, 0.04 mmol, 0.1 eq.) and Pd 2 (dba) 3 (37 mg, 0.04 mmol, 0.1 eq.) under N 2 .
- Example 81 Synthesis of 6-cyclopropyl-7-fluoro-3-(isoquinolin-4-yl)-1-methylquinazoline- 2,4(1H,3H)-dione (81) Step 1: To a mixture of 6-bromo-7-fluoro-3-(isoquinolin-4-yl)quinazoline-2,4(1H,3H)-dione (140 mg, 0.36 mmol, 1.0 eq.) and K 2 CO 3 (150 mg, 1.09 mmol, 3.0 eq.) in DMF (2 mL) was added MeI (77 mg, 0.54 mmol, 1.5 eq.). The mixture was stirred at 0°C for 2 hrs.
- Step 2 To a mixture of 6-bromo-7-fluoro-3-(isoquinolin-4-yl)-1-methylquinazoline-2,4(1H,3H)- dione (120 mg, 0.30 mmol, 1.0 eq.), cyclopropylboronic acid (39 mg, 0.45 mmol, 1.5 eq.) and K 2 PO 4 (65 mg, 0.03 mmol, 2.5 eq.) in toluene (2 mL) and H 2 O (0.2 mL) was added sphos (13 mg, 0.03 mmol, 0.1 eq.) and Pd 2 (dba) 3 (28 mg, 0.03 mmol, 0.1 eq.).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
L'invention concerne des composés de formule (I) et des compositions pour le traitement, la gestion ou la prévention de maladies associées au coronavirus. En particulier, l'invention concerne des composés dione cycliques qui sont des inhibiteurs de la protéase principale du SARS-CoV-2 (M), des compositions pharmaceutiques comprenant de tels composés, un procédé de synthèse de tels composés et des procédés d'utilisation de tels composés et compositions pour le traitement, la gestion ou la prévention de maladies associées au coronavirus.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163179078P | 2021-04-23 | 2021-04-23 | |
US63/179,078 | 2021-04-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022224223A1 true WO2022224223A1 (fr) | 2022-10-27 |
Family
ID=81580936
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2022/053794 WO2022224223A1 (fr) | 2021-04-23 | 2022-04-22 | Composés et compositions pour le traitement de maladies associées au coronavirus |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022224223A1 (fr) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3064491A1 (fr) * | 2013-10-29 | 2016-09-07 | EA Pharma Co., Ltd. | Dérivé de sulfonamide et son utilisation médicinale |
WO2020063982A1 (fr) * | 2018-09-29 | 2020-04-02 | 山东先达农化股份有限公司 | Composé contenant un fragment de quinazolinedione, son procédé de préparation, son utilisation et herbicide |
WO2020225330A1 (fr) * | 2019-05-07 | 2020-11-12 | Universität Hamburg | Inhibiteurs de dhodh et leur utilisation en tant qu'agents antiviraux |
-
2022
- 2022-04-22 WO PCT/IB2022/053794 patent/WO2022224223A1/fr active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3064491A1 (fr) * | 2013-10-29 | 2016-09-07 | EA Pharma Co., Ltd. | Dérivé de sulfonamide et son utilisation médicinale |
WO2020063982A1 (fr) * | 2018-09-29 | 2020-04-02 | 山东先达农化股份有限公司 | Composé contenant un fragment de quinazolinedione, son procédé de préparation, son utilisation et herbicide |
WO2020225330A1 (fr) * | 2019-05-07 | 2020-11-12 | Universität Hamburg | Inhibiteurs de dhodh et leur utilisation en tant qu'agents antiviraux |
Non-Patent Citations (19)
Title |
---|
"Remington's Pharmaceutical Sciences", 1990, MACK PRINTING COMPANY, pages: 1289 - 1329 |
ANGEW. CHEM., vol. 21, 1982, pages 567 - 583 |
BUCKMAN B O ET AL: "Solid-Phase Synthesis of 1,3-Dialkyl Quinazoline-2,4-Diones", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM , NL, vol. 37, no. 26, 24 June 1996 (1996-06-24), pages 4439 - 4442, XP004029035, ISSN: 0040-4039, DOI: 10.1016/0040-4039(96)00878-7 * |
CHEM. COMMUN., vol. 50, 2014, pages 7269 - 7272 |
DAI, W. ET AL.: "Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease", SCIENCE, vol. 368, no. 6497, 2020, pages 1331 - 1335 |
DOUANGAMATH, A ET AL.: "Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease", NATURE COMMUNICATIONS, vol. 11, no. 1, 2020, pages 5047 |
ENCISO EDUARDO ET AL: "Synthesis of new quinazolin-2,4-diones as anti-Leishmania mexicanaagents", MOLECULAR DIVERSITY, SPRINGER INTERNATIONAL PUBLISHING, CHAM, vol. 20, no. 4, 16 August 2016 (2016-08-16), pages 821 - 828, XP036072058, ISSN: 1381-1991, [retrieved on 20160816], DOI: 10.1007/S11030-016-9693-8 * |
GHAHREMANPOUR, M. M. ET AL.: "Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2", ACS MED CHEM LETT, vol. 11, 2020, pages 2526 |
GUENTHER, S. ET AL.: "X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease", SCIENCE, 2021, Retrieved from the Internet <URL:https://doi.org/10.1126/science.abf7945> |
H. GREIG NIGEL ET AL: "A Simple One-Pot Synthesis of Benzoxazine-2,4-diones and Benzothiazine-2,4-diones", HETEROCYCLES, vol. 59, no. 1, 1 January 2003 (2003-01-01), JP, pages 115, XP055946887, ISSN: 0385-5414, Retrieved from the Internet <URL:http://dx.doi.org/10.3987/COM-02-S2> DOI: 10.3987/COM-02-S2 * |
HOFFMAN, R. L. ET AL.: "Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19", JOURNAL OF MEDICINAL CHEMISTRY, vol. 63, no. 21, 2020, pages 12725 - 12747, XP055803394, DOI: 10.1021/acs.jmedchem.0c01063 |
J. F. W. MCOMIE: "Protective Groups in Organic Chemistry", 1973, PLENUM PRESS |
JIN, Z. ET AL.: "Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors", NATURE, vol. 582, no. 7811, 2020, pages 289 - 293 |
KUINDERSMA M. ET AL: "Ketanserin as potential additive drug to improve V/Q mismatch in COVID-19?", CRITICAL CARE, vol. 24, no. 1, 1 December 2020 (2020-12-01), XP055947238, Retrieved from the Internet <URL:https://ccforum.biomedcentral.com/track/pdf/10.1186/s13054-020-03257-y.pdf> DOI: 10.1186/s13054-020-03257-y * |
MA, C. ET AL.: "Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease", CELL RESEARCH, vol. 30, no. 8, 2020, pages 678 - 692, XP037208260, DOI: 10.1038/s41422-020-0356-z |
RAVI OWK ET AL: "Copper-Catalyzed Domino C-C Bond Cleavage of 2,3-Unsubstituted Indoles/Indolines and Oxindoles via Oxidation and Directed Insertion of 2-Aminopyridines: Direct Access to Quinazolinediones", ADVANCED SYNTHESIS AND CATALYSIS, vol. 360, no. 16, 17 August 2018 (2018-08-17), pages 3009 - 3014, XP055947173, ISSN: 1615-4150, Retrieved from the Internet <URL:https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fadsc.201800536> DOI: 10.1002/adsc.201800536 * |
RIVA, L.: "Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing", NATURE, vol. 586, no. 7827, 2020, pages 113 - 119, XP037258306, DOI: 10.1038/s41586-020-2577-1 |
T. W. GREENEP. G. M. WUTS: "Protective Groups in Organic Synthesis", 1999, WILEY |
ZHANG, L. ET AL.: "Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved a-ketoamide inhibitors", SCIENCE, vol. 368, no. 6489, 2020, pages 409 - 412, XP055814007, DOI: 10.1126/science.abb3405 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI543981B (zh) | 作為c-kit激酶抑制劑之化合物及組合物 | |
TWI594997B (zh) | 流感病毒複製之抑制劑 | |
CN107089985B (zh) | 作为詹纳斯相关激酶(jak)抑制剂的吡咯并[2,3-d]嘧啶衍生物 | |
CN109563103B (zh) | 用于治疗或预防与其相关的病症的β-3肾上腺素能受体的调节剂 | |
AU2014400628A1 (en) | Aminopyridazinone compounds as protein kinase inhibitors | |
TW201313717A (zh) | 作為c-Kit激酶抑制劑之化合物及組合物 | |
JP2011529952A (ja) | ジアザインドール誘導体およびc−JunN末端キナーゼの阻害におけるそれらの使用 | |
JP7222590B2 (ja) | 3-アザビシクロ[3,1,1]ヘプタン誘導体及びこれを含む薬学的組成物 | |
WO2013033116A1 (fr) | Composés et compositions pouvant être utilisés en tant qu'inhibiteurs de la kinase c-kit | |
CN103619841A (zh) | 杂芳基化合物及其使用方法 | |
TW202309020A (zh) | KEAP1-Nrf2蛋白-蛋白交互作用抑制劑 | |
CA3093877A1 (fr) | Analogues d'hexahydropyrimidine antipaludiques | |
JP2023522725A (ja) | 3-アザビシクロアルキル誘導体およびこれを含む薬剤学的組成物 | |
JP6739516B2 (ja) | 呼吸器合胞体ウイルス阻害剤 | |
WO2023002409A1 (fr) | Composés et compositions pour le traitement de maladies associées au coronavirus | |
WO2021113682A1 (fr) | Inhibiteurs de masp-2 et procédés d'utilisation | |
CA3015166C (fr) | Composes 6,7-dihydro-5 h-pyrazolo [5,1-b] [1,3]oxazine-2-carboxamide | |
WO2022224223A1 (fr) | Composés et compositions pour le traitement de maladies associées au coronavirus | |
WO2022235945A1 (fr) | Composés destinés à cibler la dégradation de la tyrosine kinase de bruton | |
US20240287076A1 (en) | Compounds for targeting degradation of bruton's tyrosine kinase | |
AU2022269034A1 (en) | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | |
TW201722962A (zh) | 四氫氧呯並吡啶化合物 | |
NZ621092B2 (en) | COMPOUNDS AND COMPOSITIONS AS c-KIT KINASE INHIBITORS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22721480 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22721480 Country of ref document: EP Kind code of ref document: A1 |